Document:

EX-10.6

 Exhibit 10.6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 

			
	Confidential	  	EXECUTION VERSION

 LICENSE AGREEMENT 

This LICENSE AGREEMENT (“Agreement”) is made as of January 31, 2018 (“Effective Date”), by and between
TheraVida, Inc., a corporation organized and existing under the laws of Delaware (“TheraVida”), having its principal place of business at 177 Bovet Rd., Suite 600, San Mateo, California 94402, and Roivant Sciences
GmbH, a Swiss limited liability company (“Roivant”), having an address of Viaduktstrasse 8, 4051 Basel, Switzerland. Roivant and TheraVida are referred to individually as a “Party” and collectively as the
“Parties.” 
 RECITALS 

WHEREAS, TheraVida has developed a proprietary pharmaceutical product comprising a combination of Oxybutynin and Pilocarpine and known as THVD-102; 
 WHEREAS, TheraVida owns and/or controls certain intellectual property rights relating to THVD-102; 
 WHEREAS, Roivant wishes to obtain from TheraVida an exclusive license to develop and, if
successful, commercialize THVD-102 and/or any other products within the scope of Roivant’s license under this Agreement, and TheraVida is willing to grant such license to Roivant, all under the terms and
conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the
receipt and sufficiency which are hereby acknowledged, Roivant and TheraVida hereby agree as follows. 
 ARTICLE 1 

DEFINITIONS 
 Unless the
context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

1.1 “Active Pharmaceutical Ingredient” means any substance intended to be used in a pharmaceutical product that when
used becomes an active ingredient of that product intended to exert a pharmacological, immunological or metabolic action with a view to restoring, correcting or modifying physiological functions in man or animal or to make a medical diagnosis (such
pharmacological, immunological or metabolic action, the “Intended Action”); but excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release technologies. 

1.2 “Actual Combination Product Net Sales” has the meaning set forth in Section 1.56 (Net Sales). 

  
 1 

			
	Confidential	  	EXECUTION VERSION

  

 1.3 “Affiliate” means, with respect to a Party, any Person that,
directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with that Party, but for only so long as such control exists. For the purpose of this definition, “control” (including, with
correlative meaning, the terms “controlled by” and “under common control”) means (a) to possess, directly or indirectly, the power to direct the management or policies of an 

entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise; or (b) direct or
indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such
entity. 
 1.4 “Aggregate Annual Net Sales” has the meaning set forth in Section 8.4(a) (Royalty Payments). 

1.5 “Applicable Laws” means the applicable provisions of any and all national, supranational, regional, state and local
laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, arbitrator, Regulatory Authority or Governmental Authority
having jurisdiction over or related to the subject item. 
 1.6 “Auditor” has the meaning set forth in
Section 8.11 (Audit Dispute). 
 1.7 “Business Day” means a day other than a Saturday, Sunday or a bank or other
public holiday in Basel or New York. 
 1.8 “Calendar Quarter” means each respective period of three
(3) consecutive months ending on March 31, June 30, September 30, and December 31. 
 1.9 “Calendar
Year” means each respective period of twelve (12) consecutive months ending on December 31. 
 1.10 “CFR”
means the U.S. Code of Federal Regulations. 
 1.11 “CIOMS” means the Council for International Organizations of
Medical Sciences. 
 1.12 “Claims” means all Third Party demands, claims, actions, proceedings and liability (whether
criminal or civil, in contract, tort or otherwise) for losses, damages, legal costs and other expenses of any nature. 
 1.13
“CMC” means chemistry, manufacturing, and controls. 
 1.14 “CMO” means contract manufacturing
organization. 
 1.15 “Combination Product” means any Licensed Product comprising a fixed-dose combination of:
(a) a Proprietary Drug and (b) at least one Other Active. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

2 

			
	Confidential	  	EXECUTION VERSION

  

 1.16 “Commercialization” means the conduct of all activities
undertaken before and after Regulatory Approval relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering Licensed Products to
customers) of Licensed Products in or outside of the Territory, including: (a) sales force efforts, detailing, advertising, medical education, planning, marketing, sales force training, and sales and distribution; and (b) scientific and
medical affairs. For clarity, Commercialization does not include any Development activities, whether conducted before or after Regulatory Approval. “Commercialize” and “Commercializing” have correlative meanings.

 1.17 “Commercially Reasonable Efforts” means, with respect to an entity’s obligations under this Agreement
relating to Proprietary Drugs and Licensed Products, those efforts and resources that are consistent with the exercise of customary scientific and business practices as applied in the pharmaceutical industry for a company of a similar stage and size
as the entity and having similar resources, for development, regulatory, manufacturing and commercialization activities conducted with respect to products at a similar stage of development or commercialization and having similar commercial
potential, taking into account relative safety and efficacy, product profile, the regulatory environment, payors’ policies and regulations, competitiveness of the marketplace and the market potential of such products, the nature and extent of
market exclusivity, including patent coverage and regulatory data protection, and price and reimbursement status. 
 1.18
“Confidential Information” of a Party means all Know-How, unpublished patent applications and other information and data of a financial, commercial, business, operational or technical nature
of such Party that is disclosed or made available by or on behalf of such Party or any of its Affiliates to the other Party or any of its Affiliates, whether made available orally, in writing or in electronic or other form. The terms of this
Agreement are the Confidential Information of both Parties. 
 1.19 “Control” or “Controlled” means, with
respect to any Know-How, Patent or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise, other than by virtue of any license granted to
such Party by the other Party pursuant to this Agreement) to grant a license, sublicense, access or other right (as applicable) under such Know-How, Patent, or other intellectual property rights to the other
Party on the terms and conditions set forth herein, in each case without breaching the terms of any agreement with a Third Party. 

1.20 “Develop” or “Development” means to develop (including clinical,
non-clinical and CMC development), analyze, test and conduct preclinical, clinical and all other regulatory trials for a Proprietary Drug or Licensed Product, including all post-approval clinical trials, as
well as all related regulatory activities and any and all activities pertaining to new Indications, pharmacokinetic studies and all related activities including work on new formulations, new methods of treatment and CMC activities including new
manufacturing methods. “Developing” and “Development” have correlative meanings. 
 1.21
“Disclosing Party” has the meaning set forth in Section 10.1(a) (Duty of Confidence—subsection (a)). 

1.22 “Dollar” means U.S. dollars, and “ $” shall be interpreted accordingly. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

3 

			
	Confidential	  	EXECUTION VERSION

  

 1.23 “EMA” means the European Medicines Agency or any successor
entity thereto. 
 1.24 “EU” means the European Union. 

1.25 “Excluded Claim” has the meaning set forth in Section 14.9(g) (Dispute Resolution—subsection (g)). 

1.26 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 

1.27 “Field” means the treatment, prevention and diagnosis of any and all human and animal diseases, disorders and
conditions with the exception of overactive bladder. 
 1.28 “First Commercial Sale” means, with respect to any
Licensed Product in any country or jurisdiction in the Territory, the first arm’s length sale of such Licensed Product by Roivant, its Affiliates or Sublicensees to a Third Party for distribution, use or consumption in such country or
jurisdiction after Regulatory Approval has been obtained for such Licensed Product in such country or jurisdiction. 
 1.29
“Fiscal Year” means the period from [***] of a Calendar Year through [***] of the following Calendar Year. 
 1.30
“GAAP” means the then-current Generally Accepted Accounting Principles or International Financial Reporting Standards (IFRS), whichever is adopted as the standard financial accounting guideline in the United States for public
companies, as consistently applied. 
 1.31 “Generic Competition” means, on a Licensed
Product-by-Licensed Product and country-by-country basis, that, in a given Calendar
Quarter, unit sales of one or more Generic Versions of a Licensed Product in a country account for more than [***] of combined unit sales of (a) such Licensed Product and (b) such Generic Version(s), in such country, as determined by
reference to applicable sales data obtained from IQVIA or from such other independent source for such sales data as may be agreed upon by the Parties (provided that such other source, if any, shall be generally recognized as a reliable source for
pharmaceutical sales data among major pharmaceutical companies). 
 1.32 “Generic Version” means, with respect to a
Licensed Product, on a country-by-country basis, a pharmaceutical product that: (a) is sold in a given country by a Third Party, other than a Sublicensee, or any
other Third Party in a chain of distribution originating from Roivant, any of its Affiliates or any Sublicensee; (b) contains the same Proprietary Drug (and, if such Licensed Product is a fixed-dose combination that also contains any Active
Pharmaceutical Ingredient in addition to Oxybutynin and Pilocarpine, the same such other Active Pharmaceutical Ingredient) as such Licensed Product; and (c) has been approved for marketing by the relevant Regulatory Authority in such country in
reliance on the approved MAA for such Licensed Product in such country, including any such pharmaceutical product that has been approved for marketing (i) in the U.S., pursuant to Section 505(b)(2) or Section 505(j) of the Act (21
U.S.C. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

4 

			
	Confidential	  	EXECUTION VERSION

  

 §355(b)(2) or 21 U.S.C. §355(j), respectively), (ii) in the EU or an EU member state, as a
“generic medicinal product” pursuant to Article 10 of Parliament and Council Directive 2001/83/EC as amended, or (iii) in any other country or jurisdiction, pursuant to any equivalent of the foregoing laws, regulations or
directives, wherein the approval of such pharmaceutical product is based on reference to the approved MAA for such Licensed Product in such country and a demonstration of bio-equivalence to such Licensed
Product; and, in each case, which may be substituted for the Licensed Product without any action by the physician or health care practitioner. 

1.33 “Government Authority” means any federal, state, national, state, provincial or local government, or political
subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any
department, bureau or division thereof, or any governmental arbitrator or arbitral body). 
 1.34 “Incremental Withholding
Taxes” has the meaning set forth in Section 8.9(b) (Tax Cooperation). 
 1.35 “IND” means any
investigational new drug application, clinical trial application, clinical trial exemption or similar or equivalent application or submission for approval to conduct human clinical investigation filed with or submitted to a Regulatory Authority in
conformance with the requirements of such Regulatory Authority. 
 1.36 “Indemnified Party” has the meaning set forth
in Section 13.3 (Indemnification Procedure). 
 1.37 “Indemnifying Party” has the meaning set forth in
Section 13.3 (Indemnification Procedure). 
 1.38 “Indication” means a separate and distinct disease, disorder,
illness or health condition for which a separate MAA approval is required. 
 1.39 “Initial Proprietary Drug” means
any fixed-dose combination of Oxybutynin and Pilocarpine. 
 1.40 “Initiation” means, with respect to a clinical
trial, the first dosing (whether with investigational drug, comparator drug or placebo) of the first subject in such clinical trial. 

1.41 “Intended Action” has the meaning set forth in Section 1.1 (Active Pharmaceutical Ingredient). 

1.42 “Invention” shall mean any process, method, composition of matter, article of manufacture, discovery or finding,
patentable or otherwise, that is made, generated, conceived or otherwise invented as a result of a Party exercising its rights or carrying out its obligations under this Agreement, whether directly or via its Affiliates, agents or independent
contractors, including all rights, title and interest in and to the intellectual property rights therein. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

5 

			
	Confidential	  	EXECUTION VERSION

  

 1.43 “Joint Inventions” has the meaning set forth in
Section 9.1(a) (Ownership of Inventions). 
 1.44 “Joint Patents” has the meaning set forth in
Section 9.1(a) (Ownership of Inventions). 
 1.45 “Know-How” means any
information, including discoveries, improvements, modifications, processes, methods, techniques, protocols, formulas, data, inventions, know-how, trade secrets and results, patentable or otherwise, including
physical, chemical, biological, toxicological, pharmacological, safety, and pre-clinical and clinical data, dosage regimens, control assays, and product specifications, but excluding any Patents. 

1.46 “Licensed Know-How” means (a) all
Know-How that TheraVida Controls as of the Effective Date or during the Term that is necessary or reasonably useful for the Development, manufacture and/or Commercialization of any Proprietary Drug, and
(b) TheraVida’s Sole Inventions and TheraVida’s joint ownership interest in Joint Inventions. 
 1.47 “Licensed
Manufacturing Know-How” has the meaning set forth in Section 6.2(a) (Manufacturing Technology Transfer—subsection (a)). 

1.48 “Licensed Patents” means: (a) the Patents listed on Exhibit C; (b) all other Patents Controlled by
TheraVida as of the Effective Date or during the Term that (i) claim the composition of matter, or any method of manufacture or use, of any Proprietary Drug in the Field in the Territory or (ii) in the absence of a license or similar
right, would be infringed (assuming issuance thereof in the case of any patent application) by the manufacture, use, sale, offer for sale or import of any Proprietary Drug in the Field in the Territory; and (c) TheraVida’s joint ownership
interest in Joint Patents. For clarity, the Licensed Patents exclude any Patent Controlled by TheraVida as of the Effective Date or during the Term, the claims of which are limited to methods of using any Proprietary Drug or Muscarinic Modulator
solely outside of the Field. 
 1.49 “Licensed Product” means any pharmaceutical product that contains a Proprietary
Drug, alone or in combination with one or more Other Actives, in any dosage form or formulation, including THVD-102. 

1.50 “Licensed Technology” means the Licensed Know-How and Licensed Patents.

 1.51 “MAA” or “Marketing Authorization Application” means an application to the appropriate Regulatory
Authority for approval to market a Licensed Product (but excluding Pricing Approval) in any particular jurisdiction and all amendments and supplements thereto, including an NDA filed with the FDA in the U.S. 

1.52 “Major Markets” has the meaning set forth in Section 4.2 (Development Diligence). 

1.53 “Manufacturing Transfer Period” has the meaning set forth in Section 6.2(a) (Manufacturing Technology
Transfer—subsection (a)). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

6 

			
	Confidential	  	EXECUTION VERSION

  

 1.54 “Muscarinic Modulator” means any Active Pharmaceutical
Ingredient that is a muscarinic antagonist or a muscarinic agonist; except, in each case, for any such Active Pharmaceutical Ingredient the activity of which as a muscarinic antagonist or a muscarinic agonist (as applicable) (a) is incidental
and (b) is not responsible (in whole or in part) for exerting the Intended Action of such Active Pharmaceutical Ingredient. By way of example and not of limitation, Oxybutynin and Pilocarpine are Muscarinic Modulators. 

1.55 “NDA” means a New Drug Application (as more fully defined in 21 C.F.R. §314.5 et seq. or successor
regulation) and all amendments and supplements thereto filed with the FDA. 
 1.56 “Net Sales” means, with respect to
any Licensed Product, the gross amounts invoiced for sales or other dispositions of such Licensed Product by or on behalf of Roivant, its Affiliates and Sublicensees (each, a “Selling Party”) to Third Parties (other than a Selling Party),
less the following deductions to the extent included in the gross amounts invoiced for such Licensed Product or otherwise actually paid or incurred by the Selling Party with respect to the sale or other disposition of such Licensed Product: 

(a) [***] 
 (b)
[***] 
 (c) [***] 

(d) [***] 
 (e)
[***] 
 (f) [***] 

(g) [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

7 

			
	Confidential	  	EXECUTION VERSION

  

 [***] 

(h) [***] 
 Such amounts
shall be determined in accordance with GAAP, consistently applied. In no event shall any particular amount identified above be deducted more than once in calculating Net Sales (i.e., no “double counting” of deductions). 

The sale of any Licensed Product by a Selling Party to another Selling Party for resale by such Selling Party to a Third Party (other than a
Selling Party) shall not be deemed a sale for purposes of this definition of “Net Sales,” provided that the subsequent resale is included in the computation of Net Sales. Further, transfers or dispositions of Licensed
Products as free promotional samples in commercially reasonable amounts, consistent with prevailing industry standards, and Licensed Products provided at or below their manufacturing cost and used in research, development or regulatory activities,
compassionate use, indigent programs, investigator-initiated trials or on a named patient basis shall be disregarded in determining Net Sales. 

If any discounts or other deductions or rebates are made in connection with sales of a Licensed Product that is bundled or sold together with
other products of the Selling Parties, then the discount, deduction or rebate applied to the Licensed Product shall not exceed the discount, deduction or rebate applied to any of the other products of the Selling Parties in such arrangement based
upon the respective list prices of the Licensed Product and such other products prior to applying the discount. 
 On a country-by-country basis, if a Licensed Product is sold in a country as part of a Combination Product, Net Sales of such Licensed Product for the purpose of determining
royalties and commercial milestone payments due hereunder shall be calculated as follows: 
 (i) [***] 

(i) [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

8 

			
	Confidential	  	EXECUTION VERSION

  

 (ii) [***] 

(iii) [***] 
 1.57
“Other Active” means any Active Pharmaceutical Ingredient that is not a Muscarinic Modulator. 
 1.58
“Oxybutynin” means the drug known by the generic name oxybutynin, having the chemical structure set forth in Exhibit B, and/or any pharmaceutically acceptable salt form, base form, pro-drug,
ester, ether, isomer, metabolite, crystalline polymorph, and hydrate or solvate thereof. 
 1.59 “Patent” means all
patents and patent applications, including all provisionals, substitutions, divisionals, reissues, reexaminations, renewals, continuations, continuations-in-part,
substitute applications, priority applications and inventors’ certificates, extensions and supplemental certificates and any and all foreign equivalents of the foregoing. 

1.60 “Person” means any individual, partnership, limited liability company, firm, corporation, association, trust,
unincorporated organization or other entity. 
 1.61 “Phase 2 Clinical Trial” means a human clinical trial that would
satisfy the requirements for a Phase 2 study as defined in 21 CFR § 312.21(b) (or any amended or successor regulations) or any equivalent regulations in other countries in the Territory, regardless of where such clinical trial is conducted.

 1.62 “Phase 3 Clinical Trial” means a human clinical trial that would satisfy the requirements for a Phase 3 study
as defined in 21 CFR § 312.21(c) (or any amended or successor regulations) or any equivalent regulations in other countries in the Territory, regardless of where such clinical trial is conducted. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

9 

			
	Confidential	  	EXECUTION VERSION

  

 1.63 “Pilocarpine” means the drug known by the generic name
pilocarpine, having the chemical structure set forth in Exhibit B, and/or any pharmaceutically acceptable salt form, base form, pro-drug, ester, ether, isomer, metabolite, crystalline polymorph, and hydrate or
solvate thereof. 
 1.64 “Pivotal Trial” means: (a) a Phase 3 Trial; or (b) any other human clinical trial
that the applicable Regulatory Authority has agreed, whether before first dosing of the first patient in such trial (e.g., pursuant to a special protocol assessment agreement with the FDA) or after first dosing of the first patient in such trial
(e.g., based on an interim data analysis), is sufficient to form the primary basis of an efficacy claim in an MAA submission, regardless of whether the sponsor of such trial characterizes or refers to such trial as a “Phase 3,” “Phase
2b” or “Phase 2b/3” trial (or otherwise) in the applicable protocol, on clinicaltrials.gov, or in any other context. If a human clinical trial does not constitute a Pivotal Trial at the time of first dosing of the first patient in
such trial, but is later determined by the applicable Regulatory Authority to be sufficient to form the primary basis of an efficacy claim in an MAA submission, then, for purposes of Section 8.2 (Regulatory Milestone Payments) hereof, and
notwithstanding Section 1.40 (Initiation) hereof, “Initiation” of such Pivotal Trial shall be deemed to have occurred on the date of such determination by the applicable Regulatory Authority. 

1.65 “PMDA” means Japan’s Pharmaceuticals and Medical Devices Agency or any successor entity thereto. 

1.66 “Pricing Approval” means such governmental approval, agreement, determination or decision establishing prices for
a Licensed Product that can be charged and/or reimbursed in a regulatory jurisdiction where the applicable Governmental Authorities approve or determine the price and/or reimbursement of pharmaceutical products and where such approval or
determination is necessary for the commercial sale of such Licensed Product in such jurisdiction. 
 1.67 “Product
Infringement” has the meaning set forth in Section 9.4(a) (Notice). 
 1.68 “Proprietary Drug” means
(a) the Initial Proprietary Drug and (b) any other product that comprises a fixed-dose combination of two or more Muscarinic Modulators (but does not comprise or contain any Other Active). 

1.69 “Receiving Party” has the meaning set forth in Section 10.1(a) (Duty of Confidence—subsection (a)). 

1.70 “Regulatory Approval” means all approvals, including Pricing Approvals and MAAs, that are necessary for the
commercial sale of a Licensed Product in a given country or regulatory jurisdiction. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

10 

			
	Confidential	  	EXECUTION VERSION

  

 1.71 “Regulatory Authority” means any applicable Government Authority
responsible for granting Regulatory Approvals for Licensed Product, including the FDA, the EMA, the PMDA, and any corresponding national or regional regulatory authorities. 

1.72 “Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any
Regulatory Authority with respect to a pharmaceutical product other than Patents, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, or pediatric exclusivity. 

1.73 “Regulatory Filings” means, with respect to a Proprietary Drug or Licensed Products, any submission to a
Regulatory Authority of any appropriate regulatory application specific to the Proprietary Drug or Licensed Products, and shall include, without limitation, any submission to a regulatory advisory board and any supplement or amendment thereto. For
the avoidance of doubt, Regulatory Filings shall include any IND, NDA, MAA, Regulatory Approval or the corresponding application in any other country or jurisdiction. 

1.74 “Roivant Know-How” means all
Know-How that Roivant Controls as of the Effective Date or during the Term that is necessary or reasonably useful for the Development, manufacture or Commercialization of any Proprietary Drug or Licensed
Product in the Field, including Roivant’s Sole Inventions and Roivant’s joint ownership interest in Joint Inventions. 

1.75 “Roivant Indemnitees” has the meaning set forth in Section 13.1 (Indemnification by TheraVida). 

1.76 “Roivant Patents” means all Patents that Roivant Controls as of the Effective Date or during the Term that are
necessary or reasonably useful for the Development, manufacture or Commercialization of any Proprietary Drug or Licensed Product in the Field. For clarity, Roivant Patents include Roivant’s joint ownership interest in Joint Patents. 

1.77 “Roivant Technology” means the Roivant Know-How and the Roivant Patents.

 1.78 “Royalty Term” has the meaning set forth in Section 8.4(b) (Royalty Term). 

1.79 “SEC” has the meaning set forth in Section 10.5(a) (Publicity/Use of Names—subsection (a)). 

1.80 “Selling Party” has the meaning set forth in Section 1.56 (Net Sales). 

1.81 “Sole Inventions” has the meaning set forth in Section 9.1(a) (Ownership of Inventions). 

1.82 “Sublicense” means a license or sublicense to Develop, make, use, import, promote, offer for sale or sell any
Proprietary Drug or Licensed Product. 
 1.83 “Sublicensee” means a Third Party to whom Roivant or its Affiliate has
granted a Sublicense in accordance with the terms of this Agreement. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

11 

			
	Confidential	  	EXECUTION VERSION

  

 1.84 “Sublicensee Revenue” means all amounts received by Roivant and
its Affiliates from any Sublicensee in consideration of the grant to such Sublicensee of a Sublicense. Without limiting the generality of the foregoing, Sublicensee Revenue shall include up-front fees, license
fees, milestone payments (except as expressly specified below), technology access fees, premiums above the fair market value on sales of debt or equity securities of Roivant or its Affiliate, and annual agreement maintenance fees, and any other
payments attributable to the grant to such Sublicensee of a Sublicense; provided, however, that [***]. Notwithstanding the foregoing, Sublicensee Revenue shall exclude: (i) royalties and commercial milestone payments paid or
payable by any Sublicensee to Roivant or its Affiliates with respect to a Sublicensee’s sales or other dispositions of Proprietary Drugs or Licensed Products; (ii) bona fide research and development funding (e.g., FTE
funding) received from a Sublicensee for Roivant’s or its Affiliate’s employees’ performance of specified research and development work with respect to any Proprietary Drug or Licensed Product after the date of the Sublicense, which
may be calculated on a fully-burdened basis, and reimbursement by such Sublicensee of documented external costs incurred by Roivant or its Affiliate after the date of the Sublicense for specialized materials (except for standard materials costs
included in Roivant’s or its Affiliate’s fully-burdened FTE rate), specialized equipment and Third Party services, in each case, specifically for such specified research and development work with respect to any Proprietary Drug or Licensed
Product; (iii) payments for equity securities of Roivant or its Affiliate [***], as determined in good faith by Roivant’s or its Affiliate’s Board of Directors, if such securities are not then traded on a public securities exchange,
or as determined by the closing price of such securities of Roivant or its Affiliate (as applicable) on the date of receipt, if such securities are then traded on a public securities exchange; (iv) payments for debt securities of Roivant or its
Affiliate [***] in full (whether in cash or in kind); and (v) payments and reimbursements by any Sublicensee of patent costs actually incurred by Roivant or its Affiliate after the date of the Sublicense. 

1.85 “Tax” or “Taxes” means any (a) all federal, provincial, territorial, state, municipal,
local, foreign or other taxes, imposts, rates, levies, assessments and other charges in the nature of a tax (and all interest and penalties thereon and additions thereto imposed by any governmental authority), including without limitation all
income, excise, franchise, gains, capital, real property, goods and services, transfer, value added, gross receipts, windfall profits, severance, ad valorem, personal property, production, sales, use, license, stamp, documentary stamp, mortgage
recording, employment, payroll, social security, unemployment, disability, escheat, estimated or withholding taxes, and all customs and import duties, together with all interest, penalties and additions thereto imposed with respect to such amounts,
in each case whether disputed or not; (b) any liability for the payment of any amounts of the type described in clause (a) as a result of being or having been a member of an affiliated, consolidated, combined 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

12 

			
	Confidential	  	EXECUTION VERSION

  

 or unitary group; and (c) any liability for the payment of any amounts as a result of
being party to any tax sharing agreement or arrangement or as a result of any express or implied obligation to indemnify any other person with respect to the payment of any amounts of the type described in clause (a) or (b). 

1.86 ”Term” has the meaning set forth in Section 11.1 (Term). 

1.87 “Territory” means worldwide, excluding the Republic of Korea and the Democratic People’s Republic of Korea.

 1.88 “TheraVida CMOs” has the meaning set forth in Section 6.2(b) (Manufacturing Technology
Transfer—subsection (b)). 
 1.89 “TheraVida Indemnitees” has the meaning set forth in Section 13.2
(Indemnification by Roivant). 
 1.90 “Third Party” means any Person other than a Party or an Affiliate of a Party.

 1.91 “Third Party Licenses” has the meaning set forth in Section 8.5(a) (Royalty Adjustments for Third Party
Royalties). 
 1.92 “THVD-102” means TheraVida’s proprietary fixed-dose
combination of Oxybutynin and Pilocarpine known as THVD-102, in the form and formulation described in Exhibit A hereto. 

1.93 “Transfer Plan” has the meaning set forth in Section 2.4 (Initial Transfer of
Know-How and Materials). 
 1.94 “Transfer Tax” has the meaning set forth in
Section 8.9(c) (Transfer Tax). 
 1.95 “United States” or “U.S.” means the United States of America
including its territories and possessions. 
 1.96 “Valid Claim” means, with respect to any country, a claim
contained in (a) an issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) which has not been held unenforceable, unpatentable or invalid by a decision of a court or
other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise, or (b) a
patent application that has not been irretrievably cancelled, withdrawn or abandoned and that has been pending for less than (i) [***] from the filing date from which such claim takes priority in the case of a U.S. patent application or (ii) [***]
from the filing date from which such claim takes priority in the case of any non-U.S. patent application. If a claim of a patent application that ceased to be a Valid Claim under clause (b) of the
preceding sentence because of the passage of time later issues as a part of a patent within clause (a) of the preceding sentence, then it shall again be considered a Valid Claim effective as of the issuance of such patent. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

13 

			
	Confidential	  	EXECUTION VERSION

  

 1.97 Interpretation. In this Agreement, unless otherwise specified: 

(a) “includes” and “including” shall mean, respectively, includes without limitation and including without
limitation; 
 (b) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all
genders; 
 (c) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and
not merely to the particular provision in which such words appear; and 
 (d) the Exhibits and other attachments form part of the
operative provision of this Agreement and references to this Agreement shall include references to the Exhibits and attachments. 

ARTICLE 2 
 LICENSE

 2.1 Licenses to Roivant. Subject to the terms and conditions of this Agreement, TheraVida hereby grants to Roivant an
exclusive (even as to TheraVida, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses including through multiple tiers in accordance with Section 2.2 (Sublicense Rights), under the Licensed
Technology to research, Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize Proprietary Drugs and Licensed Products, in each case, in the Field in the Territory. 

2.2 Sublicense Rights. Subject to the terms of this Section 2.2 (Sublicense Rights), Roivant may grant a sublicense of the
licenses granted in Section 2.1 (Licenses to Roivant) through multiple tiers to an Affiliate of Roivant or any Third Party without the prior written authorization of TheraVida. Each authorized sublicense granted hereunder, if any, whether to an
Affiliate or Sublicensee, shall (a) be in writing, (b) be subject and subordinate in all respects to, and consistent with, all terms of this Agreement and (c) incorporate terms and conditions sufficient to enable Roivant to comply
with this Agreement. Roivant shall provide TheraVida with a copy of any sublicense agreement entered into by Roivant or its Affiliate, and any amendment thereto, within [***] of its execution (provided that Roivant may redact from such copy any
confidential information contained therein that is not necessary to ascertain compliance with this Agreement). Roivant shall be liable for the failure of its Affiliates and Sublicensees to comply with this Agreement and shall, [***], enforce
compliance by Affiliates and Sublicensees with the terms of their respective sublicense agreements. 
 2.3 TheraVida’s
Retained Rights. TheraVida retains the right under the Licensed Technology to exercise its rights and perform its obligations under this Agreement. In addition, but subject to Section 2.6 (Exclusivity), TheraVida retains, and hereby
expressly reserves, the exclusive right to practice, and to grant licenses under, the Licensed Technology for any and all purposes other than the specific purposes for which the Licensed Technology is exclusively licensed to Roivant under
Section 2.1 (Licenses to Roivant). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

14 

			
	Confidential	  	EXECUTION VERSION

  

 2.4 Initial Transfer of Know-How and
Materials. As promptly as practicable (and in any event within [***]) after the Effective Date, the Parties shall agree on a plan for the transfer of Licensed Know-How (including the data therein) and
certain tangible materials Controlled by TheraVida as of the Effective Date to Roivant (the “Transfer Plan”). As soon as practical after mutual agreement on the Transfer Plan, TheraVida shall commence disclosing and making available
to Roivant the Licensed Know-How and materials listed in the Transfer Plan, according to the timeline set forth in the Transfer Plan, and will complete such transfer no later than [***] after the Parties
mutually agree on the Transfer Plan. The Parties shall cooperate with each other in good faith to enable a smooth transfer of the Licensed Know-How to Roivant. [***], TheraVida shall provide reasonable
technical assistance, including making appropriate existing personnel available to Roivant at reasonable times, places and frequency, and [***], for the purpose of assisting Roivant to understand and use the Licensed
Know-How in connection with Roivant’s Development of Licensed Products. For clarity, TheraVida makes no representation or warranty, and does not covenant, that any such assistance provided by TheraVida
will enable Roivant to Develop Licensed Products, and TheraVida shall have no obligation to obtain or generate any Know-How that is not within TheraVida’s possession and Control as of the Effective Date.
If, during the Term and as a result of discussions between the Parties via the JDC (or otherwise), either: (a) TheraVida becomes aware of Licensed Know-How that was Controlled by TheraVida as of the
Effective Date but, despite TheraVida’s good faith efforts to identify and include in the Transfer Plan all Licensed Know-How existing on the Effective Date, was not identified and included in the
Transfer Plan and disclosed and made available to Roivant; or (b) one or both Parties become aware of Licensed Know-How that first came within the Control of TheraVida after the Effective Date and was
therefore not included in the Transfer Plan and transferred to Roivant pursuant thereto; then, in each case ((a) and (b)), TheraVida shall promptly disclose and make available such Licensed Know-How to Roivant
and shall provide reasonable technical assistance, including making appropriate then-current personnel available to Roivant at reasonable times, places and frequency, and upon reasonable prior notice, for the purpose of assisting Roivant to
understand and use such Licensed Know-How in connection with Roivant’s Development of Licensed Products; provided that [***]. 

2.5 No Implied Licenses; Negative Covenant. Except as set forth herein, neither Party shall acquire any license or other
intellectual property interest, by implication or otherwise, under any Know-How, Patents, trademarks or other intellectual property rights owned or controlled by the other Party. Roivant hereby covenants not
to practice, and not to permit or cause any of its Affiliate or any Third Party to practice, any Licensed Technology for any purpose other than as expressly authorized in this Agreement. Without limiting the generality of the foregoing, Roivant
shall not, directly or indirectly: (a) practice Licensed Technology to Develop, make, have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise Commercialize any Proprietary Drug or Licensed Product for use
(i) outside of the Field or (ii) outside of the Territory; or (b) permit or cause any of its Affiliates or any Third Party to engage in any of the activities described in the preceding clause (a). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

15 

			
	Confidential	  	EXECUTION VERSION

  

 2.6 Exclusivity. During the Term of this Agreement, TheraVida shall not
conduct, itself or through an Affiliate or Third Party, and shall not enable a Third Party to conduct, any clinical development, promotion or commercialization of any product: (a) comprising a Muscarinic Modulator or a combination of two or
more Muscarinic Modulators or (b) for the [***]. 
 ARTICLE 3 

GOVERNANCE 
 3.1
Joint Development Committee. Within [***] after the Effective Date, the Parties shall establish a joint development committee (the “Joint Development Committee” or the “JDC”), composed of one
(1) representative of each Party, to guide the collaboration of the Parties under this Agreement and to oversee the exchange of information between the Parties with respect to the Development of Proprietary Drugs and Licensed Products until the
end of the first Phase 3 Clinical Trial for any Licensed Product. Each JDC representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the
JDC’s responsibilities. The JDC shall in particular: 
 (a) provide a forum for the discussion of the Development of Proprietary
Drugs and Licensed Products until the end of the first Phase 3 Clinical Trial for any Licensed Product; 
 (b) oversee the transfer of
Licensed Know-How and materials to Roivant under Section 2.4 (Initial Transfer of Know-How and Materials); and 

(c) provide a forum for Roivant to keep TheraVida reasonably informed regarding the Development of Licensed Products including the
status of any Regulatory Filings, Regulatory approvals, or clinical trials. 
 The JDC shall have only such powers as are expressly assigned to it in this
Agreement, and such powers shall be subject to the terms and conditions of this Agreement. For clarity, the JDC shall primarily be advisory and provide a forum for information exchange, with Roivant having ultimate decision making authority to the
extent any decisions must be made by the JDC; provided, however, that neither the JDC, nor Roivant in the exercise of its ultimate decision making authority, shall have any right, power or authority: (i) to determine any issue in a manner that
would conflict with the express terms and conditions of this Agreement; or (ii) to modify or amend the terms and conditions of this Agreement. Upon the first approval by the FDA of an NDA for any Licensed Product or the first approval by the
EMA of an MAA for any Licensed Product (whichever occurs first), the JDC will cease to exist and the Parties will no longer have any obligations with respect to the JDC. 

3.2 JDC Membership and Meetings. 

(a) Members. TheraVida’s initial JDC representative will be [***], TheraVida, Inc. and Roivant’s initial JDC
representative will be [***], Dermavant Sciences, Inc. Each Party may replace its JDC representative on written notice to the other 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

16 

			
	Confidential	  	EXECUTION VERSION

  

 
Party, but each Party shall strive to maintain continuity. The JDC members shall jointly prepare an agenda and shall direct the preparation of reasonably detailed minutes for each JDC meeting,
which shall be approved and circulated within [***] of such meeting. 
 (b) Meetings. The JDC shall hold meetings at such times
as it elects to do so, but in no event shall such meetings be held less frequently than once every [***]. Meetings may be held in person, or by audio or video teleconference; provided, that unless otherwise agreed by both Parties, at least one
(1) meeting per year shall be held in person, and all in-person JDC meetings shall be held at locations alternately selected by the Parties. Each Party shall be responsible for all of its own expenses of
participating in JDC meetings. 
 (c) Non-Member Attendance. Each Party may from time
to time invite a reasonable number of participants, in addition to its representative, to attend JDC meetings in a non-voting capacity; provided, that if either Party intends to have any Third Party (including
any consultant) attend such a meeting, such Party shall provide at least [***] prior written notice to the other Party and obtain the other Party’s approval for such Third Party to attend such meeting, which approval shall not be unreasonably
withheld or delayed. Such Party shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement. 

ARTICLE 4 
 DEVELOPMENT

 4.1 General. Subject to the terms and conditions of this Agreement, Roivant shall be solely responsible for the
Development of Proprietary Drugs and Licensed Products in the Field in the Territory, including the performance of preclinical and clinical studies of any Proprietary Drug or Licensed Product in the Field and the manufacture and supply of
Proprietary Drugs and Licensed Products for use in such Development work. Roivant shall provide TheraVida with [***], both via the JDC and in accordance with Section 4.5 (Development Reports), of its
pre-clinical and clinical Development plans, progress and results for Proprietary Drugs and Licensed Products. 

4.2 Development Diligence. Roivant, directly and/or with or through Affiliates or Sublicensees, shall use Commercially Reasonable
Efforts to Develop, and to obtain Regulatory Approval with respect to, at least one Proprietary Drug and Licensed Product in the Field in [***]. For clarity, such Commercially Reasonable Efforts shall be determined on a country-by-country basis [***]and it is anticipated that the level of efforts constituting Commercially Reasonable Efforts in one country [***] may differ from the level of
efforts constituting Commercially Reasonable Efforts in another country [***]. Without limiting the generality of the foregoing, the Parties acknowledge that Roivant may prioritize the Development of a Licensed Product in one or more countries [***]
over the Development of a Licensed Product in another country [***] and that the timing of Development may differ in each country [***], and the Parties agree that such prioritization and timing of Development shall not, by themselves, cause
Roivant’s Development efforts in any such country not to constitute Commercially Reasonable Efforts. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

17 

			
	Confidential	  	EXECUTION VERSION

  

 4.3 Development Costs. As between the Parties, Roivant shall be solely
responsible for the cost for the Development of Proprietary Drugs and Licensed Products in the Field in the Territory. 
 4.4
Development Records. Roivant shall use Commercially Reasonable Efforts to maintain reasonably complete, current and accurate records of all Development activities conducted by or on behalf of Roivant, its Affiliates and Sublicensees for any
Proprietary Drug and Licensed Product in the Field, and all data and other information resulting from such activities. Such records shall properly reflect all work done and results achieved in the performance of the Development activities in good
scientific manner appropriate for regulatory and patent purposes. 
 4.5 Development Reports. Roivant shall keep TheraVida
reasonably informed as to the progress and results of its and its Affiliates’ and Sublicensees’ Development and regulatory activities under this Agreement. Without limiting the foregoing, on [***] of each year beginning on [***], Roivant
shall provide TheraVida with a written report summarizing material Development and regulatory activities performed in the preceding Calendar Year and the results thereof, and the Development and regulatory activities planned for the current Calendar
Year. Roivant shall promptly respond to TheraVida’s reasonable questions or requests for additional information relating to the progress and results of its and its Affiliates’ and Sublicensees’ Development and regulatory activities
under this Agreement. In addition, [***], Roivant and TheraVida will meet to discuss the status of the Development and regulatory activities within a reasonable time [***]. Such meeting may occur either in person, telephonically, or by video
conference at TheraVida’s discretion. 
 4.6 Compliance. Roivant agrees that in performing its obligations under this
Agreement: (a) it shall comply with all Applicable Laws; and (b) it will not employ or engage any Person who has been debarred or disqualified by any Regulatory Authority, or, to its knowledge, is the subject of debarment or
disqualification proceedings by a Regulatory Authority. 
 4.7 Subcontractor. Roivant shall have the right to engage
subcontractors for the performance of its obligations under the Agreement, and shall cause the subcontractor(s) engaged by it to be bound by written obligations of confidentiality and non-use of
TheraVida’s Confidential Information and invention assignment consistent with those contained herein, and Roivant shall remain primarily responsible for the performance of such subcontractor(s). 

ARTICLE 5 
 REGULATORY

 5.1 Regulatory Responsibilities. Roivant shall be responsible for all regulatory activities necessary to obtain and
maintain Regulatory Approval of Proprietary Drugs and Licensed Products in the Field in the Territory. Roivant shall keep TheraVida informed of regulatory developments related to Proprietary Drugs and Licensed Products in the Field in the Territory
both via the JDC and Roivant’s reports pursuant to Section 4.5 (Development Reports). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

18 

			
	Confidential	  	EXECUTION VERSION

  

 5.2 Regulatory Filings. Roivant shall prepare and submit all Regulatory Filings
for Proprietary Drugs and Licensed Products in the Field in the Territory and shall own all Regulatory Filings and Regulatory Approvals for Proprietary Drugs and Licensed Products in the Field in the Territory. 

5.3 Adverse Events. With respect to adverse experiences associated with the Licensed Product in the Field in the Territory, after
the Effective Date, Roivant shall be solely responsible for the collection, review, assessment, tracking and regulatory submission of the adverse experiences in the Territory, in accordance with the Applicable Laws governing adverse experiences in
the Territory. 
 5.4 Legacy Safety Data. As soon as possible after the Effective Date, TheraVida shall provide Roivant with an
electronic copy of the CIOMS I forms of all legacy data of adverse events within TheraVida’s safety database with respect to the Licensed Product that is within TheraVida’s possession, for inclusion in Roivant’s safety database for
the Licensed Product; provided, that TheraVida shall promptly provide Roivant with any CIOMS I received or generated by TheraVida referencing the Licensed Product following the Effective Date. 

5.5 Global Safety Database. [***] after the Effective Date, or sooner if agreed between the Parties, TheraVida shall transfer the
global safety database for Licensed Product to Roivant and, thereafter, Roivant will maintain the global safety database pursuant to its own policy and as necessary to comply with Applicable Laws governing adverse experiences in the Territory. 

ARTICLE 6 
 MANUFACTURING

 6.1 Manufacturing Responsibilities. Roivant shall be solely responsible for all preclinical, clinical and commercial
manufacture and supply of Proprietary Drugs and Licensed Products for all uses under this Agreement, at its sole expense. Roivant may conduct such manufacturing activities itself or through a Third Party CMO, subject to Section 4.7
(Subcontractor). 
 6.2 Manufacturing Technology Transfer. In order to enable Roivant to manufacture Proprietary Drugs and
Licensed Products, TheraVida shall perform or facilitate technology transfer to Roivant as set forth below: 
 (a) During a mutually
agreed time period of no more than [***] (the “Manufacturing Transfer Period”), TheraVida shall make available and transfer to Roivant, copies of existing embodiments of the Licensed Know-How
in TheraVida’s possession that are necessary or useful in the manufacture of Proprietary Drugs and Licensed Products and as of such date are being used by TheraVida to manufacture Proprietary Drugs and Licensed Products (the “Licensed
Manufacturing Know-How”) solely for Roivant and/or its contract manufacturer to manufacture or have manufactured Proprietary Drugs and Licensed Products in accordance with the terms and conditions of
this Agreement. To the extent that any Licensed Manufacturing Know-How is in the Control of TheraVida but is in the possession of a Third Party CMO of TheraVida (and is not in TheraVida’s possession),
Section 6.2(b) shall apply. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

19 

			
	Confidential	  	EXECUTION VERSION

  

 (b) During the Manufacturing Transfer Period, [***], TheraVida will provide
(i) introductions to TheraVida’s Third Party CMOs (“TheraVida CMOs”) for Proprietary Drugs and Licensed Products and (ii) written authorization and instructions to any such TheraVida CMO in possession of Licensed
Manufacturing Know-How to make such Licensed Manufacturing Know-How available to Roivant and its Affiliates [***] (it being understood that if Roivant wishes to have a
TheraVida CMO perform technology transfer to Roivant or its designee with respect to Licensed Manufacturing Know-How other than providing copies of existing embodiments of Licensed Manufacturing Know-How in the Control of TheraVida but in the possession of the TheraVida CMO, [***]). Roivant, in its sole discretion [***], may contract with any such TheraVida CMO for technical assistance (both on site and
otherwise) in the transfer and demonstration of the Licensed Manufacturing Know-How that is necessary to manufacture Proprietary Drugs and Licensed Products. After the Manufacturing Transfer Period, if
requested by Roivant, TheraVida will in good faith endeavor to provide additional technical assistance in the transfer of Licensed Manufacturing Know-How to Roivant. 

ARTICLE 7 

COMMERCIALIZATION 

7.1 General. Subject to the terms and conditions of this Agreement, Roivant shall be responsible for all aspects of the
Commercialization of the Licensed Products in the Field in the Territory, including: (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable governmental
authorities regarding the price and reimbursement status of the Licensed Products and obtaining and maintaining Pricing Approvals; (c) marketing and promotion; (d) booking sales and distribution and performance of related services;
(e) handling all aspects of order processing, invoicing and collection, inventory and receivables; (f) providing customer support, including handling medical queries, and performing other related functions; and (g) conforming its
practices and procedures to Applicable Law relating to the marketing, detailing and promotion of Licensed Products in the Field in the Territory. As between the Parties, Roivant shall be solely responsible for the costs and expenses of
Commercialization of the Licensed Products in the Field in the Territory. 
 7.2 Commercial Diligence. Roivant, directly and/or
with or through Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field in each country in the Territory in which it receives Regulatory Approval. 

7.3 Commercialization Reports. Roivant shall keep TheraVida reasonably informed of Roivant’s, its Affiliates’ and
Sublicensees’ Commercialization activities with respect to the Licensed Products in the Field in the Territory. Without limiting the foregoing, on [***] of each Calendar Year, beginning in the Calendar Year of Roivant’s first submission of
an MAA for a Licensed Product in the Territory, Roivant shall provide TheraVida with a written report summarizing material Commercialization activities with respect to the Licensed 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

20 

			
	Confidential	  	EXECUTION VERSION

  

 Products in the Field in the Territory performed in the preceding Calendar Year and Commercialization
activities with respect to the Licensed Products in the Field in the Territory planned for the current Calendar Year. Roivant shall promptly respond to TheraVida’s reasonable questions or requests for additional information relating to the
progress and results of its and its Affiliates’ and Sublicensees’ Commercialization activities under this Agreement. In addition, [***], Roivant and TheraVida will hold a meeting to discuss the status of the Commercialization activities
within a reasonable time [***]. Such meeting may occur either in person, telephonically, or by video conference at the Parties’ discretion. 

ARTICLE 8 
 FINANCIAL
PROVISIONS 
 8.1 Upfront Payment. Within ten (10) Business Days after the Effective Date, Roivant shall pay to
TheraVida a one-time, non-refundable and non-creditable upfront payment of two million Dollars ($2,000,000). 

8.2 Regulatory Milestone Payments. Within [***] after the first achievement of each milestone event below by or on behalf of
Roivant or any of its Affiliates or Sublicensees, Roivant shall notify TheraVida of the achievement of such milestone event and TheraVida shall invoice Roivant for the applicable non-refundable, non-creditable milestone payment corresponding to such milestone event as shown below. Roivant shall remit payment to TheraVida within [***] of the receipt of such invoice. 

 

			
	 Regulatory Milestone Events
	  	Milestone Payments (in
U.S. Dollars)
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

21 

			
	Confidential	  	EXECUTION VERSION

  

 8.3 Commercial Milestones. 

(a) Within [***] after the end of the Calendar Quarter in which Aggregate Annual Net Sales of all Licensed Products in the Territory in
a Calendar Year first reach any threshold indicated in the milestone events listed below, Roivant shall notify TheraVida of the achievement of such milestone event and TheraVida shall invoice Roivant for the corresponding non-refundable, non-creditable milestone payment set forth below. Roivant shall remit payment to TheraVida within [***] of the receipt of such invoice. 

 

			
	 Annual Net Sales Milestone Events
	  	Milestone Payments
(in U.S. Dollars)
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 (b) For purposes of determining whether a Net Sales milestone event has been achieved, Net Sales of all
Licensed Products in the Territory shall be aggregated. For clarity, each of the annual Net Sales milestone payments set forth in Section 8.3(a) (Commercial Milestones—subsection (a)) shall be payable only once for all Licensed Products,
upon the first achievement of the applicable milestone event. 
 (c) If a Milestone Event in Section 8.3(a) (Commercial
Milestones—subsection(a)) is achieved and payment with respect to any previous milestone event has not been made, then such previous milestone event shall be deemed achieved, TheraVida shall invoice Roivant for such unpaid previous milestone
event(s) and Roivant shall pay TheraVida such unpaid previous milestone payment(s) within [***] of receipt of such invoice. If more than one Milestone Event in Section 8.3(a) (Commercial Milestones—subsection(a)) is achieved in a Calendar
Year, then the corresponding milestone payment for each such achievement shall be due and owing with respect to such Calendar Year. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

22 

			
	Confidential	  	EXECUTION VERSION

  

 8.4 Royalty Payments. 

(a) Royalty Rate. Roivant shall pay to TheraVida non-refundable, non-creditable royalties on aggregate annual Net Sales of all Licensed Products in the Territory in each Calendar Year (“Aggregate Annual Net Sales”) at the applicable rate(s) set forth below, with
such royalties to be calculated by multiplying the applicable incremental amount of Aggregate Annual Net Sales in such Calendar Year by the corresponding royalty rate set forth in the table below: 

 

			
	 Aggregate Annual

Net Sales of the Licensed Products
	  	Royalty Rate
	 [***]
	  	[***]
	 [***]
	  	[***]

 (b) Royalty Term. Royalties under this Section 8.4 (Royalty Payments) shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis from the First Commercial
Sale of a Licensed Product in a country until the latest of: (i) expiration of the last-to-expire Valid Claim of the Licensed Patents that would, but for the
licenses granted hereunder, be infringed by the manufacture, use or sale of such Licensed Product (or the Proprietary Drug contained therein) in such country in the Territory; (ii) expiration of Regulatory Exclusivity for such Licensed Product
in such country; and (iii) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country (the “Royalty Term” for such Licensed Product and country). 

(c) Royalty Reports and Payment. Within [***] after each Calendar Quarter, commencing with the Calendar Quarter during which the
First Commercial Sale of any Licensed Product is made anywhere in the Territory, Roivant shall provide TheraVida with a report that contains the following information for the applicable Calendar Quarter, on a Licensed
Product-by-Licensed Product and country-by-country basis: (i) gross sales and Net
Sales in the Territory; (ii) itemized deductions from gross sales (by each subsection set forth in the definition of Net Sales); (iii) a calculation of the royalty payment due on Net Sales in the Territory, including details of any royalty
adjustments made pursuant to Section 8.5(a) (Royalty Adjustment for Third Party Royalties) on a Third Party License-by-Third Party License basis and any other
royalty adjustments made pursuant to Section 8.5 (Royalty Adjustments); (iv) Sublicensee Revenue received on a Sublicensee-by-Sublicensee basis and amounts due
thereon pursuant to Section 8.6 (Sublicensing Revenue); and (v) the exchange rates used. Concurrent with the delivery of such report, Roivant will pay TheraVida all royalties owed with respect to Net Sales and all amounts due with respect
to Sublicensee Revenue for such Calendar Quarter. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

23 

			
	Confidential	  	EXECUTION VERSION

  

 8.5 Royalty Adjustments. Except as otherwise set forth in this Agreement,
royalties due hereunder are subject to adjustment as set forth below (such adjustments to be prorated for the Calendar Quarter in which the adjustment becomes applicable). 

(a) Royalty Adjustment for Third Party Royalties. If Roivant or any of its Affiliates or Sublicensees determines, in its
reasonable judgment, that it is necessary or reasonably useful to obtain one or more licenses under Patents of Third Parties in order to manufacture, use or sell a Proprietary Drug in a country (hereinafter “Third Party Licenses”),
[***] of the royalties with respect to sales of Licensed Products containing such Proprietary Drug (or commercial milestone payments specifically and solely attributable to sales of Licensed Products containing such Proprietary Drug) actually paid
under such Third Party Licenses by Roivant or its Affiliate or Sublicensee in such country in a Calendar Quarter will be creditable against the royalty payments owed by Roivant to TheraVida with respect to Net Sales of such Licensed Product in such
country pursuant to Section 8.4(a) (Royalty Rate) for such Calendar Quarter; provided, however, that in no event will the royalties owed by Roivant to TheraVida pursuant to Section 8.4(a) (Royalty Rate) with respect to Net Sales of
such Licensed Product in such country for such Calendar Quarter be reduced by more than [***] as a result of any and all such credits in the aggregate; and provided, further, that Roivant will not be entitled to credit any portion of
royalties or commercial milestone payments paid by Roivant or its Affiliate or Sublicensee to Third Parties with respect to Patents claiming or covering any Other Active. 

(b) Royalty Adjustment for No Valid Claim. During any portion of the Royalty Term for a Licensed Product in a country when no
Valid Claim of the Licensed Patents would be infringed (or, in the case of a Valid Claim in a pending patent application, would be infringed if issued) by the manufacture, use, sale, offer for sale or import of such Licensed Product or the
Proprietary Drug contained therein in such country, but there is Regulatory Exclusivity for such Licensed Product in such country, the royalties payable under Section 8.4(a) (Royalty Rate) with respect to Net Sales of such Licensed Product in
such country shall be reduced by [***]. During any portion of the Royalty Term for a Licensed Product in a country when (A) no Valid Claim of the Licensed Patents would be infringed (or, in the case of a Valid Claim in a pending patent
application, would be infringed if issued) by the manufacture, use, sale, offer for sale or import of such Licensed Product or the Proprietary Drug contained therein in such country, and (B) there is no Regulatory Exclusivity for such Licensed
Product in such country, the royalties payable under Section 8.4(a) (Royalty Rate) with respect to Net Sales of such Licensed Product in such country shall be reduced by [***] 

(c) Royalty Adjustment for Generic Competition. If there is Generic Competition for a particular Licensed Product in a particular
country in a particular Calendar Quarter, the royalties payable to TheraVida on Net Sales of such Licensed Product in such country in such Calendar Quarter shall be reduced by [***] 

(d) Royalty Floor. In no event shall the effective royalty rate applicable to Net Sales of a Licensed Product in a country in a
Calendar Quarter be reduced to [***] of Net Sales of such Licensed Product in such country in such Calendar Quarter as a result of any and all adjustments made pursuant to Section 8.5(a) (Royalty Adjustment for Third Party Royalties),
Section 8.5(b) (Royalty Adjustment for No Valid Claim) and Section 8.5(c) (Royalty Adjustment for Generic Competition) in the aggregate. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

24 

			
	Confidential	  	EXECUTION VERSION

  

 8.6 Sublicensing Revenue. If Roivant or its Affiliate grants a Sublicense to a
Sublicensee [***] of any Licensed Product, Roivant shall pay to TheraVida [***] of all Sublicensee Revenue received from such Sublicensee. If Roivant grants a Sublicense to a Sublicensee [***] for any Licensed Product, Roivant shall pay to TheraVida
[***] of all Sublicensee Revenue received from such Sublicensee. Within [***] after receipt of any Sublicensee Revenue subject to this Section 8.6 (Sublicensing Revenue), Roivant shall notify TheraVida of the receipt of such Sublicensee Revenue
and the amount due to TheraVida and TheraVida shall invoice Roivant for the corresponding amount. Roivant shall remit payment to TheraVida within [***] of the receipt of such invoice. 

8.7 Currency; Exchange Rate. All payments to be made by Roivant to TheraVida under this Agreement shall be made in Dollars by
bank wire transfer in immediately available funds to a bank account designated by written notice from TheraVida. If any currency conversion shall be required in connection with any payment hereunder, such conversion shall be made by using the
exchange rates at the closing on the last Business Day of the Calendar Quarter to which such payment relates as reported in The Wall Street Journal on the following day. 

8.8 Late Payments. Late payments shall be subject to an interest charge of [***] per month, or maximum rate permitted by law,
whichever is lower. The payment of such interest shall not limit TheraVida from exercising any other rights it may have as a consequence of the lateness of any payment. 

8.9 Taxes. 

(a) Taxes on Income. Except as otherwise set forth in this Section 8.9 (Taxes), each Party shall be solely responsible for
the payment of all Taxes imposed on such Party’s income arising directly or indirectly from the activities of the Parties under this Agreement. 

(b) Tax Cooperation. The Parties agree to use commercially reasonable efforts to cooperate with one another and use commercially
reasonable efforts to avoid or reduce, to the extent permitted by Applicable Laws, tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Roivant to TheraVida under this Agreement. If
withholding taxes are imposed on any such payment, the liability for such taxes shall be the sole responsibility of TheraVida, and Roivant shall (i) deduct or withhold such Taxes from the payment made to TheraVida, (ii) timely pay such
Taxes to the proper taxing authority, and (iii) send proof of payment to TheraVida within [***] following such payment. Each Party shall comply with (or provide the other Party with) any certification, identification or other reporting
requirements that may be reasonably necessary in order for Roivant to not withhold Tax or to withhold Tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with commercially reasonable assistance
to enable the 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

25 

			
	Confidential	  	EXECUTION VERSION

  

 
recovery, as permitted by Applicable Laws, of withholding Taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of TheraVida as the
Party bearing the cost of such withholding Tax under this Section 8.9(b) (Tax Cooperation). Notwithstanding the foregoing, if as a result of any assignment or sublicense by Roivant, any change in Roivant’s tax residency, any change in the
entity that originates the payment, or any failure on the part of Roivant to comply with Applicable Laws with respect to withholding Taxes (including filing or record retention requirements), withholding Taxes are imposed that would not otherwise
have been imposed (“Incremental Withholding Taxes”), then Roivant shall be solely responsible for the amount of such Incremental Withholding Taxes and shall increase the amounts payable to TheraVida so that TheraVida receives a sum
equal to the sum which it would have received had there been no such imposition of Incremental Withholding Taxes, except to the extent that such Incremental Withholding Taxes would not have been imposed but for the failure of TheraVida to comply
with any certification, identification or other reporting requirements if such compliance is required or imposed by Applicable Law as a precondition to an exemption from, or reduction in, such Incremental Withholding Taxes. 

(c) Transfer Tax. Roivant shall bear and pay any transfer, stamp, value added, sales, use, or similar Taxes or obligations
(“Transfer Tax”) imposed on amounts payable by Roivant to TheraVida in connection with this Agreement. If TheraVida is required by Applicable Laws to directly pay any Transfer Taxes, Roivant shall indemnify TheraVida for such
Transfer Taxes and shall promptly reimburse TheraVida for any such Transfer Tax. Roivant shall be responsible for the timely filing of any Tax returns related to any such Transfer Taxes provided that TheraVida shall cooperate to file any such Tax
returns if required by Applicable Laws. 
 8.10 Financial Records and Audit. Roivant shall (and shall ensure that its
Affiliates and Sublicensees will) maintain complete and accurate records in sufficient detail to permit TheraVida to confirm the accuracy of any royalty payments and other amounts payable under this Agreement and to verify the achievement of
milestone events under this Agreement. Upon at least [***] prior notice, such records shall be open for examination, during regular business hours, for a period of [***] from the end of the Calendar Year to which such records pertain, and not more
often than [***], by an independent certified public accountant selected by TheraVida and reasonably acceptable to Roivant, for the sole purpose of verifying for TheraVida the accuracy of the financial reports furnished by Roivant under this
Agreement or of any payments made, or required to be made, by Roivant to TheraVida pursuant to this Agreement. The independent certified public accountant shall disclose to TheraVida only whether the audited reports are correct or incorrect and the
specific details concerning any discrepancies. No other information shall be provided to TheraVida. No record may be audited more than once. TheraVida shall bear the full cost of such audit unless such audit reveals an underpayment by Roivant of
more than [***] of the amount actually due for any Calendar Year being audited, in which case Roivant shall reimburse TheraVida for the reasonable costs for such audit. Roivant shall pay to TheraVida any underpayment discovered by such audit within
[***] after the accountant’s report, plus interest (as set forth in Section 8.8 (Late Payments)) from the original due date. If the audit reveals an overpayment by Roivant, then Roivant may take a credit for such overpayment against any
future payments due to TheraVida. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

26 

			
	Confidential	  	EXECUTION VERSION

  

 8.11 Audit Dispute. If Roivant disputes the results of any audit conducted
pursuant to Section 8.10 (Financial Records and Audit), the Parties shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***], the dispute shall be
submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the
Auditor shall be final and the costs of such procedure as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. If the Auditor determines that there has been an underpayment by Roivant, Roivant
shall pay to TheraVida the underpayment within [***] after the Auditor’s decision, plus interest (as set forth in Section 8.8 (Late Payments)) from the original due date. If the Auditor determines that there has been an overpayment by
Roivant, then Roivant may take a credit for such overpayment against any future payments due to TheraVida. 
 ARTICLE 9 

INTELLECTUAL PROPERTY RIGHTS 

9.1 Ownership. 

(a) Ownership of Inventions. Ownership of all Inventions shall be based on inventorship, as determined in accordance with the
rules of inventorship under United States patent laws. Each Party shall solely own any Inventions made solely by its or its Affiliates’ employees, agents or independent contractors (“Sole Inventions”). The Parties shall jointly
own any Inventions that are made jointly by one or more employees, agents or independent contractors of one Party or its Affiliates and one or more employees, agents or independent contractors of the other Party or its Affiliates (“Joint
Inventions”). All Patents claiming Joint Inventions shall be referred to herein as “Joint Patents.” Each Party agrees to assign, and hereby assigns, to the other Party an equal, undivided
one-half ownership in and to all Joint Inventions and Joint Patents. 
 (b) Disclosure of
Inventions. Each Party shall promptly disclose to the other Party all Sole Inventions that are related to Proprietary Drugs or Licensed Products and all Joint Inventions, including any invention disclosures or other similar documents submitted
by its respective employees, agents or independent contractors describing such Inventions, and shall promptly respond to reasonable requests from the other Party for additional information relating to such Inventions. 

9.2 Patent Prosecution and Maintenance. 

(a) Roivant shall have the sole right, but not the obligation, to control the preparation, filing, prosecution (including any
interferences, reissue proceedings and reexaminations) and maintenance of all Roivant Patents worldwide, [***] and by counsel of its own choice. Roivant shall have the first right, but not the obligation, to control the preparation, filing,
prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of all Joint Patents and Licensed Patents in the Territory, [***] and by counsel selected by Roivant and reasonably acceptable to 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

27 

			
	Confidential	  	EXECUTION VERSION

  

 
TheraVida. Roivant shall consult with TheraVida and keep TheraVida reasonably informed of the status of such Patents and shall promptly provide TheraVida with all material correspondence received
from any patent authority in connection therewith. In addition, Roivant shall promptly provide TheraVida with drafts of all proposed material filings and correspondence to any patent authority with respect to such Patents for TheraVida’s review
and comment prior to the submission of such proposed filings and correspondence. Roivant shall confer with TheraVida and consider in good faith TheraVida’s comments prior to submitting such filings and correspondence, provided that TheraVida
provides such comments within [***] (or a shorter period reasonably designated by Roivant if [***] is not practicable given the filing deadline) of receiving the draft filings and correspondence from Roivant. 

(b) In the event that Roivant desires to abandon or cease prosecution or maintenance of any Joint Patent or Licensed Patent, Roivant
shall provide reasonable prior written notice to TheraVida of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such
Patent in the relevant patent office). In such case, upon TheraVida’s written election provided no later than [***] after such notice from Roivant, TheraVida shall have the right to assume prosecution and maintenance of such Patent [***]. If
TheraVida does not provide such election within [***] after such notice from Roivant, Roivant may, in its sole discretion, continue prosecution and maintenance of such Patent or discontinue prosecution and maintenance of such Patent. 

9.3 Cooperation of the Parties. Each Party agrees to cooperate fully in the preparation, filing, prosecution and maintenance of
Patents under Section 9.2 (Patent Prosecution and Maintenance), at its own cost. Such cooperation includes: (a) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as
enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 9.2 (Patent Prosecution and Maintenance); and (b) promptly informing the other Party of any matters coming to such Party’s
attention that may affect the preparation, filing, prosecution or maintenance of any such patent applications. 
 9.4 Infringement
by Third Parties. 
 (a) Notice. In the event that either TheraVida or Roivant becomes aware of any infringement or
threatened infringement by a Third Party of any Licensed Patent, Roivant Patent or Joint Patent in the Territory, which infringing activity involves the using, making, importing, offering for sale or selling of a Licensed Product (regardless of
whether or not Roivant is currently Developing using, making, importing, offering for sale, selling, or otherwise Commercializing the same Licensed Product), or the submission to a Party or a Regulatory Authority in the Territory of an application
for a product referencing a Licensed Product, or any declaratory judgment or equivalent action (including an action before the U.S. Patent and Trademark Office such as an inter partes review) challenging any Licensed Patent, Roivant Patent or Joint
Patent in the Territory in connection with any such infringement (each, a “Product Infringement”), it will promptly notify the other Party in writing to that effect. Any such notice shall include evidence to support an allegation of
infringement or threatened infringement, or declaratory judgment or equivalent action, by such Third Party. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

28 

			
	Confidential	  	EXECUTION VERSION

  

 (b) Enforcement of Licensed Patents and Joint Patents. 

(i) Roivant shall have the first right, as between TheraVida and Roivant, but not the obligation, to bring an appropriate suit or take
other action against any Person or entity engaged in, or to defend against, a Product Infringement of any Licensed Patent or Joint Patent, [***] and by counsel of its own choice. TheraVida shall have the right, [***], to be represented in any such
action by counsel of its own choice, and Roivant and its counsel will reasonably cooperate with TheraVida and its counsel in strategizing, preparing and prosecuting any such action or proceeding. If Roivant fails to bring an action or proceeding
with respect to such Product Infringement of any Licensed Patent or Joint Patent within (A) [***] following the notice of alleged infringement or declaratory judgment or (B) [***] before the time limit, if any, set forth in the appropriate laws and
regulations for the filing of such actions, whichever comes first, TheraVida shall have the right, but not the obligation, to bring and control any such action [***] and by counsel of its own choice, and Roivant shall have the right, [***], to be
represented in any such action by counsel of its own choice. 
 (ii) Except as otherwise agreed by the Parties as part of a
cost-sharing arrangement, any recovery or damages realized as a result of such action or proceeding with respect to Product Infringement of any Licensed Patent or Joint Patent shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and any remaining compensatory damages relating to Product Infringement of a Licensed Patent or Joint Patent
(including lost sales or lost profits) shall be [***], and in the case that Roivant brought and controlled such action or proceeding, such remaining compensatory damages shall be [***] [***], and any punitive damages relating to Product Infringement
of a Licensed Patent or Joint Patent shall be [***]. 
 (c) Enforcement of Roivant Patents. Roivant shall have the sole right,
as between TheraVida and Roivant, but not the obligation, to bring an appropriate suit or take other action against any Person or entity engaged in, or to defend against, a Product Infringement of any Roivant Patents, [***] and by counsel of its own
choice. Any recovery or damages realized as a result of such action or proceeding by Roivant with respect to Roivant Patents shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and any remaining compensatory damages relating to Product Infringement of a Roivant Patent (including lost sales or lost profits) shall be
[***], and any punitive damages relating to Product Infringement of a Roivant Patent shall be [***]. 
 (d) Cooperation. In the
event a Party brings an action in accordance with this Section 9.4 (Infringement by Third Parties), the other Party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being named as a
party to such action. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

29 

			
	Confidential	  	EXECUTION VERSION

  

 9.5 Infringement of Third Party Rights. Each Party shall promptly notify the
other in writing of any allegation by a Third Party that the manufacture, Development, importation, use, marketing, offer for sale, or sale of any Proprietary Drug or Licensed Product in the Territory infringes or may infringe the intellectual
property rights of a Third Party. If a Third Party asserts that any of its Patents or other rights are infringed by the manufacture, Commercialization or Development by Roivant or its Affiliates of any Licensed Product in the Territory, Roivant
shall have the right but not the obligation to defend against any such assertions [***]. In the event that Roivant elects not to defend against such Third Party claims within [***] of learning of same, TheraVida shall have the right, but not the
obligation, to defend against such an action. In any event, the other Party shall cooperate fully and shall provide full access to documents, information and witnesses as reasonably requested by the Party defending such action. The Party defending
the action will reimburse all Third Party costs incurred in connection with such requested cooperation. Notwithstanding the foregoing, the Parties’ rights and obligations under this Section 9.5 (Infringement of Third Party Rights),
including payment obligations, will be subject to the terms of Article 13 (Indemnification; Liability). 
 9.6 Consent for
Settlement. Neither Party shall unilaterally enter into any settlement or compromise of any action or proceeding under this Article 9 (Intellectual Property Rights) that would in any manner alter, diminish, or be in derogation of the other
Party’s rights under this Agreement without the prior written consent of such other Party, which shall not be unreasonably withheld. 

9.7 Patent Extensions. Roivant shall have discretion regarding, and TheraVida shall cooperate with Roivant in obtaining, patent
term restoration, supplemental protection certificates or their equivalents, and patent term extensions with respect to the Licensed Patents and Joint Patents in any country in the Territory where applicable. Roivant shall file for such extensions
[***]. 
 9.8 Trademarks. Roivant shall own and be responsible for all trademarks, trade names, branding or logos related to
Licensed Products in the Field in the Territory. Roivant shall be responsible for selecting, registering, prosecuting, defending, and maintaining all such marks [***]. 

ARTICLE 10 

CONFIDENTIALITY; PUBLICATION 

10.1 Duty of Confidence. Subject to the other provisions of this Article 10 (Confidentiality; Publication): 

(a) all Confidential Information disclosed by a Party (the “Disclosing Party”) or its Affiliates under this Agreement
will be maintained in confidence and otherwise safeguarded by the recipient Party (the “Receiving Party”) and its Affiliates using at least the same standard of care as the Receiving Party uses to protect its own proprietary or
Confidential Information (but in no event less than reasonable care); 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

30 

			
	Confidential	  	EXECUTION VERSION

  

 (b) the Receiving Party may only use any such Confidential Information for the
purposes of performing its obligations or exercising its rights under this Agreement; and 
 (c) the Receiving Party may disclose
Confidential Information of the Disclosing Party only to: (i) the Receiving Party’s Affiliates and, in the case of Roivant as the Receiving Party, its Sublicensees; and (ii) employees, directors, agents, contractors, consultants and
advisers of the Receiving Party and its Affiliates and, in the case of Roivant as the Receiving Party, Sublicensees, in each case to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement;
provided, that such Persons are bound to maintain the confidentiality, and not to make any unauthorized use, of the Confidential Information in a manner consistent with this Article 10 (Confidentiality; Publication). 

10.2 Exceptions. The foregoing obligations as to particular Confidential Information of a Disclosing Party shall not apply to the
extent that the Receiving Party can demonstrate by competent evidence that such Confidential Information: 
 (a) is known by the
Receiving Party at the time of its receipt, and not through a prior disclosure by the Disclosing Party, as shown by contemporaneous written documents of the Receiving Party; 

(b) is in the public domain by use and/or publication before its receipt from the Disclosing Party, or thereafter enters the public
domain through no fault of, or breach of this Agreement by, the Receiving Party; 
 (c) is subsequently disclosed to the Receiving
Party on a non-confidential basis by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the Disclosing Party; or 

(d) is developed by the Receiving Party independently and without use of or reference to any Confidential Information disclosed to it by
or on behalf of the Disclosing Party, as shown by contemporaneous written documents of the Receiving Party. 
 10.3 Authorized
Disclosures. Notwithstanding the obligations set forth in Section 10.1 (Duty of Confidence), the Receiving Party may disclose Confidential Information of the Disclosing Party and the terms of this Agreement to the extent such disclosure is
reasonably necessary in the following instances: 
 (a) filing or prosecuting of Patents as permitted by this Agreement; 

(b) enforcing the Receiving Party’s rights under this Agreement or performing the Receiving Party’s obligations under this
Agreement; 
 (c) in Regulatory Filings for Licensed Products that such Party has the right to file under this Agreement; 

(d) prosecuting or defending litigation as permitted by this Agreement; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

31 

			
	Confidential	  	EXECUTION VERSION

  

 (e) to the Receiving Party’s directors, Affiliates, actual or potential
Sublicensees (in the case of Roivant), commercial partners, independent contractors, consultants, attorneys, independent accountants or financial advisors who, in each case, have a need to know such Confidential Information in order for the
Receiving Party to exercise its rights or fulfill its obligations under this Agreement, provided, in each case, that any such Person agrees to be bound by terms of confidentiality and non-use (or, in
the case of the Receiving Party’s attorneys and independent accountants, such Person is obligated by applicable professional or ethical obligations) at least as restrictive as those set forth in this Article 10; 

(f) to actual or potential investors, investment bankers, lenders, other financing sources or acquirors (and attorneys and independent
accountants thereof) in connection with potential investment, acquisition, collaboration, merger, public offering, due diligence or similar investigations by such Third Parties or in confidential financing documents, provided, in each case, that any
such Third Party agrees to be bound by terms of confidentiality and non-use (or, in the case of the Receiving Party’s attorneys and independent accountants, such Third Party is obligated by applicable
professional or ethical obligations) that are no less stringent than those contained in this Agreement (except to the extent that a shorter confidentiality period is customary in the industry); and 

(g) such disclosure is required by court order, judicial or administrative process or Applicable Law, provided that in such event
the Receiving Party shall promptly inform the Disclosing Party of such required disclosure and provide the Disclosing Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed as required by
court order, judicial or administrative process or Applicable Law shall remain otherwise subject to the confidentiality and non-use provisions of this Article 10 (Confidentiality; Publication), and the
Receiving Party shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order, to ensure the continued confidential treatment of such Confidential Information. 

10.4 Publication. TheraVida shall not publish nor otherwise publicly disclose any data or results regarding any Proprietary Drug
or Licensed Product without the prior written consent of Roivant. Prior to publishing peer reviewed manuscripts disclosing the results of studies carried out under this Agreement, Roivant shall provide TheraVida with the opportunity to review and
comment on any proposed publication which relates to any Proprietary Drug or Licensed Product at least [***] prior to its intended submission for publication. Roivant shall: (i) consider in good faith any comments thereto provided by TheraVida
within such [***] period; and (ii) remove any Confidential Information of TheraVida identified by TheraVida as part of its review. 

10.5 Publicity/Use of Names. No disclosure of the existence, or the terms, of this Agreement may be made by either Party or its
Affiliates, and neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject
matter, without the prior express written permission of the other Party, except as may be required by law. Notwithstanding the above, each Party and its Affiliates may disclose on its website and in its promotional materials that the other Party is
a development partner of such Party for the Licensed Products and may use the other Party’s name and logo in conjunction with such disclosure. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

32 

			
	Confidential	  	EXECUTION VERSION

  

 (a) A Party may disclose this Agreement and its terms, and material developments or
material information generated under this Agreement, in securities filings with the U.S. Securities and Exchange Commission (“SEC”) (or equivalent foreign agency) to the extent required by law after complying with the procedure set
forth in this Section 10.5 (Publicity/Use of Names). In such event, the Party seeking to make such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment
for this Agreement, and the other Party agrees to promptly (and in any event, no less than [***] after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking
disclosure to file its request within the time lines prescribed by applicable SEC regulations. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of this Agreement from the SEC as
represented by the redacted version reviewed by the other Party. 
 (b) Further, each Party acknowledges that the other Party may be
legally required, or may be required by the listing rules of any exchange on which the other Party’s or its Affiliate’s securities are traded, to make public disclosures (including in filings with the SEC or other agency) of certain
material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by law or such listing rules, provided that the Party seeking such disclosure shall provide the other Party
with a copy of the proposed text of such disclosure sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment thereon. 

(c) If either Party desires to issue a press release or make a public announcement concerning the material terms of this Agreement or
the Development or Commercialization of the Licensed Product under this Agreement, such as the achievement of Regulatory Approvals of the Licensed Product, such Party shall provide the other Party with the proposed text of such announcement for
prior review and, except to the extent such press release or public announcement is permitted by subsection (a) or (b) above, approval by such other Party. 

(d) The Parties agree that after a public disclosure has been made or a press release or other public announcement has been issued in
compliance with subsection (a), (b) or (c) hereof, each Party may make subsequent public disclosures or issue press releases or other public announcements disclosing the same content without having to obtain the other Party’s prior consent
and approval. 
 10.6 Reporting of Financial Information. From and after the Effective Date, to the extent required by the SEC
in connection with Roivant or an Affiliate of Roivant registering securities in a public offering, TheraVida shall (a) cooperate with Roivant or its Affiliates and their respective accountants and auditors by providing access to information,
books, and records related to the Licensed Products as Roivant may reasonably request in connection with the preparation by Roivant or its Affiliates of historical and pro forma financial statements related to 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

33 

			
	Confidential	  	EXECUTION VERSION

  

 
the Licensed Products as may be required to be included in any filing made by Roivant or any of its Affiliates under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended, and the regulations promulgated thereunder, including Regulation S-X and (b) without limiting the foregoing, shall provide Roivant with such information as is required for Roivant or its
Affiliates to prepare audited “carve out” financial statements related to the Licensed Products, for the [***] prior to the Effective Date (or such shorter period as agreed to by Roivant) and information requested by Roivant and
reasonably necessary to prepare any applicable pro forma financial information required to be filed by Roivant with the SEC. Such cooperation shall include, as applicable, (i) the signing of management representation letters to the extent
required in connection with any such audit performed by Roivant’s auditors, (ii) providing Roivant or its Affiliates and their respective accountants and auditors with access to management representation letters provided by TheraVida to
TheraVida’s accountants and auditors, and (iii) causing TheraVida’s accountants, auditors, and counsel to cooperate with Roivant or its Affiliates and its accountants, auditors, and counsel in connection with the preparation and audit
of any financial information to be provided under this Section 10.6 (Reporting of Financial Information). If TheraVida elects to provide Roivant with the audited financial statements contemplated hereunder, the selection of an external audit
firm will be at the discretion of TheraVida. Such financial statements shall be derived from TheraVida’s historical financial statements, and accurately present in all material respects the financial position of the Licensed Products as of the
dates thereof. TheraVida hereby consents to the inclusion or incorporation by reference of any financial statements provided to Roivant under this Section 10.6 (Reporting of Financial Information) in any filing by Roivant or its Affiliates with
the SEC and, upon request therefor of Roivant, agrees to request that any auditor of TheraVida that audits any financial statements provided to Roivant or its Affiliates under this Section 10.6 (Reporting of Financial Information) consent to
the inclusion or incorporation by reference of its audit opinion with respect to such financial statements in any filing by Roivant or its Affiliates with the SEC. Roivant shall promptly pay or reimburse all documented costs incurred by TheraVida or
its Affiliates in complying with this Section 10.6 (Reporting of Financial Information). 
 ARTICLE 11 

TERM AND TERMINATION 

11.1 Term. Unless earlier terminated as permitted by this Agreement, the term of this Agreement will commence upon the Effective
Date and continue in full force and effect, on a Licensed Product-by-License Product basis, until the expiration of the last Royalty Term for such Licensed Product in
the Territory (the “Term”). Upon the expiration (but not early termination) of the Term for such Licensed Product, the licenses granted to Roivant shall continue in effect, as non-exclusive,
fully paid-up, royalty-free, transferable, perpetual and irrevocable with respect to such Licensed Product in the Field in the Territory. 

11.2 Termination. 

(a) Termination by Roivant for Convenience. At any time, Roivant may terminate this Agreement, at its sole discretion and for any
reason or no reason, by providing written notice of termination to TheraVida, which notice includes an effective date of termination at least (i) [***] after the date of the notice if the notice is given before the Regulatory Approval of any
Product; or (ii) [***] after the date of the notice if the notice is given after the Regulatory Approval of any Product. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

34 

			
	Confidential	  	EXECUTION VERSION

  

 (b) Termination for Cause. If either Party believes that the other is in
material breach of its obligations hereunder, then the non-breaching Party may deliver notice of such breach to the other Party. The allegedly breaching Party shall have [***] (or [***] in the case of any
payment breach) to cure such breach from the receipt of the notice. If the allegedly breaching Party fails to cure that breach within the applicable period set forth above, then the Party originally delivering the notice of breach may terminate this
Agreement on written notice of termination. Any right to terminate this Agreement under this Section 11.2(b) (Termination for Cause) shall be stayed and the applicable cure period tolled in the event that, during such cure period, the Party
alleged to have been in material breach shall have initiated dispute resolution in accordance with Section 14.9 (Dispute Resolution) with respect to the alleged breach, which stay and tolling shall continue until such dispute has been resolved
in accordance with Section 14.9 (Dispute Resolution). If a Party is determined to be in material breach of this Agreement, the other Party may terminate this Agreement if the breaching Party fails to cure the breach within [***] after the
conclusion of the dispute resolution procedure (and such termination shall then be effective upon written notification from the notifying Party to the breaching Party). 

(c) Termination for Patent Challenge. Except to the extent the following is unenforceable under the laws of a particular
jurisdiction, TheraVida may terminate this Agreement immediately upon written notice to Roivant if Roivant or its Affiliates or Sublicensees, individually or in association with any other person or entity, commences a legal action challenging the
validity, enforceability or scope of any Licensed Patents and does not dismiss or withdraw such legal action within [***] of commencing such legal action. 

(d) Termination for Bankruptcy. This Agreement may be terminated at any time during the Term by either Party upon the other
Party’s filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the
case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. 

11.3 Effect of Termination. Upon termination of this Agreement [***], the following consequences shall apply and shall be
effective as of the effective date of such termination: 
 (a) If this Agreement is terminated by Roivant pursuant to
Section 11.2(a) (Termination by Roivant for Convenience) or by TheraVida pursuant to Section 11.2(b) (Termination for Cause), 11.2(c) (Termination for Patent Challenge), or 11.2(d) (Termination for Bankruptcy), then (i) Roivant’s
license under Section 2.1 (License to Roivant) shall terminate; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

35 

			
	Confidential	  	EXECUTION VERSION

  

 
and (ii) Roivant hereby grants to TheraVida, effective only upon such termination, [***] under the Roivant Technology and the Joint Inventions and Joint Patents, to research, develop, make,
have made, use, distribute, sell, offer for sale, have sold, import, export and otherwise commercialize Proprietary Drugs and Licensed Products in the Field. If this Agreement is terminated by Roivant pursuant to Section 11.2(b) (Termination
for Cause), then TheraVida may request, within [***] of termination, that Roivant enter into good faith negotiations for no more than [***] concerning the terms of an agreement with TheraVida granting TheraVida a license under the Roivant
Technology, Joint Patents, and Joint Inventions. 
 (b) TheraVida shall be solely responsible for all future Development, manufacture
and Commercialization of Proprietary Drugs and Licensed Products in the Field, at its sole cost and expense. 
 (c) Roivant shall
return to TheraVida or destroy, at TheraVida’s election, all Confidential Information of TheraVida, including all copies thereof and all materials, substances and compositions delivered or provided by TheraVida to Roivant. 

(d) Roivant shall [***] to TheraVida all Regulatory Filings and Regulatory Approvals for any Proprietary Drug and Licensed Product, and
any Roivant Know-How contained in such Regulatory Filings and Regulatory Approvals shall be subject to the license grants in Section 11.3(a) (Effects of Termination—subsection(a)) above. 

(e) Roivant shall disclose to TheraVida all Roivant Know-How and all Joint Inventions to the
extent not already known to TheraVida, which may be necessary or reasonably useful for TheraVida to continue to Develop, manufacture and Commercialize Proprietary Drugs and Licensed Products in the Field. In addition, Roivant shall, [***], provide
reasonable technical assistance and transfer all Roivant Know-How and Joint Inventions necessary to manufacture Proprietary Drugs and Licensed Products to TheraVida or its designee. 

(f) Roivant shall, at TheraVida’s request and election, use Commercially Reasonably Efforts to facilitate negotiations between
TheraVida and Roivant’s Third Party providers of clinical research, manufacturing and/or distribution services. 
 (g) Roivant
shall reasonably cooperate, at TheraVida’s request and expense, with TheraVida and its designee(s) to facilitate a smooth, orderly and prompt transition of [***] with respect to Proprietary Drugs or Licensed Products to TheraVida or its
designee(s). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

36 

			
	Confidential	  	EXECUTION VERSION

  

 (h) TheraVida shall have the right to purchase from Roivant, [***] commercial
quantities of Proprietary Drugs and Licensed Products in Roivant’s or its Affiliates’ possession or control, within [***] after receipt of TheraVida’s request. Any packaging, transport, insurance and other costs for delivery of any
such purchased materials to TheraVida or its designee shall be paid by TheraVida. 
 (i) Roivant shall, and hereby does, effective on
such termination, [***] to TheraVida all of Roivant’s and its Affiliates’ right, title and interest in and to any and all trademarks used by Roivant and its Affiliates in the Territory in connection with its Development, manufacture or
Commercialization of Licensed Products (excluding any such trademarks that include, in whole or part, any corporate name or logo of Roivant or its Affiliates), including all goodwill therein, and Roivant shall promptly take such actions and execute
such instruments, assignments and documents as may be necessary to effect, evidence, register and record such assignment. 
 11.4
Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either Party from
pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. In addition, the provisions of [***] hereof shall survive the expiration or termination of this Agreement. Solely as to
Joint Inventions, the following provisions shall also survive the expiration or termination of this Agreement: [***]. 
 11.5
Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain
available except as agreed to otherwise herein. 
 ARTICLE 12 

REPRESENTATIONS AND WARRANTIES 

12.1 Representations and Warranties of Each Party. Each Party represents and warrants to each other Party as of the Effective
Date that: 
 (a) it has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder; and

 (b) this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does
not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

37 

			
	Confidential	  	EXECUTION VERSION

  

 12.2 Representations and Warranties by TheraVida. TheraVida represents and
warrants to Roivant as of the Effective Date that: 
 (a) it has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in Licensed Technology in a manner that is inconsistent with the exclusive license granted to Roivant under Section 2.1 (Licenses to Roivant); 

(b) TheraVida has not received any written notice from a Third Party that the Development of any Proprietary Drug or Licensed Product
conducted by TheraVida prior to the Effective Date has infringed any Patents of any Third Party or misappropriated any other intellectual property of any Third Party and, without any duty to investigate, is not aware of any imminent or likely threat
from a Third Party of such infringement or misappropriation; 
 (c) TheraVida has not as of the Effective Date, and will not during
the Term, grant any right to any Third Party under the Licensed Technology that would conflict with the rights granted to Roivant hereunder; 

(d) TheraVida has no knowledge as of the Effective Date of any Third Party that is infringing or misappropriating any of the Licensed
Technology; 
 (e) no claim or action has been brought or, to TheraVida’s knowledge, threatened in writing by any Third Party
alleging that the Licensed Patents are invalid or unenforceable, and no Licensed Patent is the subject of any interference, opposition, cancellation or other protest proceeding; 

(f) the patents and patent applications listed on Exhibit C constitute all existing Licensed Patents as of the Effective Date; and 

(g) to TheraVida’s knowledge (without any duty to investigate), as of the Effective Date, there is no Know-How necessary for the Development and manufacture of the Initial Proprietary Drug (as Developed and manufactured by or on behalf of TheraVida prior to the Effective Date) that is Controlled (mutatis
mutandis) by any Third Party. 
 12.3 No Other Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY
MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS,
NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

38 

			
	Confidential	  	EXECUTION VERSION

  

 ARTICLE 13 

INDEMNIFICATION; LIABILITY 

13.1 Indemnification by TheraVida. TheraVida shall indemnify and hold Roivant, its Affiliates and Sublicensees, and their
respective officers, directors, agents and employees (“Roivant Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

(a) the use, Development, manufacture, Commercialization, handling, storage or other disposition by or on behalf of TheraVida or any of
its Affiliates or Third Party licensees (excluding Sublicensees) of any Proprietary Drug or Licensed Product outside the Territory, including any product liability claim; or 

(b) the negligence or willful misconduct of any of the TheraVida Indemnitees; or 

(c) the material breach of any of the covenants, warranties or representations made by TheraVida to Roivant under this Agreement; or

 (d) any material breach by TheraVida of its obligations pursuant to this Agreement; 

except in each case, to the extent such Claims result from the material breach by Roivant of any covenant, representation, warranty or other
agreement made by Roivant in this Agreement or the negligence or willful misconduct of any Roivant Indemnitee. 
 13.2
Indemnification by Roivant. Roivant shall indemnify and hold TheraVida, its Affiliates, and their respective officers, directors, agents and employees (“TheraVida Indemnitees”) harmless from and against any Claims arising
under or related to this Agreement against them to the extent arising or resulting from: 
 (a) the use, Development, manufacture,
Commercialization, handling, storage or other disposition by or on behalf of Roivant or any of its Affiliates or Sublicensees of any Proprietary Drug or Licensed Product in the Territory, including any product liability claim; or 

(b) the negligence or willful misconduct of any of the Roivant Indemnitees; or 

(c) the material breach of any of the covenants, warranties or representations made by Roivant to TheraVida under this Agreement; or

 (d) any material breach by Roivant of its obligations pursuant to this Agreement; 

except in each case, to the extent such Claims result from the material breach by TheraVida of any covenant, representation, warranty or other
agreement made by TheraVida in this Agreement or the negligence or willful misconduct of any TheraVida Indemnitee. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

39 

			
	Confidential	  	EXECUTION VERSION

  

 13.3 Indemnification Procedure. If either Party is seeking indemnification
under Sections 13.1 (Indemnification by TheraVida) or 13.2 (Indemnification by Roivant) (the “Indemnified Party”), it shall inform the other Party (the “Indemnifying Party”) of the claim giving rise to the
obligation to indemnify pursuant to such section as soon as reasonably practicable after receiving notice of the claim. The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the
Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified
Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party
in connection with any settlement made without such Party’s written consent, which consent shall not be unreasonably withheld or delayed. If the Parties cannot agree as to the application of Section 13.1 (Indemnification by TheraVida) or
13.2 (Indemnification by Roivant) as to any claim, pending resolution of the dispute pursuant to Section 14.9 (Dispute Resolution), the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim
indemnification from the other Party in accordance with Section 13.1 (Indemnification by TheraVida) or 13.2 (Indemnification by Roivant) upon resolution of the underlying claim. 

13.4 Mitigation of Loss. Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and
action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 13 (Indemnification; Liability). Nothing in this Agreement shall or shall be
deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 
 13.5 Special, Indirect and
Other Losses. EXCEPT IN THE EVENT OF A PARTY’S BREACH OF [***] OR ARTICLE 10 (CONFIDENTIALITY; PUBLICATION), NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN
CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided, however, that this Section 13.5 shall not be construed to limit either Party’s indemnification obligations under Section 13.1 (Indemnification by
TheraVida) or Section 13.2 (Indemnification by Roivant), as applicable. 
 13.6 Insurance. Each Party, at its own expense,
shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term. Each Party shall provide a
certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

40 

			
	Confidential	  	EXECUTION VERSION

  

 ARTICLE 14 

GENERAL PROVISIONS 

14.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York
without reference to any rules of conflict of laws with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law. 

14.2 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be
assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that either Party may assign or otherwise transfer this Agreement
and its rights and obligations hereunder without the other Party’s consent: (a) in connection with the transfer or sale of all or substantially all of the business or assets of such Party to which this Agreement relates to a Third Party,
whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets or otherwise; provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by
operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiring party to such transaction (if other than one of the Parties to this Agreement) and its affiliates existing prior to the
transaction shall not be included in the technology licensed hereunder; or (b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party
hereto for the performance and observance of all such duties and obligations by such Affiliate. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of
the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with
this Section 14.2 (Assignment) shall be null and void. 
 14.3 Entire Agreement; Modification. This Agreement is both a
final expression of the Parties’ agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise,
concerning any and all matters contained herein. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement. 

14.4 Relationship Between the Parties. The Parties’ relationship with one another, as established by this Agreement, is
solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal representative of the other Party. Neither Party can assume or
create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. 

14.5 Non-Waiver. The failure of a Party to insist upon strict performance of any
provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any
waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

41 

			
	Confidential	  	EXECUTION VERSION

  

 14.6 Force Majeure. Neither Party shall be held liable to the other Party nor
be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected
Party, potentially including, but not limited to, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of
God, or acts, omissions or delays in acting by any governmental authority or unavailability of materials related to the manufacture of Products. The affected Party shall notify the other Party of such force majeure circumstances as soon as
reasonably practical, and shall promptly undertake and continue diligently all reasonable efforts necessary to cure such force majeure circumstances or to perform its obligations in spite of the ongoing circumstances. 

14.7 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of
the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this
Agreement. 
 14.8 Notices. Any notice to be given under this Agreement must be in writing and delivered either (a) in
person, (b) by air mail (postage prepaid) requiring return receipt, (c) by overnight courier, or (d) by e-mail with delivery and return receipts requested and confirmation of delivery
thereafter, to the Party to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (i) the
date of actual receipt; (ii) if air mailed, five (5) days after the date of postmark; (iii) if delivered by overnight courier, the next day the overnight courier regularly makes deliveries or (iv) if sent by e-mail, the date of confirmation of receipt. 
  

	
	If to TheraVida:
	
	 TheraVida, Inc.

177 Bovet Rd., Suite 600

	 San Mateo, California 94402

	 [***]

	
	If to Roivant:
	
	 Roivant Sciences GmbH

	 Viaduktstrasse 8

4051 Basel, Switzerland

	 [***]

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

42 

			
	Confidential	  	EXECUTION VERSION

  

	
	with a copy (which shall not constitute notice) to:
	
	 Roivant Sciences, Inc.

320 West 37th Street, 5th Floor

	 New York, NY 10018

	 [***]

	 [***]

 14.9 Dispute Resolution 

(a) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or
related to this Agreement or the breach thereof. Subject to Section 14.9(h) (Dispute Resolution—subsection (h)), in the event the Parties cannot resolve such dispute, controversy or claim within a period of [***], then the matter shall be
referred to designated senior executives of the Parties for resolution. The initial designated senior executives shall be the Chief Business Officer of Roivant Sciences, Inc., and [***] of TheraVida. Each Party shall be entitled to name substitute
senior executives upon written notice to the other Party. 
 (b) Except as expressly set forth in Section 14.9(h) (Dispute
Resolution—subsection (h)), if, after going through this procedure, the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim (defined in Section 14.9(g)
(Dispute Resolution—subsection (g)) below) shall be finally resolved by binding arbitration administered by [***] pursuant to [***] then in effect (the “[***]”). 

(c) The arbitration shall be conducted by a panel of three (3) neutral arbitrators experienced in the pharmaceutical business, none
of whom shall be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates or any Sublicensee: within [***] after initiation of arbitration, each Party shall select one (1) person
to act as arbitrator and the two (2) Party-selected arbitrators shall select a third (3rd) arbitrator within [***] of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third (3rd) arbitrator, the
third (3rd) arbitrator shall be appointed by [***]. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. Within [***] after selection of the third arbitrator, the arbitrators shall conduct
the Preliminary Conference (as defined in the [***]). In addressing any of the subjects within the scope of the Preliminary Conference, the arbitrators shall take into account both the desirability of making discovery efficient and cost-effective
and the needs of the Parties for an understanding of any legitimate issue raised in the arbitration. The award rendered by the arbitrators shall be final, binding and non-appealable, and judgment may be
entered upon it in any court of competent jurisdiction. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

43 

			
	Confidential	  	EXECUTION VERSION

  

 (d) Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise resolved. The arbitrators’ authority to award punitive or any other type of damages not measured by a Party’s compensatory damages shall be subject to the limitation set forth
in Section 13.5 (Special, Indirect and Other Losses). Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration. 

(e) Except to the extent necessary to confirm or enforce an award or as may be required by law, neither Party nor an arbitrator may
disclose the existence, content, or results of an arbitration without the prior written consent of the other Party. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the
dispute, controversy or claim would be barred by the applicable New York statute of limitations. 
 (f) The Parties agree that, in the
event of a dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. The Parties further agree that
any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due. 

(g) As used in this Section, the term “Excluded Claim” means a dispute, controversy or claim that concerns (i) the
construction, scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright; or (ii) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

(h) Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of
competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing discussions between the Parties or any ongoing arbitration proceeding.
In addition, either Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other violations of Patents or other intellectual property
rights, and no such claim shall be subject to arbitration pursuant to subsections (b) and (c) of this Section 14.9 (Dispute Resolution). 

14.10 Performance by Affiliates. Each Party may discharge any obligations and exercise any rights hereunder through any of its
Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any
breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate. 
 14.11 Headings. The captions to the several Articles, Sections and subsections hereof are not a part
of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. 
 14.12
Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

44 

			
	Confidential	  	EXECUTION VERSION

  

 Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the
drafting Party shall not apply. 
 14.13 Business Day Requirements. In the event that any notice or other action or omission is
required to be taken by a Party under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to require to be taken on the next occurring Business Day. 

14.14 English Language. This Agreement has been prepared in the English language, and the English language shall control its
interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language. 

14.15 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
 {REMAINDER OF PAGE INTENTIONALLY LEFT BLANK} 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

45 

			
	Confidential	  	EXECUTION VERSION

  

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to
be executed by their duly authorized representatives. 
  

									
	ROIVANT SCIENCES GMBH	 		  	THERAVIDA INC.
					
	By:	 	 [***]
	 		  	By:	  	 [***]

	Name:	 	[***]	 	                    	  	Name:	  	[***]
	Title:	 	[***]	 		  	Title:	  	[***]
	Date:	 	[***]	 		  	Date:	  	[***]

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

46 

			
	    	  	

  

 LIST OF EXHIBITS 
  

	
	Exhibit A: THVD-102
	Exhibit B: Chemical Structures of Oxybutynin and Pilocarpine
	Exhibit C: Licensed Patents Existing as of the Effective Date

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

			
	    	  	

  

 Exhibit A 

THVD-102 

THVD-102 is a combination of Oxybutynin and Pilocarpine. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 A-1 

			
	    	  	

  

 EXHIBIT B 

[***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 B-1 

			
	    	  	

  

 EXHIBIT C 

LICENSED PATENTS EXISTING AS OF THE
EFFECTIVE DATE 
 [***] 

  
 [***] = THREE
PAGES OF CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO 17 CFR 230.406 OF THE SECURITIES ACT OF 1933, AS
AMENDED. 
 C-1EX-10.15

 Exhibit 10.15 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

Execution Version 

CONFIDENTIAL 
 Dated
August 20, 2018 
 GlaxoSmithKline Trading Services Limited 

– and – 

Dermavant Sciences GmbH 
  

 
 CLINICAL MANUFACTURING AND SUPPLY
AGREEMENT 
 in respect of Tapinarof and Clinical Placebo 

 
  

 CONFIDENTIAL 
  

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 1. DEFINITIONS AND INTERPRETATION
	  	 	1	 
		
	 2. GSK’S OBLIGATIONS
	  	 	16	 
		
	 3. DEVELOPMENT SERVICES
	  	 	18	 
		
	 4. PURCHASER’S OBLIGATIONS
	  	 	20	 
		
	 5. PURCHASE, MAINTENANCE, AND DESTRUCTION OF EXISTING CLINICAL API
	  	 	21	 
		
	 6. MATERIALS
	  	 	22	 
		
	 7. PURCHASER MATERIALS
	  	 	22	 
		
	 8. INTELLECTUAL PROPERTY
	  	 	23	 
		
	 9. PRODUCT FORECASTS AND ORDERS
	  	 	24	 
		
	 10. DELIVERY OF PRODUCT
	  	 	26	 
		
	 11. PRICE
	  	 	27	 
		
	 12. INVOICE AND PAYMENT
	  	 	29	 
		
	 13. ELECTRONIC SYSTEMS
	  	 	30	 
		
	 14. QUALITY ASSURANCE
	  	 	31	 
		
	 15. DEFECTIVE PRODUCTS
	  	 	31	 
		
	 16. PRODUCT LICENCE
	  	 	32	 
		
	 17. PRODUCT SPECIFICATIONS
	  	 	32	 
		
	 18. WRITE OFFS
	  	 	33	 
		
	 19. REGULATORY COMPLIANCE
	  	 	34	 
		
	 20. PRODUCT EVENTS
	  	 	35	 
		
	 21. PHARMACOVIGILANCE
	  	 	36	 
		
	 22. CONFIDENTIALITY
	  	 	36	 
		
	 23. FORCE MAJEURE
	  	 	38	 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

					
	 24. CAPACITY CONSTRAINTS
	  	 	39	 
		
	 25. AUDIT AND INSPECTION RIGHTS
	  	 	40	 
		
	 26. NO COMMERCIALISATION OF PRODUCT; ADDITIONAL AGREEMENTS
	  	 	41	 
		
	 27. WARRANTIES
	  	 	41	 
		
	 28. INDEMNITIES
	  	 	42	 
		
	 29. LIABILITY
	  	 	44	 
		
	 30. TECHNOLOGY TRANSFER
	  	 	45	 
		
	 31. TERM AND TERMINATION
	  	 	46	 
		
	 32. CONSEQUENCES OF EXPIRY OR TERMINATION
	  	 	47	 
		
	 33. SURVIVAL OF RIGHTS, DUTIES AND OBLIGATIONS
	  	 	49	 
		
	 34. NOTICES
	  	 	50	 
		
	 35. RELATIONSHIP OF THE PARTIES
	  	 	51	 
		
	 36. ASSIGNMENT AND NOVATION
	  	 	51	 
		
	 37. SUB-CONTRACTORS
	  	 	52	 
		
	 38. ENTIRE AGREEMENT
	  	 	53	 
		
	 39. SEVERABILITY
	  	 	53	 
		
	 40. VARIATION, WAIVER AND AMENDMENT
	  	 	53	 
		
	 41. COUNTERPARTS
	  	 	53	 
		
	 42. NO SET OFF
	  	 	54	 
		
	 43. LANGUAGE
	  	 	54	 
		
	 44. NO COMPENSATION
	  	 	54	 
		
	 45. DISPUTE RESOLUTION
	  	 	55	 
		
	 46. GOVERNING LAW AND JURISDICTION
	  	 	55	 
		
	 SCHEDULE 1 PRODUCTS AND PRICES
	  	 	58	 
		
	 SCHEDULE 2 SCOPE OF WORK FOR DEVELOPMENT SERVICES
	  	 	67	 
		
	 SCHEDULE 3 TOLL MANUFACTURE PROVISIONS
	  	 	70	 
		
	 SCHEDULE 4 FEES
	  	 	73	 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 THIS AGREEMENT is made the 20th day of August, 2018 (“Effective Date”)
BETWEEN: 
  

	(1)	 GlaxoSmithKline Trading Services Limited a company registered in Ireland (company registration
number 406446), whose registered office is at Currabinny, Carrigaline, Cork, Ireland (“GSK”); 

 AND 

 

	(2)	 Dermavant Sciences GmbH, a company incorporated under the laws of Switzerland (company registration
number CHE-449.750.216) whose registered office is at Viaduktstrasse 8, 4051 Basel, Switzerland (the “Purchaser”). 

WHEREAS: 
  

	(A)	 The GSK Group is engaged in, among other things, the manufacture of medicinal products and consumer healthcare
products. 

  

	(B)	 The Purchaser is engaged in, among other things, the development, distribution and sale of medicinal products
and/or consumer healthcare products. 

  

	(C)	 The Purchaser wishes to engage the services of a third party contract manufacturer for the Products and GSK is
willing to (i) supply Existing Clinical Products, Existing Clinical Placebo and Existing Clinical API to the Purchaser, (ii) manufacture (or have manufactured), as applicable, the New Clinical Products, New Clinical Placebo, and New
Clinical API for the Purchaser, and (iii) provide certain development services in connection with the supply of Clinical Products and Clinical Placebo as requested by Purchaser, in each case in accordance with the terms and conditions of this
Agreement. 

 NOW IT IS AGREED as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 Each capitalized term used but not otherwise defined in this Agreement has the meaning given to such term in
the Purchase Agreement. The following additional terms have the respective meanings set forth in the preamble to this Agreement or below. This Agreement shall control to the extent any conflict exists between any defined term used in this Agreement
and any defined term used in the Purchase Agreement. 

 “Actual Cost” means, in respect of a Toll
Material, the cost to the Purchaser (and/or its relevant Affiliates) of acquiring and supplying that Toll Material to GSK (or the Nominated Supplier), including the costs of Delivery of such Toll Material but excluding (for the avoidance of doubt)
any profit made by the Purchaser or any of its Affiliates through the application of transfer pricing.  
 “Adverse
Event” means any untoward medical occurrence associated with the use of a Product in humans, whether or not considered drug-related (including any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a
Product (whether or not considered related to the Product)), any failure to produce expected benefits and any adverse event associated with circumstances of overdose, medication error, abuse or misuse. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 1 

 CONFIDENTIAL 
  

 “Affected Party” has the meaning given in the definition of “Force
Majeure Event” in this Clause 1.1. 
 “Affected Products” has the meaning given in Clause 24.2, and
“Affected Product” shall be construed accordingly. 
 “Affected Site” has the meaning given in Clause 24.1.

 “Affiliate” means any corporation or business entity Controlled by, Controlling, or under common Control with a Party to
this Agreement. 
 “Allocation” has the meaning given in Clause 24.2. 

“API” means, in respect of a Clinical Product, a substance used in that Clinical Product intended to furnish pharmacological
activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings. 

“API Base Cost” has the meaning given in Schedule 1, Part B.  

“Applicable Law” means, with respect to a country or registrational jurisdiction in the Territory, any Federal, state, local
or country constitution, law, statute, ordinance, Order, rule or regulation, including any rules, regulations, guidelines or other requirements of the Regulatory Authorities applicable to the Development, Manufacturing or Commercialisation a
Product, that may be in effect from time to time in a country or registrational jurisdiction. 
 “Business Day” means any
day other than (i) a Saturday, Sunday or other day on which banks in New York, New York, Basel, Switzerland and London, England are permitted or required to close by law or regulation or (ii) the nine (9) consecutive calendar days
beginning on December 24th and continuing through January 1st of each Calendar Year. 
 “Calendar Quarter” means a three
(3) month period commencing on the day following any Calendar Quarter Day and ending on the next-following Calendar Quarter Day. 

“Calendar Quarter Day” means any of March 31st, June 30th, September 30th and December 31st. 

“Calendar Year” means a period of twelve (12) months commencing on January 1st. 

“CAPAs” has the meaning given in Clause 14.2. 

[***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 2 

 CONFIDENTIAL 
  

 “Certificate of Analysis” means a document identified as such, signed or
released by a Qualified Person (or Person designated by the Qualified Person to sign or release such document) in accordance with cGMP that: 
  

	 	(A)	 sets forth the analytical test results for each specified lot of Products Delivered to the Purchaser under this
Agreement; and 

  

	 	(B)	 confirms that such Products have been Manufactured in accordance with the applicable Specifications.

 “China Territory” means, collectively, the People’s Republic of China, including Hong Kong Special
Administrative Region, Macau Special Administrative Region and Taiwan (as specified in the Welichem Agreement (as such term is defined in the Purchase Agreement)).  

“Claim” has the meaning given in Clause 28.4. 

“Clinical Products” means Existing Clinical Products and New Clinical Products, individually or collectively as the context
may require. 
 “Clinical Placebo” means Existing Clinical Placebo and New Clinical Placebo, individually or collectively as
the context may require. 
 “Clinical Trial” means any clinical investigation of a Product (whether pre- or post-Regulatory Approval), including any study or clinical investigation required by a Regulatory Authority.  

“CoGs” means, in respect of a Product, [***], but excluding: 

 

	 	(A)	 costs of [***]; and 

  

	 	(B)	 [***]. 

“Commercialise” means any and all activities, whether initiated or conducted prior to or following Regulatory Approval,
constituting using, marketing, promoting, distributing, offering for sale, selling and importing a Product (other than for the purposes of a Clinical Trial), and “Commercialising” and “Commercialisation” shall be
construed accordingly. 
 “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party to
achieve any objective, the reasonable, [***]. 
 “Confidential Information” means: 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 3 

 CONFIDENTIAL 
  

	 	(A)	 all information (including but not limited to trade secrets, protocols, specifications, techniques, source and
object code, business and marketing plans and projections, capital investment plans, arrangements and agreements with third parties and the content thereof, customer information, Intellectual Property, formulae, suppliers and customer lists,
financial data, designs and models) passing from the Disclosing Party to the Receiving Party (or its Personnel), whether deliberately or inadvertently, before, on or after the date of this Agreement, relating to the business affairs or finances of
the Disclosing Party that is designated, marked, or described as confidential, or might be reasonably regarded by the Disclosing Party as confidential to it; and 

 

	 	(B)	 the existence, provisions and subject matter of this Agreement (in respect of which each Party shall be deemed
to be a Disclosing Party). 

 “Consent” means any consent, authorisation, permit, certificate, licence or
approval of, exemption by, or filing or registration with, any Regulatory Authority (including any Product Licence). 

“Contract” means any contract, agreement, lease, undertaking, indenture, commitment, loan, note, license, arrangement,
understanding or other legally binding obligation, whether written or oral. 
 “Contract Year” means a period of [***]
commencing on the Effective Date or any anniversary thereof. 
 “Control” (and variations thereof) means: 

 

	 	(A)	 with respect to any Know-How, Patents, Regulatory Documentation or
other information, the possession by a Party, including its Affiliates, of the ability (without taking into account any rights granted by one Party to the other Party under the terms of this Agreement) to disclose, licence, or sublicense such Know-How, Patents, Regulatory Documentation or other information without violating the terms of any Contract or other arrangement with, or necessitating the consent of, any Third Party; and 

 

	 	(B)	 as to a Person, the power to direct or cause the direction of the management and policies of such Person,
whether, through the ownership of voting securities, by contract or otherwise. 

 “Current Good Manufacturing
Practice” or “cGMP” means current practices for the Manufacture of Products required: 
  

	 	(A)	 if the Manufacturing Site is within the European Union or the Product is to be supplied to a country within the
European Union, by the provisions of Chapter II of EC Commission Directive 2003/94/EC together with the Guide to Good Manufacturing Practice published by the EC Commission in 1992 (ISBN 92- 826-3180-X) (as the same may be amended from time to time); or 

  

	 	(B)	 if the Product is to be supplied to a region covered by the International Conference on Harmonisation of
Technical Requirements for Registration of 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 4 

 CONFIDENTIAL 
  

	 	
Pharmaceuticals for Human Use (“ICH”), by the relevant ICH Quality Guidelines relating to good manufacturing practice (as the same may be amended from time to time); or

  

	 	(C)	 if the Manufacturing Site is in any other part of the world and the Product is not to be supplied to a country
within the European Union, by such standards as may be agreed in writing between the Parties to reflect the requirements of a Regulator in the country where the Product is Manufactured or supplied; or 

 

	 	(D)	 by such other requirements as may be agreed between the Parties and set forth in the Quality Agreement,

 each as reflected in the Quality Management System and the GSK Group’s policies and guidelines from time to time.

 “Defaulting Party” has the meaning given in Clause 31.3. 

“Defect” means, in respect of a Product, a failure to comply with the applicable Specification and/or to have been
Manufactured in accordance with cGMP. 
 “Defective” and “Defective Product” shall be construed
accordingly. 
 “Delivery” means, in respect of any quantity of Product, delivery of that Product in accordance with the
Delivery Terms; provided that such Product has first been released by GSK or its Affiliate pursuant to (and to the extent required by) the Quality Agreement. “Deliver”, “Delivery” and
“Delivered” shall be construed accordingly. 
 “Delivery Terms” means: 

 

	 	(A)	 for (i) Purchased Clinical API and (ii) Maintained Excess Clinical API subsequently purchased by the
Purchaser pursuant to Clause 2.2, FCA (current location of Purchased Clinical API or Maintained Excess Clinical API, as applicable) (Incoterms 2010), except for Purchased Clinical API or Maintained Excess Clinical API that the Parties agree will be
left in GSK’s possession on consignment pursuant to Clause 10 (Delivery of Product); provided that GSK will be responsible for the transportation of Purchased Clinical API (or Maintained Excess Clinical API subsequently purchased
by the Purchaser pursuant to Clause 2.2) to Barnard Castle as required (and transportation costs and any Taxes associated therewith (to the extent not separately reimbursed by the Purchaser) will be part of the LAV for the Manufacture of New
Clinical Products); 

  

	 	(B)	 for Existing Clinical Product and Existing Clinical Placebo, FCA (current location of Existing Clinical Product
or Existing Clinical Placebo) (Incoterms 2010); 

  

	 	(C)	 for New Clinical API, FCA (Cork, Ireland) (Incoterms 2010), except for New Clinical API that the Parties agree
will be left in GSK’s possession on consignment pursuant to Clause 10 (Delivery of Product); provided that GSK will be responsible for the transportation of New Clinical API to Barnard Castle as required (and transportation costs
and any Taxes associated therewith (to the extent not separately reimbursed by the Purchaser) will be part of the LAV for the Manufacture of New Clinical Products); and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 5 

 CONFIDENTIAL 
  

	 	(D)	 for New Clinical Product and New Clinical Placebo, FCA (Barnard Castle) (Incoterms 2010).

 “Development” means all pre-clinical, clinical, CMC (chemistry,
manufacturing and controls) and regulatory activities with respect to a Product in a given country or jurisdiction in the Territory prior to Regulatory Approval of such Product in such country is obtained for the indication under study.
“Development” includes the preparation, filing, and maintenance of Regulatory Documentation relating to obtaining Regulatory Approval for the first time for a Product. When used as a verb, “Develop” means to engage
in Development. 
 “Development Services” has the meaning given in Clause 3.1. 

“Disclosing Party” has the meaning given in Clause 22.1. 

“Dispute” has the meaning given in Clause 45.2. 

“Effective Date” has the meaning set forth in the preamble. 

“Excess Clinical API” has the meaning given in Clause 5.1(C).  

“Existing Clinical API” has the meaning set forth in Schedule 1. 

“Existing Clinical Products” means Existing 1% Clinical Product and Existing 0.5% Clinical Products, individually or
collectively as the context may require. 
 “Existing 1% Clinical Product” has the meaning set forth in Schedule 1. 

“Existing 0.5% Clinical Product” has the meaning set forth in Schedule 1. 

“Existing Clinical Placebo” has the meaning set forth in Schedule 1. 

“Expected Loss” means, in respect of each New Clinical Product, the expected loss of the Toll Materials specified in Schedule
3 (Toll Manufacture Provisions) (taking account of samples of Toll Materials and/or New Clinical Product that GSK is required by Applicable Law to retain). 

“FDA” means the United States Food and Drug Administration, or a successor agency in the United States with responsibilities
comparable to those of the United States Food and Drug Administration. 
 “Firm Order” has the meaning given in Clause 9.4.

 “Firm Zone” has the meaning given in Clause 9.2. 

“Force Majeure Event” means, in relation to a Party (the “Affected Party”), any circumstances beyond the
reasonable control of the Affected Party or its Affiliate which directly prevent or have a material adverse effect on the Affected Party’s performance of its obligations under this Agreement and includes any of the following: 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 6 

 CONFIDENTIAL 
  

	 	(A)	 war, threat of or preparation for war, armed conflict; 

 

	 	(B)	 terrorist attack, civil war, civil commotion or riots; 

 

	 	(C)	 epidemic or pandemic; 

 

	 	(D)	 any law or government order, rule, regulation or direction, or any action taken by a Governmental Entity,
including but not limited to imposing an embargo, export or import restriction, quota or other restriction or prohibition, or failing to grant a necessary licence or consent; and 

 

	 	(E)	 to the extent beyond the reasonable control of the Affected Party, any labour dispute, including strikes,
industrial action or lockouts. 

 “Forecast Schedule” has the meaning given in Clause 9.1. 

“Governmental Entity” means any court, administrative body, local authority or other governmental or quasi-governmental entity
with competent jurisdiction, any supra-national, national, federal, state, municipal, provincial or local governmental, regulatory or administrative authority, agency, commission, court, tribunal, arbitral body, self-regulated entity, private body
exercising any regulatory, taxing, importing or other governmental or quasi-governmental authority or other governmental entity, including any relevant Regulatory Authority. 

“GSK Group” means GSK together with its Affiliates. 

“GSK Indemnitee” has the meaning given in Clause 28.2. 

“GSK Arising IP” has the meaning given in Clause 8.2. 

“GSK Background IP” means any Intellectual Property, including the Licensed Know-How
that is 
  

	 	(A)	 owned (or licensed to) the GSK Group at the Effective Date; or 

 

	 	(B)	 developed or acquired by, or licensed to (other than by the Purchaser), the GSK Group on or after the Effective
Date. 

 “GSK Intellectual Property” means GSK Background IP and GSK Arising IP. 

“GSK System” has the meaning given in Clause 13.1. 

“GSK System IP” means any and all Intellectual Property subsisting in the GSK System that is GSK Intellectual Property. 

“Indemnified Party” has the meaning given in Clause 28.4. 

“Indemnifying Party” has the meaning given in Clause 28.4. 

“Independent Expert” means a laboratory or other expert mutually agreed upon by the Parties (or, if no such agreement can be
reached within a reasonable time, a laboratory or other expert appointed by the President of the International Chamber of Commerce of London or his nominee upon the application of either Party) with expertise relevant to the matter to be determined.

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 7 

 CONFIDENTIAL 
  

 “Initial Term” has the meaning given in Clause 31.1.  

“Invoice Currency” means pounds sterling (GBP). 

“Insolvency Event” means, in relation to a Person: 
  

	 	(A)	 it is, or is deemed for the purpose of any Applicable Law, to be insolvent or unable to pay its debts as they
fall due; 

  

	 	(B)	 it admits an inability to pay debts as they fall due; 

 

	 	(C)	 it suspends making payments on any of its debts or announces an intention to do so; 

 

	 	(D)	 by reason of actual or anticipated financial difficulties, it begins negotiations with any creditor for the
rescheduling of any of its indebtedness outside the ordinary course of business; 

  

	 	(E)	 it is in breach of any covenant or other term of a loan or financial facility and a counterparty accelerates,
or calls for repayment of, any outstanding indebtedness as a result of such breach; 

  

	 	(F)	 the fair value of its assets is less than its liabilities (taking into account contingent and prospective
liabilities and disregarding inter-company loans between Affiliates); or 

  

	 	(G)	 a moratorium is declared in respect of any indebtedness. 

“Insolvency Proceeding” means, in relation to a Person: 

 

	 	(A)	 any step is taken with a view to a moratorium or a composition or similar arrangement with its creditors;

  

	 	(B)	 a meeting of its shareholders or directors is convened for the purpose of considering any resolution for, to
bring an application for, or to file documents with a court or any registrar for, its winding-up, judicial management or dissolution or any such resolution is passed; 

 

	 	(C)	 any Person brings an application for, or files documents with a court or any registrar for, its winding-up, judicial management or dissolution or such order is made; or 

  

	 	(D)	 a liquidator, judicial manager, administrator or similar officer is appointed in respect of any of its assets.

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 8 

 CONFIDENTIAL 
  

 “Intellectual Property” means Patents, utility models, trademarks, service
marks, rights in designs, copyrights, rights in databases and rights in Know-How (whether or not any of these is registered or capable of registration and including applications for registration of any such
thing) and all other similar rights or forms of protection of a similar nature or having equivalent or similar effect to any of these which may subsist anywhere in the world. 

“Know-How” means any non-public, proprietary
technical information (including information relating to an invention), discovery, process, method, composition, formula, procedure, protocol, technique, result of experimentation or testing, data, trade secret, drawing or other know-how, whether or not patentable or copyrightable. 
 “Latent Defect” means, in respect
of a Product, a Defect existing at the time of Delivery of that Product which [***]. 
 “LAV” or “Local Added
Value” means, in respect of a Product, the [***], but excluding: 
  

	 	(A)	 [***] 

  

	 	(B)	 [***] 

  

	 	(C)	 [***] 

“Lead Time” means the period of time that, from the date of a Firm Order, GSK will require to: 

 

	 	(A)	 supply the relevant Existing Clinical API, Existing Clinical Product or Existing Clinical Placebo (including
sufficient time to allow for ordering and delivery of Materials); or 

  

	 	(B)	 Manufacture and supply to the Third Party responsible for undertaking analytical testing in respect of the
applicable Product, the relevant New Clinical Product, New Clinical Placebo or New Clinical API (including sufficient time to allow for ordering and delivery of Materials and Existing Clinical API), 

in each case as specified in Part A of Schedule 1 or as otherwise notified in writing by GSK to the Purchaser from time to time. For the
avoidance of doubt, Delivery in respect of New Clinical Product, New Clinical Placebo and/or New Clinical API shall not occur until (i) the Third Party responsible for undertaking analytical testing in respect of the applicable Product has
conducted the relevant analytical tests and provided the results of those test to GSK and (ii) GSK has conducted a technical release of that Product on the basis of such results and in accordance with the Quality Agreement and, accordingly, the
Lead Time does not identify the expected date of Delivery in respect of New Clinical Product, New Clinical Placebo and/or New Clinical API. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 9 

 CONFIDENTIAL 
  

 “Losses” means all losses, claims, liabilities, costs, awards, fines,
penalties, expenses (including reasonable legal fees and other professional expenses) and damages of any nature whatsoever and whether or not reasonably foreseeable or avoidable. 

“Maintained Excess Clinical API” has the meaning given in Clause 5.1(C).  

“Manufacture” means the planning, purchasing of Materials for, manufacturing, processing, compounding, storage, filling,
packaging, labelling, leafleting, testing, waste disposal, quality assurance and control, despatch, sample retention and, to the extent permitted by Applicable Law, stability testing and technical release. 

“Manufacturing Licence” means all licences necessary for or in connection with the Manufacture of a Product at the
Manufacturing Site. 
 “Manufacturing Site” means: 
  

	 	(A)	 in respect of Existing Clinical API and (if applicable) New Clinical API, the manufacturing site operated by
GSK or its Affiliate at Cork, Ireland; and 

  

	 	(B)	 in respect of Existing Clinical Products, Existing Clinical Placebo, New Clinical Products and New Clinical
Placebo, the manufacturing site operated by GSK or its Affiliate at Barnard Castle, UK. 

 “Materials”
means APIs, raw materials, intermediates, excipients, processing aids, packaging and labelling materials and components used in Manufacture of the Products. 

“Minimum Order Quantity” or “MOQ” means, in respect of a Product, the quantity equivalent to a standard batch
size for such Product, as specified in Part A of Schedule 1 or as otherwise notified by GSK in writing. 
 “New Clinical
API” has the meaning set forth in Schedule 1.  
 “New Clinical Placebo” has the meaning set forth in
Schedule 1.  
 “New Clinical Products” means New 1% Clinical Products and New 0.5% Clinical Products,
individually or collectively as the context may require. 
 “New 1% Clinical Product” has the meaning set forth in Schedule
1. 
 “New 0.5% Clinical Product” has the meaning set forth in Schedule 1. 

“Nominated Manufacturer” means any member of the GSK Group to whom GSK subcontracts the Manufacture of Products at the
Manufacturing Site. 
 “Nominated Supplier” means any member of the GSK Group to whom GSK
sub-contracts the supply of Products to the Purchaser. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 10 

 CONFIDENTIAL 
  

 “Order” means any binding judgments, orders, writs, injunctions, decisions,
rulings, decrees and awards of any Governmental Entity or arbitral body. 
 “Party” means a party to this Agreement, and
“Parties” shall be construed accordingly. 
 “Patents” means (i) all patents and pending patent
applications, including any and all provisional applications, substitutions, continuations, continuations-in-part, renewals, supplementary protection certificates,
registrations, extensions, reissues, reexaminations or divisionals; (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these,
including divisionals, continuations, continuations-in-part, substitutions, provisionals, converted provisionals, and continued prosecution applications; (iii) any
and all patents that have issued or in the future issue from the foregoing patents and patent applications described in clauses (i) and (ii), including utility models, petty patents and design patents and certificates of invention;
(iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations, supplemental examinations, inter partes reviews,
post-grant reviews, oppositions and other existing or future post-issuance proceedings, and extensions (including future pending or issued unexpired patent term extension or supplemental protection certificate or equivalent extension right) of the
foregoing patents or patent applications described in clauses (i), (ii) and (iii); (v) any and all letters patent in the United States and all foreign countries which may be granted therefore and thereon; and (vi) all rights under the
International Convention for the Protection of Industrial Property. 
 “Person” means any individual, general partnership,
limited partnership, limited liability partnership, limited liability company, corporation, trust, joint venture, association, organization or other entity or Governmental Entity, or any agency or political subdivisions thereof. 

“Personnel” has the meaning given in Clause 22.2. 

“Price” means: 
  

	 	(A)	 in respect of a Product, the price set forth in (or determined in accordance with) Part B of Schedule 1 and
Clause 11; and 

  

	 	(B)	 in respect of a Development Service, the price set forth in (or determined in accordance with) Schedule 2 and
the applicable Scope of Work. 

 “Proceedings” means any action, arbitration, investigation, litigation or
suit commenced, brought, conducted, or heard by or before, or otherwise involving, any Governmental Entity or arbitrator. 

“Product” means the Existing Clinical API, Existing Clinical Products, Existing Clinical Placebo, New Clinical API, New
Clinical Products, and New Clinical Placebo, individually or collectively as the context may require. 
 “Product Base Cost”
has the meaning given in Schedule 1, Part B.  
 “Product Event” has the meaning given in Clause 20.2. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 11 

 CONFIDENTIAL 
  

 “Product Licence” means any product licence, marketing authorisation or
other authorisation(s) required for the Development, Commercialisation, clinical investigation, import or export of the Products in the Territory. 

“Purchase Agreement” means the Asset Purchase Agreement dated July 10, 2018 by and among GlaxoSmithKline Intellectual
Property Development Limited, Glaxo Group Limited and Dermavant Sciences GmbH. 
 “Purchased Clinical API” has the meaning
given in Clause 5.1(B) 
 “Purchaser Arising IP” has the meaning given in Clause 8.3. 

“Purchaser Background IP” means any Intellectual Property that is 

 

	 	(A)	 owned by (or licensed to) the Purchaser or its Affiliates at the Effective Date, including the Transferred IP;
or 

  

	 	(B)	 developed or acquired by, or licensed to (other than by GSK), the Purchaser or its Affiliates on or after the
Effective Date. 

 “Purchaser Indemnitee” has the meaning given in Clause 28.1. 

“Purchaser Intellectual Property” means Purchaser Background IP and Purchaser Arising IP. 

“Purchaser Materials” means the Purchased Clinical API and other Toll Materials. 

“Purchaser Materials Certificate of Analysis” means a document identified as such, signed or released by a Qualified Person
(or Person designated by the Qualified Person to sign or release such document) in accordance with cGMP that: 
  

	 	(A)	 sets forth the analytical test results for each specified lot of Purchaser Materials; and

  

	 	(B)	 confirms that such Purchaser Materials have been manufactured in accordance with the applicable Specifications.

 “Qualified Person” means the Person employed (or whose services are otherwise engaged) by (i) GSK
or its Affiliate (in respect of Existing Clinical API, Existing Clinical Product and Existing Clinical Placebo) or (ii) the Purchaser or its Affiliate (in respect of New Clinical API, New Clinical Product and New Clinical Placebo) who is
responsible for authenticating the pharmaceutical analysis of the applicable Product, as required under Applicable Law (including, if applicable, EC Directive 2001/83/EC). 

“Quality Agreement” means the quality agreement between GSK (or its Affiliate) and the Purchaser to be entered into within
[***] after the Effective Date. 
 “Quality Management System” means the GSK Group’s system of quality management
controls designed to ensure regulatory compliance and to assure product safety, quality and efficacy in the GSK Group’s operations with regard to the manufacture and supply of investigational materials or products for sale or distribution and
implemented pursuant to the GSK Group’s Corporate Policy entitled Quality Management System (POL-GSKF-514). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 12 

 CONFIDENTIAL 
  

 “Receiving Party” has the meaning given in Clause 22.1. 

“Reconciliation Value” means the value calculated in accordance with the formula set forth in Schedule 3 (Toll Manufacture
Provisions), paragraph 3.3. 
 “Regulatory Approval” means, in a particular country or regulatory jurisdiction, any and
all approvals (including pricing and reimbursement approvals), licences, registrations or authorizations of any Regulatory Authority or any other Governmental Entity (including INDs, product approvals, pricing approvals, import permits, and, in each
case any supplements and amendments thereto) necessary or useful for the testing, commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export and sale of any compound or (bio)pharmaceutical product in a given
country or regulatory jurisdiction. 
 “Regulatory Approval Application” means an application submitted to the appropriate
Regulatory Authority seeking Regulatory Approval of a Product in a country in the Territory, including INDs and NDAs (new drug applications). 

“Regulatory Authority” means, in a particular country or regulatory jurisdiction, any applicable supranational, national,
regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Entity involved in granting Regulatory Approval for a product in such country or regulatory jurisdiction, including without limitation, the
FDA. 
 “Regulatory Documentation” means any and all (i) applications, registrations, licenses, authorizations and
approvals, and non-clinical and clinical study authorization applications or notifications (including all INDs, Regulatory Approval Applications, Regulatory Approvals and amendments and supplements to any of
the foregoing and all supporting files, writings, data, studies and reports) prepared for submission to a Regulatory Authority or any other Governmental Entity with a view to the obtaining or maintaining of any Regulatory Approval,
(ii) substantive correspondence to or with the FDA, any Regulatory Authority or any other Governmental Entity, (iii) pharmacovigilance databases, adverse drug experience reports and associated documents, and investigations of adverse drug
experience reports, and (iv) nonclinical, clinical and other data contained or referenced in or supporting any of the foregoing.  

“Rejection Notice” has the meaning given in Clause 15.1. 

“Renewal Term” has the meaning given in Clause 31.1. 

“Reporting Year” means, in respect of each New Clinical Product, (i) the period commencing on the Effective Date and
ending on the next occurring December 31st and (ii) each subsequent Calendar Year during the Term.  
 “Returns”
shall mean any and all returns, reports, forms (including elections, declarations, amendments, claims for refund, schedules, information returns or attachments thereto) and any other documents filed or required to be filed with a Governmental Entity
with respect to Taxes. 
 “Safety Stock Fee” has the meaning given in Clause 6.3. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 13 

 CONFIDENTIAL 
  

 “Sales Tax” means any sales, goods, services, turnover, value-added, or
similar Tax and any Tax charged on the import or export of any goods or services, including VAT but excluding any Tax imposed on or with respect to the income of GSK or any of its Affiliates (however denominated). 

“Scope Change” has the meaning given in Clause 3.6.  

“Scope of Work” has the meaning given in Clause 3.2. 

“Storage Fee” has the meaning given in Clause 5.4. 

“Specifications” means, with respect to each Product, the technical specifications for the required quality and
characteristics of the Product as agreed between the Parties in writing in the Quality Agreement (as the same may be amended from time to time in accordance with this Agreement). 

“Tax” or “Taxes” means any and all taxes, assessments, levies, tariffs, duties, or other charges imposed by a
Governmental Entity, including all federal, state, territory, local, foreign and other income, franchise, profits, gross receipts, capital gains, capital stock, transfer, sales, use, Value Added Tax, ad valorem, occupation, property, excise,
severance, windfall profits, stamp, licence, payroll, employment, unemployment, disability, social security, withholding, escheat, environmental, customs duty, estimated and other taxes, assessments, charges, duties, fees, levies or other
governmental charges imposed by any Governmental Entity of any kind whatsoever (whether payable directly or by withholding and whether or not requiring the filing of a Return), together with any penalties and interest and any additional amounts with
respect thereto and shall include any liability for such amounts as a result of (i) being a transferee or successor or member of a combined, consolidated, unitary or affiliated group, or (ii) a contractual obligation to indemnify any
Person or other entity. 
 “Technical Change Procedure” means the procedure for changing the Specifications for the Product,
as set forth in the Quality Agreement. 
 “Technology Transfer” has the meaning given in Clause 30.1.  

“Technology Transfer Plan” has the meaning given in Clause 30.1. 

“Term” has the meaning given in Clause 31.1. 

“Terminating Party” has the meaning given in Clause 31.3. 

“Territory” means worldwide, excluding the China Territory. 

“Third Party” means a Person who or which is neither a Party nor an Affiliate of a Party. 

“Third Party Claim” means all demands, claims, actions and Proceedings by a Third Party or liability to a Third Party (in each
case, whether criminal or civil, in contract, tort or otherwise) for Losses related to such demand, claim, action or Proceeding. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 14 

 CONFIDENTIAL 
  

 “Toll Material” means, in respect of a New Clinical Product, API for use in
the Manufacture of that New Clinical Product, including any applicable (i) Purchased Clinical API purchased by the Purchaser pursuant to Clause 5, (ii) Maintained Excess Clinical Supply maintained by GSK on behalf of the Purchaser pursuant to
Clause 5 and subsequently purchased by Purchaser in accordance with Clause 2.2(B), or (iii) New Clinical API Manufactured by GSK and purchased by the Purchaser pursuant to this Agreement. 

“Value Added Tax” or “VAT” means the tax imposed by Council Directive 2006/112/EC of the European Community
and any national legislation implementing that directive together with legislation supplemental thereto and in particular, in relation to the United Kingdom, the tax imposed by the Value Added Tax Act of 1994 or other tax of a similar nature imposed
elsewhere instead of or in addition to value added tax; and outside the European Union (and including the United Kingdom in the event that the United Kingdom ceases to be a member of the European Union during the term of this Agreement), any tax
corresponding to, or substantially similar to, the common system of value added tax referred to in this definition, excluding any Tax imposed on or with respect to the income of GSK or any of its Affiliates. 

“WIP” has the meaning given to it in Schedule 3 (Toll Manufacture Provisions) paragraph 2.1. 

“Working Hours” means 09:00 to 17:00 on a Business Day. 

 

	1.2	 In this Agreement, unless otherwise specified: 

 

	 	(A)	 any Schedules form part of this Agreement and shall have the same force and effect as if set forth in the body
of this Agreement, and references to this Agreement include them; 

  

	 	(B)	 references to Recitals, Clauses and Schedules are to recitals and clauses of, and schedules to, this Agreement
and references in a Schedule or part of a Schedule to paragraphs are to paragraphs of that Schedule or that part of that Schedule; 

  

	 	(C)	 the headings and contents table in this Agreement are for convenience only and do not affect its
interpretation; 

  

	 	(D)	 references to the singular include the plural and vice versa; 

 

	 	(E)	 words denoting persons include individuals, companies, partnerships, unincorporated associations and other
bodies (in each case, wherever resident and whether or not having separate legal personality) and references to a company shall include any company, corporation or other body corporate wherever or however incorporated or established;

  

	 	(F)	 a reference to: 

  

	 	(i)	 a statute, statutory provision, regulation, directive or other enactment shall be construed as including a
reference to any subordinate legislation or instrument made from time to time under that statute, provision, regulation, directive or enactment whether before, on or after the date of this Agreement; and 

 

	 	(ii)	 a statute, statutory provision, regulation, directive, enactment or subordinate legislation shall be construed
as including a reference to that statute, provision, regulation, directive, enactment or subordinate legislation as in force at the date of this Agreement and as from time to time amended, modified, consolidated, superseded, re-enacted or replaced (whether with or without modification) after the date of this Agreement; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 15 

 CONFIDENTIAL 
  

	 	(G)	 general words shall not be given a restrictive meaning by reason of the fact that they are preceded by or
followed by particular examples intended to be embraced by the general words and accordingly: 

  

	 	(i)	 the rule known as ejusdem generis shall not apply; and 

 

	 	(ii)	 the words “includes”, “including” and “in particular” (or
similar term) are not to be construed as implying any limitation and shall be read and construed as if immediately followed by the words “without limitation”; 

 

	 	(H)	 any reference to this Agreement or any other document is to this Agreement or that document as in force for the
time being and as amended from time to time in accordance with this Agreement and/or that document (as the case may be); 

  

	 	(I)	 if a payment under this Agreement is due on a day which is not a Business Day, the due date for that payment
shall be the next Business Day; and 

  

	 	(J)	 terms other than those defined in this Agreement shall be given their plain English meaning and those terms,
acronyms and phrases known in the pharmaceutical/ healthcare industry shall be interpreted in accordance with their generally accepted meanings. 

  

	2.	 GSK’S OBLIGATIONS 

 

	2.1	 With effect from the Effective Date and in consideration of the Price, GSK shall (i) supply to the
Purchaser Existing Clinical API in accordance with Clause 5 (Purchase, Maintenance and Destruction of Existing Clinical API), (ii) supply to the Purchaser Existing Clinical Products and 

Existing Clinical Placebo as ordered from time to time by the Purchaser in accordance with Clause 9 (Product Forecasts and Orders),
(iii) Manufacture (or have Manufactured) and supply to the Purchaser, as applicable, New Clinical API, New Clinical Products, and New Clinical Placebo as ordered from time to time by the Purchaser in accordance with Clause 2.2 and Clause 9
(Product Forecasts and Orders), and (iv) perform the Development Services as set forth in Schedule 2 (Scope of Work for Development Services), in each case subject to the terms of this Agreement. 

 

	2.2	 The Purchaser shall rely initially on Purchased Clinical API, Existing Clinical Products and Existing Clinical
Placebo to fulfil its clinical and nonclinical development program needs. 

  

	 	(A)	 To the extent Purchaser requires additional API (other than Purchased Clinical API or the Maintained Excess
Clinical API) to support its clinical and nonclinical development program needs, in each case such that GSK would be required to Manufacture (or have Manufactured) New Clinical API, the Parties will discuss applicable lead times, the MOQ, and
Pricing to support the Manufacture of such New Clinical API; provided that applicable lead times (which are likely to exceed [***]) will be dependent on the availability of GSK’s pilot plant in [***] as well as the time required to
complete the multiple stages of manufacture in relation to the New Clinical API. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 16 

 CONFIDENTIAL 
  

 [***] 
  

	 	(B)	 To the extent Purchaser requires additional Clinical Product (i.e., Clinical Product other than Existing
Clinical Products) to support its clinical and nonclinical development program needs, GSK shall Manufacture (or have Manufactured) New Clinical Product in accordance with the provisions of Schedule 3 (Toll Manufacture Provisions). The Parties
acknowledge and agree that GSK shall Manufacture (or have Manufactured) all New Clinical Product on a toll Manufacturing basis (i) initially using the Purchased Clinical API that the Purchaser shall provide to GSK on a zero cost (consignment)
basis, (ii) secondly, using the Maintained Excess Clinical API purchased by Purchaser pursuant to Clause 5.4 that the Purchaser shall provide to GSK on a [***] basis, and (iii) lastly using any New Clinical API Manufactured pursuant to
Clause 2.2(A) and provided to GSK on a [***] basis. 

  

	 	(C)	 To the extent Purchaser requires additional Clinical Placebo (i.e., Clinical Placebo other than Existing
Clinical Placebo) to support its clinical and nonclinical development program needs, GSK shall Manufacture (or have Manufactured) New Clinical Placebo in [***]. 

 

	2.3	 GSK shall Manufacture (or have Manufactured), as applicable, the New Clinical API, New Clinical Products, and
New Clinical Placebo at the Manufacturing Site (and GSK has Manufactured (or had Manufactured), as applicable, the Existing Clinical API, Existing Clinical Products, and Existing Clinical Placebo at the Manufacturing Site), in each case in
accordance with: 

  

	 	(A)	 Current Good Manufacturing Practice; 

 

	 	(B)	 the applicable Specifications (or, in respect of Existing Clinical API, Existing Clinical Products, and
Existing Clinical Placebo, the specifications in place at the date of Manufacture of such Existing Clinical API, Existing Clinical Products, and Existing Clinical Placebo); 

 

	 	(C)	 the Manufacturing Licence; 

 

	 	(D)	 the Quality Agreement; and 

 

	 	(E)	 all laws and regulations relevant to the Manufacture of the relevant Product at the Manufacturing Site.

  

	2.4	 Notwithstanding Clause 30.1, GSK shall not be required to use (and shall not use) in the Manufacture of New
Clinical Product any API that has not been Manufactured by GSK or its Affiliate. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 17 

 CONFIDENTIAL 
  

	2.5	 Subject to Clause 3 (Development Services), GSK shall perform the Development Services, if any are
requested and agreed by the Parties, in accordance with the Scope of Work and all laws and regulations relevant to the performance of the Development Services. 

 

	2.6	 Subject to Clause 2.3 and without prejudice to the generality of Clause 37
(Sub-Contractors), the Parties hereby acknowledge that GSK may: 

  

	 	(A)	 use any member of the GSK Group to Manufacture the New Clinical API, New Clinical Products, and New Clinical
Placebo for and on behalf of GSK, provided that: 

  

	 	(i)	 such Manufacture shall take place at the Manufacturing Site; and 

 

	 	(ii)	 GSK shall remain primarily liable to the Purchaser as principal obligor for the performance of its obligations
under this Agreement in respect of such Manufacture; and 

  

	 	(B)	 nominate any member of the GSK Group to act as its Nominated Supplier under this Agreement to supply Products
to, and receive payment from, the Purchaser, provided that GSK shall remain primarily liable to the Purchaser as principal obligor for the performance of its obligations under this Agreement in respect of such supply.

  

	2.7	 GSK reserves the right to change the Nominated Manufacturer and/or the Nominated Supplier from time to time by
notice in writing to the Purchaser. 

  

	2.8	 Notwithstanding the entry into force of this Agreement in accordance with Clause 31.1, the commencement of
GSK’s obligations under this Agreement with respect to the Manufacture and supply of the Products, as applicable, is subject to, and conditional on, the entry of the Parties and/or their Affiliates into the Quality Agreement.

  

	2.9	 The Purchaser acknowledges that GSK will cease performing the Development Services and the Manufacture and
supply of the Products at the latest on expiry of the Term. For the avoidance of doubt, without prejudice to Clause 32 (Consequences of Expiry or Termination) and except as otherwise provided for under Clause 30 (Technology Transfer),
the Purchaser shall be solely responsible for making alternative arrangements for the Manufacture and supply of the Products and the performance of any development services in connection with the Products following the expiry or termination of this
Agreement. 

  

	3.	 DEVELOPMENT SERVICES 

 

	3.1	 The Parties may agree that GSK shall perform certain development work in connection with:

  

	 	(A)	 the Manufacture and supply of New Clinical Product and/or New Clinical Placebo (including new configurations of
such Products); and/or 

  

	 	(B)	 the provision of data to enable Purchaser’s authoring of clinical trial regulatory submissions,

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 18 

 CONFIDENTIAL 
  

 (“Development Services”), provided that such Development Services
shall not include development work in anticipation of the manufacture or regulatory approval of active ingredients or products specifically for Commercialisation, provided, however, that GSK acknowledges and agrees that such
Development Services may result in deliverables that can or will subsequently be used for Commercialisation (i.e., generation of new product configurations). 
  

	3.2	 The Purchaser may from time to time request that GSK perform Development Services (but not, for the avoidance
of doubt, any other Development). GSK shall consider each such request and shall, acting reasonably but in its sole discretion, taking due account of GSK’s and/or the Nominated Manufacturer’s and/or the GSK Group’s business,
constraints, available resources and plans, determine whether or not to support the requested Development Services. Any Development Services agreed between the Parties shall be documented in a scope of work in the form set forth in Schedule 2 (each
a “Scope of Work”) which shall define the roles and responsibilities of the Parties in the performance of such Development Services, including the tasks to be completed and any deliverables to be delivered by GSK, together with a non-binding timeline for the performance, completion and/or delivery of the applicable Development Services. 

  

	3.3	 Each Party shall use its Commercially Reasonable Efforts to perform the Development Services in accordance with
the applicable Scope of Work and the timelines for the performance, completion and/or delivery of such Development Services set forth in the applicable Scope of Work. 

 

	3.4	 Neither GSK nor any of its Affiliates shall bear any liability under or in relation to this Agreement in
connection with any failure to perform, complete or deliver, or delay in performing, completing or delivering, any Development Services resulting from any failure, default or delay on the part of the Purchaser in performing the tasks and
obligations, or delivering the deliverables, assigned to the Purchaser under the applicable Scope of Work or resulting from any delay in supply, or defect in, the Purchaser. 

 

	3.5	 The Purchaser shall pay to GSK (or its nominated Affiliate) such fees, costs, expenses, payments and other sums
as may be specified in a Scope of Work. In the event that the Scope of Work does not provide for the payment of fees, costs, expenses, milestone payments or other sums, the Purchaser shall reimburse to GSK (or its nominated Affiliate) all costs and
expenses incurred in respect of the Development Services undertaken pursuant to such Scope of Work, provided that such costs and expenses are agreed in advance by the Parties. 

 

	3.6	 Any proposed change or addition to the Development Services or the timeline for the performance, completion or
delivery of such Development Services shall be deemed a proposal to change the Scope of Work (a “Scope Change”). Either Party may propose a Scope Change, but no Scope Change shall be implemented without the prior written agreement
of the other Party. If a Scope Change is agreed by the Parties, the Parties shall document the Scope Change (including any change in fees payable) in a supplementary addendum to, or an amended and restated version of, the Scope of Work and, with
effect from the date on which the Scope Change is so documented, all references in this Agreement to the Scope of Work shall be deemed to be references to the Scope of Work as so supplemented or amended and restated (as the case may be) and all
references to the Development Services shall be deemed to be references to the Development Services as documented in the supplemented, or amended and restated, Scope of Work. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 19 

 CONFIDENTIAL 
  

	3.7	 At the end of each month, GSK and the Purchaser shall review the status of the Development Services (and each
Party shall share any relevant information for the purposes of such review) and, in the event of any Scope Change and/or delay in the performance of the Development Services, each Party shall use Commercially Reasonable Efforts to agree on new
timeframes for the applicable Development Services. If the Parties fail to agree on new timeframes for the applicable Development Services within [***] of commencing discussions and a dispute arises, such dispute shall be determined in accordance
with the provisions of Clause 45 (Dispute Resolution). 

  

	3.8	 The Purchaser acknowledges that, save for the Development Services and with effect from the Effective Date, the
GSK Group will not support any development work in respect of the Manufacture of any Product (including variations to Product Licences required as a result of such work), unless such work is required by Applicable Law. The Purchaser shall [***] in
respect of any such development work undertaken pursuant to this Clause 3.8 and the implementation of such development work, provided that [***]. 

  

	3.9	 In the event that the Purchaser fails to pay any undisputed sum in respect of any Development Services, or any
development work (or its implementation) for which the Purchaser is to bear the cost pursuant to Clause 3.8, then in such an event: 

  

	 	(A)	 neither GSK nor its Affiliates shall bear any liability under this Agreement for any breach of its terms
resulting from any failure to carry out, or delay in carrying out, such Development Services or other development work; and 

  

	 	(B)	 the Purchaser shall indemnify each member of the GSK Group against all actions, Proceedings, demands and claims
by any Third Party arising from any failure to carry out, or delay in carrying out, such work. 

  

	4.	 PURCHASER’S OBLIGATIONS 

 

	4.1	 Subject to Clause 30.4, during the Term, the Purchaser shall purchase [***] of its requirements for Products
from GSK (or the Nominated Supplier) in accordance with this Agreement. 

  

	4.2	 The Purchaser shall not (itself or through any Third Party): 

 

	 	(A)	 expressly or implicitly market, advertise or otherwise promote in any way the sale of any Product as a GSK
Group product or as containing any GSK Group product; or 

  

	 	(B)	 use the name or logo of any member of the GSK Group in connection with any Product, 

in each case, unless (and only to the extent) required to do so by Applicable Law. If the Purchaser contends that it is required by Applicable
Law to do any act or thing covered by this Clause 4.2, it shall: 
  

	 	(i)	 prior to doing any such act or thing, provide GSK with a copy of all relevant materials; and

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 20 

 CONFIDENTIAL 
  

	 	(ii)	 consider in good faith any comments GSK may have in respect of the manner in which the name of any member of
the GSK Group is used in such materials; and 

  

	 	(iii)	 if such materials include the logo of any member of the GSK Group, not use such materials without GSK’s
prior written approval (such approval not to be unreasonably withheld). 

 For the avoidance of doubt, a breach of this
Clause 4.2 will constitute a material breach of this Agreement. 
  

	4.3	 Purchaser shall manage or perform all services for Clinical Trial labelling and distribution to the
Purchaser’s Clinical Trial centres. 

  

	5.	 PURCHASE, MAINTENANCE, AND DESTRUCTION OF EXISTING CLINICAL API 

 

	5.1	 The Purchaser shall: 

 

	 	(A)	 no later than [***], provide GSK with written notification of the full amount of Existing Clinical API that the
Purchaser requires for the purposes of its clinical and nonclinical development program during the Term and desires to purchase from GSK; 

  

	 	(B)	 no later than [***], purchase all such requested Existing Clinical API from GSK (the “Purchased
Clinical API”); and 

  

	 	(C)	 no later than [***], provide GSK with written notification of any excess Existing Clinical API (i.e., any
Existing Clinical API not included in the Purchased Clinical API) (the “Excess Clinical API”) Purchaser requests GSK to maintain (the “Maintained Excess Clinical API”). 

 

	5.2	 The Purchaser acknowledges and agrees that as of the Effective Date, the expectation of the Parties is that the
Existing Clinical API will be sufficient to support Purchaser’s expected clinical and nonclinical development program during the Term, unless batch failures, regulatory circumstances or unexpected results obtained in the course of any Clinical
Trial, in each case outside the control of Purchaser, or expiry warrants the Manufacture of New Clinical API. 

  

	5.3	 GSK shall invoice the Purchaser for the Purchased Clinical API. Title to such Purchased Clinical API shall pass
to the Purchaser upon receipt of such invoice. Upon such transfer of title, such Purchased Clinical API shall be a Toll Material for the purposes of Schedule 3 (Toll Manufacture Provisions). 

 

	5.4	 During the Term, the Purchaser shall pay GSK a storage fee to cover [***] incurred in connection with holding
and storing the Maintained Excess Clinical API on behalf of the Purchaser (the “Storage Fee”). The Storage Fee is set forth on Schedule 4 (Fees). During the Term, Purchaser may purchase the Maintained Excess Clinical API from
GSK (at the Price set forth in Part B of Schedule 1). GSK shall invoice the Purchaser for the subsequent purchase of Maintained Excess Clinical API. Title to such purchased Maintained Excess Clinical API shall pass to the Purchaser upon receipt of
such invoice. Upon such transfer of title, such purchased Maintained Excess Clinical API shall be a Toll Material for the purposes of Schedule 3 (Toll Manufacture Provisions) and any work-in-progress into which such purchased Maintained Excess Clinical API has been incorporated shall be WIP for the purposes of Schedule 3 (Toll Manufacture Provisions). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 21 

 CONFIDENTIAL 
  

	5.5	 After [***], GSK is entitled to destroy any Excess Clinical API not otherwise included in the Purchased
Clinical API or Maintained Excess Clinical API. 

  

	6.	 MATERIALS 

  

	6.1	 GSK (or the Nominated Manufacturer) shall be responsible for ordering and purchasing all Materials required to
enable GSK to meet its Development Services, Manufacturing and supply obligations under this Agreement; provided that for the purposes of Manufacturing New Clinical Product the Purchaser shall provide Purchased Clinical API, Maintained Excess
Clinical API and/or New Clinical API previously purchased from GSK on a [***] basis. The costs of the Materials and the management and procurement of such Materials shall be [***]. 

 

	6.2	 Subject to the terms of the Quality Agreement and Clause 17.1, GSK may change the supplier of any Materials at
any time; provided that GSK will consult with the Purchaser prior to changing or introducing any new Materials to meet its Manufacturing and supply obligations under this Agreement. 

 

	6.3	 During the Term, GSK shall maintain safety stock quantities of raw materials such that GSK will be able to
support the Purchaser’s orders for New Clinical Products or New Clinical Placebo within [***] of the current Forecast Schedule. The Purchaser shall pay GSK a storage fee to cover any GSK costs and expenses incurred in connection with holding
and storing such safety stock (the “Safety Stock Fee”). The Safety Stock Fee is set forth on Schedule 4 (Fees). 

  

	7.	 PURCHASER MATERIALS 

 

	7.1	 The Purchaser shall supply the Purchaser Materials to GSK in a timely manner [***] on a [***] basis. Purchased
Clinical API and Maintained Excess Clinical API subsequently purchased by the Purchaser pursuant to Clause 2 shall be deemed to have been supplied in a timely manner if the Parties agree that such Purchaser Materials shall be left in GSK’s
possession on consignment. 

  

	7.2	 GSK will not (and will procure that the Nominated Manufacturer does not) use the Purchaser Materials for any
purpose other than the Manufacture of New Clinical Products for the Purchaser under this Agreement (including for testing, quality and compliance purposes). 

  

	7.3	 GSK shall not be liable for any failure to meet, or for any delay in meeting, any Firm Order for New Clinical
Products if such failure is as a result of any failure by the Purchaser to supply, or delay by the Purchaser in supplying, in a timely manner sufficient quantities of Purchaser Materials that comply with all applicable requirements of Applicable
Law, cGMP and the applicable Specifications and have sufficient unexpired shelf life to enable such Purchaser Materials to be the Manufacture of Products in accordance with the schedule of Deliveries of any New Clinical Products contemplated by the
Forecast Schedule; except in the event that such failure is due to the failure of GSK to supply New Clinical API in a timely manner or that meets cGMP (having regard to the Lead Time agreed between the Parties in respect of such New Clinical API
pursuant to Clause 2.2(A) and the time required for analytical testing and GSK’s release in accordance with (and to the extent required by) the Quality Agreement prior to Delivery of such New Clinical API). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 22 

 CONFIDENTIAL 
  

	7.4	 Each consignment of Purchaser Materials will be accompanied by Certificate of Analysis relating to such
Purchaser Materials signed by, as applicable: 

  

	 	(A)	 GSK’s or its Affiliate’s Qualified Person in respect of Purchased Clinical API and/or Maintained
Excess Clinical API subsequently purchased by the Purchaser pursuant to Clause 2; or 

  

	 	(B)	 the Purchaser’s Qualified Person in respect of New Clinical API. 

 

	7.5	 The Purchaser shall retain title to the Purchaser Materials at all times. From the time Purchaser Materials are
delivered to GSK’s loading dock at the relevant Manufacturing Site to the time such Purchaser Materials are returned (or Product is delivered) to the Purchaser’s designated carrier at GSK’s loading dock, GSK shall bear the risk of
loss of or damage to such Purchaser Materials arising from [***] and shall be responsible for compensating the Purchaser for the lost or damaged Purchaser Materials (up to an amount not exceeding the Actual Cost of such Purchaser Materials to the
Purchaser). At all other times and in all other circumstances, the Purchaser and shall bear the risk of loss or destruction to the Purchaser Materials. 

  

	7.6	 For the avoidance of doubt, GSK, or its Affiliate, has Manufactured (or, in the case of any New Clinical API,
will Manufacture under this Agreement) all Purchaser Materials. 

  

	7.7	 The Purchaser shall inform and keep GSK and the Nominated Manufacturer informed of all safety hazards and
changes in regulations and guidance (statutory or otherwise) which the Purchaser or its Affiliate knows or believes affect or may affect the use, handling, storage, labelling, transport, treatment and disposal of any Purchaser Materials.

  

	8.	 INTELLECTUAL PROPERTY 

 

	8.1	 Each Party shall at all times remain the owner of its respective GSK Background IP or Purchaser Background IP.

  

	8.2	 All Intellectual Property or Know-How generated by or on behalf of GSK
(whether alone or together with Purchaser or Purchaser’s Affiliate) in the course of the performance of the obligations, services and activities under this Agreement (including Intellectual Property, KnowHow or improvements relating to the
manufacture of pharmaceutical products generally or related to the Manufacturing Site), other than Intellectual Property or Know-How that is exclusive to Developing, Manufacturing, or Commercialising the API,
Clinical Products, Clinical Placebo or the Purchaser Background IP, shall be owned by GSK (the “GSK Arising IP”). For clarity, GSK Arising IP shall not include Purchaser Background IP or Purchaser Arising IP. 

 

	8.3	 All Intellectual Property or Know-How generated by or on behalf of the
Parties (or either of them) in the course of the performance of the obligations, services and activities under this Agreement that is exclusive to Developing, Manufacturing, or Commercialising the API, Clinical Products. Clinical Placebo or the
Purchaser Background IP shall be owned by the Purchaser (the “Purchaser Arising IP”). For clarity, Purchaser Arising IP shall not include GSK Background IP or GSK Arising IP. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 23 

 CONFIDENTIAL 
  

	8.4	 The Purchaser hereby grants to GSK and its Affiliates a non-exclusive,
worldwide, fully paid-up and royalty free licence (with the right to grant sub-licences to Nominated Manufacturers) to use the Purchaser Intellectual Property solely as necessary for the performance of
GSK’s obligations under this Agreement, including supplying and Manufacturing (or having Manufactured) the applicable Products and the performance of the Development Services. GSK will not use any Purchaser Background IP, Purchaser Know-How or Purchaser Arising IP for any other purpose nor will it disclose or otherwise share any Purchaser Background IP, Purchaser Know-How or Purchaser Arising IP with any
Third Party. 

  

	8.5	 To the extent that the output of the Development Services or any deliverables or results produced by GSK in
connection with its performance under this Agreement incorporates any GSK Background IP, GSK Know-How or GSK Arising IP, GSK hereby grants to the Purchaser a
non-exclusive, perpetual, fully paid-up and royalty free licence (with the right to grant sublicences, including through multiple tiers) to use any such GSK Background
IP, GSK KnowHow or GSK Arising IP solely and exclusively to the extent necessary for the purposes of Developing, Manufacturing or Commercialising the Products. Except as otherwise expressly provided for under the Purchase Agreement, the Purchaser
shall not use any GSK Background IP, GSK Know-How or GSK Arising IP anywhere else or for any other purpose and shall not disclose or otherwise share GSK Background IP, GSK
Know-How or GSK Arising IP with any Third Party. 

  

	8.6	 At the other Party’s reasonable expense, each Party shall do all such further acts and things, and execute
all such other documents as the other Party may from time to time reasonably require in order to give full effect to the assignments and licences of rights granted under this Agreement. 

 

	8.7	 Nothing in this Agreement shall be deemed or implied to be, and each Party disclaims all implied rights to, the
grant by a Party to the other Party of any right, title or interest in such Party’s Confidential Information or Intellectual Property, except as are expressly set forth in this Agreement. 

 

	9.	 PRODUCT FORECASTS AND ORDERS 

 

	9.1	 The Purchaser shall provide to GSK or (if GSK so directs) the Nominated Manufacturer, on the [***] (or on such
other date or at such frequency, as the Parties may agree in writing), a rolling forecast schedule of volume requirements for each Clinical Product and Clinical Placebo for at least the following [***] or such shorter period as may then remain under
the Term (the “Forecast Schedule”). The Forecast Schedule shall show estimates of required Product quantities by SKU on a [***] basis for the Firm Zone and thereafter on a [***] basis. Without prejudice to Clause 2.8, the first such
Forecast Schedule shall be provided to GSK on the Effective Date. 

  

	9.2	 The quantity requirements shown for Clinical Product and Clinical Placebo in the [***] of the Forecast Schedule
(the “Firm Zone”) will constitute a binding commitment on the part of the Purchaser to purchase such specified quantities of such Products. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 24 

 CONFIDENTIAL 
  

	9.3	 The Purchaser shall deliver purchase orders or equivalent documentation, corresponding to the Clinical Product
and Clinical Placebo volumes shown in [***] of the Firm Zone to GSK on a [***] basis. Each purchase order shall, as applicable, unless otherwise agreed between the Parties: 

 

	 	(A)	 comprise of quantities equivalent to the MOQ (or a multiple thereof, each as set forth on Schedule 1) for each
Product covered by that purchase order. If GSK does (in its discretion) accept a purchase order for a quantity of Product that is not the applicable MOQ (or a multiple thereof), the Purchaser shall remain liable under Clause 18 (Write Offs)
for [***]; and 

  

	 	(B)	 specify the quantities of Product ordered (by SKU and by country), and required date for despatch to the Third
Party responsible for undertaking analytical testing of that Product, which shall be no less than the applicable Lead Time (as set forth on Schedule 1) from the date of the relevant purchase order. Unless expressly agreed otherwise between the
Parties or as otherwise set forth on Schedule 1, (i) no New Clinical Product or New Clinical Placebo shall have a Lead Time of less than [***] and (ii) no New Clinical API shall have a Lead Time of less than [***]. 

 

	9.4	 Purchase orders issued by the Purchaser under Clause 9.3 shall be delivered either electronically or by such
other means, and to such location or contact person or system, as GSK shall specify in writing. GSK or the Nominated Manufacturer shall respond to each such purchase order received from the Purchaser within [***] of receipt. Provided
that the quantity requirements for any purchase order comply with the restrictions set forth in Clause 9.3 and subject to Clause 9.5, GSK shall accept the purchase order (each such order then becoming a “Firm Order”) and its
response shall include confirmation of the quantity and the date for Delivery. 

  

	9.5	 In the event that discussion is required regarding the timing of Manufacture and Delivery of any Firm Order (or
any adjustment to the quantities set forth in the Firm Order), the relevant planning personnel from both Parties will use reasonable endeavours to agree and confirm any necessary changes to the Firm Order concerned and to the Forecast Schedule.
Notwithstanding the foregoing, GSK shall have no obligation to agree to any production schedule or Delivery timetable which would exceed GSK’s (or the Nominated Manufacturer’s) anticipated capacity or otherwise present an unreasonable
interference with GSK’s (or the Nominated Manufacturer’s) other operations, including any current operational processes (including shift patterns), or allocation of manufacturing capacity. 

 

	9.6	 GSK shall use Commercially Reasonable Efforts during Working Hours to satisfy any changes in quantity, Delivery
phasing or Delivery dates requested by the Purchaser in respect of a Firm Order or any additional order, provided that: 

  

	 	(A)	 the Purchaser shall [***] in the event it is able to meet such change; and 

 

	 	(B)	 without prejudice to Clause 9.6(A), if the Purchaser wishes to reduce the quantities of Product in any Firm
Order and GSK (or the Nominated Manufacturer) agrees to such reduction, the Purchaser shall in any event [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 25 

 CONFIDENTIAL 
  

 [***]. 
  

	9.7	 It is understood that without prejudice to Clause 18 (Write Offs), the remaining [***] of each Forecast
Schedule (i.e., the period after the Firm Zone) constitutes an estimate of the future Product requirement of the Purchaser and does not comprise a specific purchase requirement or a commitment by the Purchaser to purchase such Product (except as
otherwise provided in this Agreement). It is further understood that each such Forecast Schedule does not constitute a commitment by GSK to Manufacture or supply such Product. 

 

	9.8	 Each Party shall notify the other in writing with the name of a technical manager who will be responsible for
dealing with all day-to-day operational matters relevant to this Agreement. Unless otherwise agreed between the Parties, the technical managers and other appropriate
representatives from each Party shall endeavour to meet no less than once every Calendar Quarter to discuss the forecasts delivered by Purchaser pursuant to this Agreement and other matters relevant to the Manufacture and supply of Products under
this Agreement. The Purchaser shall provide to GSK at such meetings all readily available and appropriate data relating to the Products or the Purchaser’s prospective demands and trends for the Products. 

 

	9.9	 The provisions of this Clause 9 (Product Forecasts and Orders) are subject to the provisions of Clause
24 (Capacity Constraints) in the event that an Allocation is required to be made. 

  

	10.	 DELIVERY OF PRODUCT 

 

	10.1	 Subject to Clause 24 (Capacity Constraints), GSK (or the Nominated Supplier) shall Deliver the Products
on the date specified in the relevant Firm Order, provided that: 

  

	 	(A)	 the quantity of Product Delivered by GSK may vary by [***] from the quantity specified in the relevant Firm
Order; and 

  

	 	(B)	 the date of Delivery may vary by [***] from the date specified in the relevant Firm Order,

 and such variance shall not constitute a breach of this Agreement by GSK or entitle the Purchaser to reject such
Delivery. Delivery of New Clinical API, New Clinical Products and New Clinical Placebo shall take place following release by GSK of such Products in accordance with (and the extent required by) the Quality Agreement. 

 

	10.2	 In respect of Existing Clinical API and (if applicable) New Clinical API, the Parties may agree that some or
all of the quantities of such Existing Clinical API or New Clinical API Delivered pursuant to Clause 10.1 shall remain in the possession of GSK or its Affiliate on consignment. 

 

	10.3	 Subject to paragraph 2 of Schedule 3 (Toll Manufacturing Provisions), the risk in and title to the
Existing Clinical Products, Existing Clinical Placebo, New Clinical Products and New Clinical Placebo shall remain with GSK (or its Affiliate) until Delivered, at which point it shall pass to the Purchaser. Title to Existing Clinical API and New
Clinical API (if applicable) shall pass to the Purchaser when such Existing Clinical API or New Clinical API is purchased by Purchaser, but risk in such Existing Clinical API and New Clinical API shall remain with GSK in accordance with Clause 7.5
for so long as such Existing Clinical API or New Clinical API is in GSK’s possession as Purchaser Materials.  

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 26 

 CONFIDENTIAL 
  

	10.4	 Other than in respect of Existing Clinical API or New Clinical API that the Parties agree shall be retained by
GSK on consignment, the Purchaser shall collect the Products Delivered from the Manufacturing Site on the date of Delivery, or such date as GSK, the Nominated Supplier or the Nominated Manufacturer may notify to the Purchaser from time to time.

  

	11.	 PRICE 

  

	11.1	 The Purchaser shall pay: 

 

	 	(A)	 the applicable Price (as determined in accordance with this Clause 11 (Price)) for Products supplied
under this Agreement; 

  

	 	(B)	 the fees in respect of Development Services supplied under this Agreement as set forth in (or determined in
accordance with) the applicable Scope of Work; 

  

	 	(C)	 the fees payable in respect of any Technology Transfer undertaken pursuant to this Agreement (except as
otherwise expressly set forth in this Agreement); and 

  

	 	(D)	 any Storage Fee and/or Safety Stock Fee payable pursuant to this Agreement. 

 

	11.2	 The Price and other fees payable pursuant to this Agreement shall be exclusive of Sales Tax imposed on or with
respect to such payments, which the Purchaser shall pay in addition to the Price or other fee upon presentation by GSK of a valid Sales Tax invoice. 

  

	11.3	 The Price for the Existing Clinical API, Existing Clinical Product, and Existing Clinical Placebo shall be that
specified in Schedule 1, which reflects GSK’s fully allocated CoGs of Manufacturing such Existing Clinical API, Existing Clinical Product, and Existing Clinical Placebo plus a margin (which is no greater than the margin applied for the
Manufacture of New Clinical API, New Clinical Products, and New Clinical Placebo). 

  

	11.4	 The Price for the New Clinical API shall be equal to the API Base Cost [***] and the Price for New Clinical
Products and New Clinical Placebo shall be equal to the Product Base Cost [***], as further detailed in Schedule 1. 

  

	11.5	 The CoGs and LAV on the basis of which the API Base Cost and Product Base Cost are respectively based shall be
reviewed annually and thereafter fixed on an annual basis for each Calendar Year. For the Calendar Year in which the Effective Date falls, the LAV, Product Base Cost and Price in respect of New Clinical Product and New Clinical Placebo shall be as
specified in Schedule 1. The Parties acknowledge and agree that no New Clinical API will be required to be Manufactured during such Calendar Year. 

  

	11.6	 At least [***] prior to the end of each Calendar Year, GSK shall notify the Purchaser of the Price for New
Clinical Product and New Clinical Placebo and the LAV and Base Product Cost on the basis of which such Price shall be calculated during the following Calendar Year. Insofar as the Manufacture of any New Clinical API is anticipated to be required
during such Calendar Year pursuant to Clause 2.2(A), the provisions of this Clause 11.6 shall apply mutatis mutandis in respect of such New Clinical API and the CoGs, API Base Cost and Price thereof. LAV (and, if applicable, CoGs) shall be
determined on the basis of the volumes of New Clinical Product and New Clinical Placebo (and, if applicable, New Clinical API) then forecast for the relevant Calendar Year. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 27 

 CONFIDENTIAL 
  

	11.7	 The Parties shall meet at least [***] before the end of each Calendar Year during the Term to discuss the LAV,
CoGs (if applicable), Base Product Cost, Base API Cost (if applicable) and Prices notified in respect of the following Calendar Year pursuant to Clause 11.6. The LAV for New Clinical Products and New Clinical Placebo (and, if applicable, the CoGs
for New Clinical API) for each subsequent Calendar Year shall be finalized by [***] of the then-current Calendar Year on the basis of the volume forecast supplied by the Purchaser for the subsequent Calendar Year. 

 

	11.8	 If the Purchaser disputes the LAV and/or CoGs notified pursuant to Clause 11.6 and such dispute cannot be
resolved through the discussions held pursuant to Clause 11.7, the Purchaser may, by notice in writing given not later than [***] of the then-current Calendar Year, require that an Independent Expert be permitted to verify the applicable CoGs and/or
LAV. If the Purchaser so requires, then: 

  

	 	(A)	 the Independent Expert shall not be permitted to disclose to the Purchaser any of the data relating to
GSK’s costs; 

  

	 	(B)	 if the Independent Expert determines that GSK has correctly determined the relevant CoGs or LAV, and has
determined such CoGs or LAV in a manner consistent with that used in determining the standard cost of other products manufactured for GSK, its Affiliates and Third Parties, the Prices notified by GSK shall apply and the Purchaser shall bear the fees
of such Independent Expert; and 

  

	 	(C)	 if the Independent Expert determines that GSK has not correctly determined the relevant CoGs or LAV, or has not
determined such CoGs or LAV in a manner consistent with that used in determining the standard cost of products manufactured for GSK, its Affiliates and Third Parties, the Independent Expert shall determine the applicable CoGs or LAV, the Prices in
respect of the relevant Calendar Year shall be determined on that basis and GSK shall bear the fees of the Independent Expert, 

provided that, for the avoidance of doubt, the Parties acknowledge that the prices actually charged to GSK, its Affiliates or Third
Parties in respect of other products may not be determined by reference to the standard cost of manufacturing such products in the same way as Prices are determined under this Agreement on the basis of CoGs and LAV and the assessment undertaken by
the Independent Expert shall not consider the manner in which such prices are determined (rather such Independent Expert will only consider the applicable standard cost of manufacturing for such products in its assessment). 

 

	11.9	 Pending a determination by an Independent Expert pursuant to Clause 11.8, the Price for the Products in the
subsequent Calendar Year shall be the same as that prevailing in the current Calendar Year, provided that: 

  

	 	(A)	 the Price in respect of New Clinical Product and New Clinical Placebo shall be adjusted at the start of the
subsequent Calendar Year by the Consumer Prices Index published by the [***] for the previous twelve (12) months; and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 28 

 CONFIDENTIAL 
  

	 	(B)	 if applicable, the Price in respect of New Clinical API shall be adjusted at the start of the subsequent
Calendar Year by the Consumer Price Index published by the [***] for the previous twelve (12) months. 

  

	12.	 INVOICE AND PAYMENT 

 

	12.1	 GSK (or the Nominated Supplier) shall invoice the Purchaser upon each Delivery of Products or performance of
the Development Services. Each invoice shall specify, as applicable: 

  

	 	(A)	 the Price in respect of the Products Delivered or the Development Services performed (or the development work
undertaken pursuant to Clause 3.8 and the implementation of such development work); 

  

	 	(B)	 the quantity of Products Delivered; 

 

	 	(C)	 the amount of Sales Tax due in respect of the Products Delivered or Development Services performed (or the
development work undertaken pursuant to Clause 3.8 and the implementation of such development work); and 

  

	 	(D)	 any other fees payable or amounts reimbursable to GSK pursuant to this Agreement. 

 

	12.2	 Any amounts reimbursable to GSK pursuant to this Agreement other than the Price for Product Delivered or
Development Services performed and any associated Sales Tax may be invoiced separately from any invoice relating to the Price for Product Delivered or Development Services performed and any associated Sales Tax. 

 

	12.3	 The Purchaser shall pay the invoices issued by GSK or the Nominated Supplier in the Invoice Currency within
[***] from the date of receipt of the respective invoice by electronic transfer to the account nominated by GSK or the Nominated Supplier in writing. 

  

	12.4	 If Purchaser fails to make any payment pursuant to this Agreement when due, simple interest shall thereafter
accrue on the sum due to GSK (or the Nominated Supplier) until the date of payment at the per annum rate of [***] above the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by Applicable Laws, whichever is
the lower. 

  

	12.5	 All payments by the Purchaser under this Agreement shall be made without any deduction or withholding of any
monies, unless required by Applicable Law. In the event that monies are deducted or withheld, the Purchaser shall promptly pay the amount withheld to the appropriate Governmental Entity and shall provide GSK (or the Nominated Supplier) with the
original receipt issued by that Governmental Entity or other sufficient evidence of payment. To the extent that amounts are so withheld and paid to the proper taxing authority, such amounts shall be treated for all purposes of this Agreement as
having been paid to GSK (or the applicable Nominated Supplier) with respect to whom such amounts were withheld. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any
relevant agreement or treaty which is in effect. The Parties shall discuss and cooperate regarding applicable mechanisms for minimizing such Taxes to the extent possible in compliance with applicable Law. In addition, the Parties shall cooperate in
accordance with applicable Law to minimize indirect Taxes (including Sales Tax) in connection with this Agreement. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 29 

 

 CONFIDENTIAL 
  

	13.	 ELECTRONIC SYSTEMS 

 

	13.1	 GSK hereby grants, or shall procure the grant of, a limited licence (being a royalty-free licence under the GSK
System IP, for the Term and revocable by GSK in the event of a breach by the Purchaser of the obligations set forth in this Clause 13 (Electronic Systems)) to use the GSK Group’s “Collaborate” information technology
system or such successor or alternative demand management software or system as the GSK Group may deploy (the “GSK System”). Such licence shall permit the Purchaser to use the GSK System only for the purposes of complying with its
obligations under this Agreement and meeting GSK’s requirements for demand planning, management and Delivery of Products. The use of such GSK System shall be subject to the following further conditions: 

 

	 	(A)	 other than the warranty set forth in Clause 27.1(B), GSK gives no representation or warranty as to the GSK
System, including that it shall be available at any time, or shall operate in error-free fashion, and the Purchaser agrees that any failure of such GSK System shall not limit or exclude any obligation or responsibility on the part of the Purchaser;

  

	 	(B)	 the Purchaser shall remain responsible for maintaining (i) such internet or telecommunications
connectivity and (ii) such minimum IT hardware requirements as may be necessary to enable the Purchaser to access such GSK System; and 

  

	 	(C)	 if the GSK Group provides the Purchaser with passwords or other access or authentication credentials, to use
the GSK System, the Purchaser shall provide those credentials only to named personnel (and shall communicate the names of such personnel to GSK and/or its Affiliate), and shall procure that the named personnel shall not share their credentials with
any other Purchaser personnel. 

  

	13.2	 The Purchaser shall take reasonable care to ensure that: 

 

	 	(A)	 nothing done by its employees shall contaminate, corrupt, impair or adversely affect any of the GSK
Group’s computers, computer software and computer data and, without prejudice to the generality of the foregoing, shall take due care to ensure that no invasive programs, “computer viruses” or “logic bombs” shall be
introduced to any of the GSK Group’s computers, computer software or data; and 

  

	 	(B)	 it operates reasonably up to date commercially available anti-virus software, including regularly updating the
virus signature files of such software (as recommended by the relevant licensor), and an electronic firewall and such other technical safeguards as good IT practice requires in relation to the Purchaser’s network or IT infrastructure (in each
case to the extent that such network or infrastructure may connect to the GSK System). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 30 

 CONFIDENTIAL 
  

	14.	 QUALITY ASSURANCE 

 

	14.1	 GSK shall maintain such records as are necessary and appropriate to demonstrate compliance with cGMP in
connection with the supply of the Development Services and the Manufacture of the New Clinical API, New Clinical Products, and New Clinical Placebo. 

  

	14.2	 GSK shall be responsible for devising and implementing any corrective actions and/or preventative actions
(“CAPAs”) that may be required in connection with the Manufacture and technical release of Products, other than any CAPAs relating to analytical testing and release, which shall be the responsibility of the Purchaser.

  

	14.3	 The respective responsibilities of each Party in relation to technical and quality matters are further set
forth in the Quality Agreement. In the event of a conflict between the terms of the Quality Agreement and the terms of this Agreement, the terms of the Quality Agreement shall, to the extent of such conflict, prevail. 

 

	15.	 DEFECTIVE PRODUCTS 

 

	15.1	 The Purchaser shall notify GSK or the Nominated Supplier (or ensure that GSK or the Nominated Supplier is
notified) in writing within [***] of any Delivery of Products if the Delivery is incomplete in accordance with the terms of this Agreement (a “Rejection Notice”). GSK shall use its Commercially Reasonable Efforts to rectify the
incomplete delivery within [***] of receipt of the Rejection Notice. If no Rejection Notice is provided to GSK or the Nominated Supplier within [***] of the Delivery of Products, the Delivery shall be deemed complete. 

 

	15.2	 The Purchaser shall have the right to reject any allegedly Defective Products upon written notice to GSK, such
notice to include the reason(s) for the rejection and to be accompanied with any supporting documentation or other evidence, such right to be exercised within the period stipulated in the Quality Agreement (or, if no such period is stipulated,
within (i) [***] after the Delivery of Products or (ii) in the case of Latent Defects, [***] after discovery of the Latent Defect). Unless the Purchaser complies with the provisions of this Clause 15.2, the Delivery of Products shall be deemed
accepted by the Purchaser and the Purchaser shall have no right to reject the same. 

  

	15.3	 If the Purchaser purports to reject any Products pursuant to Clause 15.2: 

 

	 	(A)	 the Purchaser shall store the rejected Products in quarantine in accordance with GSK’s reasonable
instructions and shall allow GSK (or its nominated representatives) to inspect and/or analyse the same; 

  

	 	(B)	 the Parties shall use reasonable endeavours to agree whether or not the rejected Products are Defective; and

  

	 	(C)	 if, within [***] of GSK or the Nominated Supplier being notified pursuant to Clause 15.2, the Parties fail to
agree whether or not the rejected Products are Defective, the dispute shall be referred to and determined by an Independent Expert whose decision shall be final and binding on the Parties. The Independent Expert shall act as an expert and not as an
arbitrator and (unless the Independent Expert otherwise determines) his or her fees shall be paid by the Party against whom the Independent Expert’s decision is given. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 31 

 CONFIDENTIAL 
  

	15.4	 If the Parties agree, or if the Independent Expert finds, that any Products are Defective and have been
properly rejected, GSK shall, at its option, either replace the Defective Products or refund to the Purchaser the Price paid for such Defective Products. In addition, GSK shall, at its option, either collect at its own expense the Defective Products
from the Purchaser or reimburse the Purchaser for any reasonable costs incurred in its disposal of the Defective Products. Subject to Clause 28 (Indemnities) and Clause 29 (Liability), the remedy set forth in this Clause 15.4, together
with any additional remedy set forth in Clause 20.3 (if applicable), shall be the Purchaser’s sole and complete remedy under this Agreement with respect to any Defective Products properly rejected by the Purchaser in accordance with Clause
15.2. 

  

	15.5	 If any rejected Products are found by the Independent Expert not to be Defective, the Purchaser shall pay for
such Products in accordance with the payment provisions set forth in this Agreement. 

  

	16.	 PRODUCT LICENCE 

 

	16.1	 The Purchaser shall (or shall procure that its Affiliate shall), at its own expense, obtain and maintain all
Product Licences in the Territory which may from time to time be required by any Regulatory Authority or other Governmental Entity. The Purchaser shall be responsible for responding to all requests for information related to such Product Licences
made by, and for making all legally required filings relating to such Product Licences with, any Regulatory Authority or other Governmental Entity having jurisdiction to make such requests or require such filings. 

 

	16.2	 Without prejudice to the Purchaser’s obligations under Clause 16.1, if any Product Licence relating
directly to any of the Products is suspended or revoked after the Effective Date, the Purchaser shall promptly notify GSK (and, if applicable, each of the Nominated Manufacturer and the Nominated Supplier) of the event and shall promptly inform GSK
of the anticipated impact on the Purchaser’s purchases of the affected Product and the Purchaser’s general intentions with respect to the affected Product. 

 

	17.	 PRODUCT SPECIFICATIONS 

 

	17.1	 Subject to the provisions of Clause 2 (GSK’s Obligations) and unless otherwise required to do so by
a Governmental Entity, GSK shall not without the prior written consent of the Purchaser, make any change to the Specifications that might reasonably be expected to impact the Product Licence. 

 

	17.2	 Each application by GSK for any consent pursuant to Clause 17.1 shall be submitted in writing and assessed by
the Purchaser in accordance with the Technical Change Procedure. Any agreed change made under this Clause 17.2 shall be implemented at GSK’s cost. 

  

	17.3	 The Purchaser shall bear the costs of any change to the Specifications or the Manufacturing process required by
Applicable Law or a Governmental Entity (including the cost of any write-off in accordance with Clause 18 (Write Offs) and/or any related development work in accordance with Clause 3 (Development
Services)). Notwithstanding the foregoing, if a required change to the Specifications or any Manufacturing process is such that GSK cannot reasonably implement the change without significant interference with its other operations at the
Manufacturing Site, the provisions of Clause 31.2 shall apply. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 32 

 CONFIDENTIAL 
  

	17.4	 Prior to implementation of any change referred to in this Clause 17 (Product Specifications), the
Parties shall agree on a procedure to ensure that the change is approved by the relevant Governmental Entity, and that GSK is given a reasonable period of time to implement any changes which such Governmental Entity may approve.

  

	18.	 WRITE OFFS 

  

	18.1	 Where: 

  

	 	(A)	 the Purchaser submits a purchase order for a quantity of Product other than the MOQ (or a multiple thereof) and
GSK agrees to Deliver such quantity; 

  

	 	(B)	 any changes to the Manufacture of the Products and/or Specification are implemented pursuant to a request of
any Regulatory Authority or pursuant to Applicable Law; provided that the foregoing shall be limited to Product deliverable [***]; 

  

	 	(C)	 GSK or the Nominated Manufacturer agrees to any changes requested by the Purchaser in accordance with this
Agreement; or 

  

	 	(D)	 solely in relation to long-lead time Materials and safety stock of Materials held pursuant to Clause 6.3, the
quantity requirement for a Product shown for any month in any Forecast Schedule varies from the quantity requirements forecast for that month in any previous Forecast Schedule, [***], the provisions of Clause 18.2 shall apply. 

 

	18.2	 Where this Clause 18.2 applies, the Purchaser shall reimburse to GSK or the Nominated Manufacturer the cost of write-off (calculated in accordance with IFRS) of: 

  

	 	(A)	 Materials reasonably purchased or ordered by GSK or the Nominated Manufacturer in view of quantities indicated
in any Forecast Schedule and the terms agreed with the supplier of such Materials, including any applicable minimum order quantity and/or lead times (which may exceed the Firm Zone); 

 

	 	(B)	 Purchaser Materials reasonably purchased or ordered by GSK or the Nominated Manufacturer in view of quantities
indicated in any Forecast Schedule; 

  

	 	(C)	 safety stock quantities of Materials as required pursuant to Clause 6.3; and 

 

	 	(D)	 work-in-progress and/or
Products Manufactured in light of the quantity requirements shown in the Forecast Schedule (taking due account of the applicable Lead Time), 

to the extent that such Materials, Purchaser Materials,
work-in-progress and/or Products will not be used: 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 33 

 CONFIDENTIAL 
  

	 	(i)	 in the Manufacture of Products to meet Firm Orders (or in the case of certain Materials with long lead times
and/or safety stock of Materials held pursuant to Clause 6.3, prior to the Firm Zone); or 

  

	 	(ii)	 in the case of Materials not used by GSK or the Nominated Manufacturer at the Manufacturing Site exclusively in
the Manufacture of Products, in the manufacture at the relevant Manufacturing Site of other products for GSK, its Affiliates or Third Parties, 

in each case within the shelf-life of such Materials, Purchaser Materials,
work-in-progress or Products, whether as a result of expiry of the Term, termination of this Agreement or otherwise. GSK shall provide the Purchaser with the cost of
long-lead time Materials and the associated lead times provided by GSK’s supplier. Each of GSK and the Nominated Manufacturer at the Manufacturing Site will use Commercially Reasonable Efforts to use Materials that are not used exclusively in
the Manufacture of Products in the manufacture at the relevant Manufacturing Site of other products for GSK, its Affiliates or Third Parties. To the extent that neither GSK nor the Nominated Manufacturer at the Manufacturing Site will be able to use
Materials that are not used exclusively in the Manufacture of Products, then, at the election of Purchaser, GSK will (in connection with the write off of such Materials pursuant to this Clause 18.2) allow the Purchaser to collect any such Materials
or ship any such Materials to Purchaser (in each case, at Purchaser’s cost). 
  

	18.3	 For the avoidance of doubt, it is acknowledged that Purchaser Materials are held by GSK or the Nominated
Manufacturer on a [***] basis and, accordingly, the cost to GSK or the Nominated Manufacturer of writing off Purchaser Materials will not exceed the cost (if any) incurred by GSK of the Nominated Manufacturer in destroying or otherwise disposing of
such Purchaser Materials or in storing such Purchaser Materials pending collection by, or shipment to, the Purchaser (or its designee) from the Manufacturing Site. 

 

	19.	 REGULATORY COMPLIANCE 

 

	19.1	 GSK or the Nominated Manufacturer shall: 

 

	 	(A)	 provide to the Purchaser all such documents and information available to GSK or the Nominated Manufacturer as
may be required by a Regulatory Authority from the Purchaser with respect to the Manufacture of the Product; and 

  

	 	(B)	 allow such inspections of the Manufacturing Site as may be requested by such Regulator. 

Upon request by the Purchaser, GSK shall notify the Purchaser in writing of the findings of such inspections insofar as they affect the
Products or their Manufacture. 
  

	19.2	 At the time that any Existing Clinical API, Existing Clinical Products, or Existing Clinical Placebo are
Delivered to the Purchaser, GSK (or the Nominated Manufacturer) shall supply a completed copy of the Certificate of Analysis, duly signed or released by a Qualified Person (or a Person designated by the Qualified Person to sign or release such
document) in accordance with cGMP, that sets forth the analytical test results for each specified lot of Existing Clinical API, Existing Clinical Products, or Existing Clinical Placebo Delivered to the Purchaser and confirms that such Products have
been manufactured in accordance with the Specifications. At the time 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 34 

 CONFIDENTIAL 
  

	 	
that any New Clinical API, New Clinical Products, or New Clinical Placebo are Delivered to the Purchaser, GSK (or the Nominated Manufacturer) shall perform batch investigations (if applicable), a
technical release and quality assurance approval for the purposes of Purchaser’s Qualified Person signing a Certificate of Analysis in respect of such New Clinical API, New Clinical Products, or New Clinical Placebo. The Purchaser will assume
management of all CMO agreements related to analytical testing and release and shall be responsible for batch investigations (if applicable) relating to analytical testing and release. 

 

	19.3	 Each Party shall maintain in accordance with and for the period required under cGMP and Applicable Law all such
records relating to the Manufacture and distribution of the Products as it may be required to hold under such Applicable Law. 

  

	20.	 PRODUCT EVENTS 

 

	20.1	 Any and all complaints of which GSK becomes aware relating to the quality or efficacy any Product shall
promptly be forwarded to the Purchaser’s senior quality officer or that person’s designee. The Purchaser shall promptly inform GSK and/or the Nominated Manufacturer of any and all complaints that the Purchaser receives which may relate to
manufacturing or other processes at the Manufacturing Site. Notification shall be given by telephone, with a written confirmation immediately following. 

  

	20.2	 In the event that a Regulatory Authority requires, or the Purchaser decides to initiate, a recall, withdrawal
or field correction (each, a “Product Event”) with respect to any Product Manufactured and supplied under this Agreement, the Purchaser shall immediately notify GSK and each Party shall fully cooperate with the other Party to
implement the same. 

  

	20.3	 If (and only if and to the extent that) the Product Event is: 

 

	 	(A)	 required by Applicable Law or customary industry practice; and 

 

	 	(B)	 necessitated by a failure on the part of GSK to comply with all its obligations under this Agreement,

 GSK shall: 
  

	 	(i)	 replace the Product recalled; or 

 

	 	(ii)	 (at the Purchaser’s election or where it is not reasonably practicable for GSK to replace the Product)
refund the Purchaser for the recalled Product; and 

  

	 	(iii)	 within [***] of receipt of an invoice for the same, reimburse the Purchaser for its reasonable out of pocket
expenses incurred in carrying out the Product Event, provided that: 

  

	 	(a)	 such expenses are evidenced in writing; and 

 

	 	(b)	 GSK shall not be liable for any costs or expenses arising to the extent of attributable to the acts or
omissions of the Purchaser, its Affiliates or its or their distributors, wholesalers or other customers. Subject to Clause 28 (Indemnities) and Clause 29 (Liability), the remedy set forth in this Clause 20.3 shall be the
Purchaser’s sole and complete remedy under this Agreement with respect to any Product Event. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 35 

 CONFIDENTIAL 
  

	20.4	 Subject to Clause 20.3, [***] relating to a Product Event shall be borne by the Purchaser. The Purchaser shall
reimburse to GSK all costs and expenses incurred by GSK and its Affiliates in respect of a Product Event within [***] of receipt of an invoice for the same. 

  

	20.5	 In the event of a dispute between the Parties in relation to the allocation of costs between the Parties in
relation to a Product Event in accordance with this Clause 20 (Product Events), the matter shall be determined by an Independent Expert and the decision of the Independent Expert shall be final and binding on the Parties. The Independent
Expert shall act as an expert and not as an arbitrator and (unless the Independent Expert otherwise determines) its fees shall be borne between the Parties in the same proportion as the costs of the Product Event are allocated between them by the
Independent Expert. 

  

	21.	 PHARMACOVIGILANCE 

 

	21.1	 If a Party becomes aware of any action that may be or will be taken or required by any Regulatory Authority for
safety reasons connected with any product containing the same active substance as the Product, it shall immediately, and in any event not later than [***] after so becoming aware, notify the other Party’s senior quality officer in writing and
provide all available relevant details. 

  

	21.2	 Without prejudice to Clause 21.1, GSK shall notify the Purchaser promptly following its receipt of information
of a possible Adverse Event with respect to any Product. To the extent an Adverse Event of which the Purchaser becomes aware may relate to manufacturing or other processes at the Manufacturing Site, the Purchaser shall inform GSK of such Adverse
Event and shall disclose to GSK any information it has regarding that Adverse Event. 

  

	21.3	 Upon receipt of notification of a Product complaint and/or Adverse Event in respect of any of the Products, GSK
will conduct an internal investigation to determine the validity of such complaint. The findings of such investigation shall be reported in writing to the Purchaser. 

 

	22.	 CONFIDENTIALITY 

 

	22.1	 All Confidential Information disclosed by a Party (together with its Affiliates, the “Disclosing
Party”) to the other Party (together with its Affiliates, the “Receiving Party”) shall be used by the Receiving Party solely in connection with the activities contemplated by this Agreement, shall be maintained in
confidence by the Receiving Party, and shall not otherwise be disclosed by the Receiving Party to any other Person, firm or agency, governmental or private (other than a Party’s Affiliates), without the prior written consent of the Disclosing
Party. 

  

	22.2	 The Receiving Party may disclose Confidential Information to (a) its Affiliates, directors, officers,
employees, consultants, attorneys, vendors, suppliers, contractors, collaborators and advisors (“Personnel”) who have a need to know for the Development, Manufacture, and Commercialisation of Products in accordance with this
Agreement, prosecution and maintenance of any Patent or to enforce or exercise rights under this Agreement, including in connection with Regulatory Approval Applications and obtaining Regulatory Approvals or (b) to 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 36 

 CONFIDENTIAL 
  

 actual or potential investors, acquirers, permitted licensees/sublicensees and other financial or commercial
partners who need to know such Confidential Information in connection with their evaluating or carrying out an actual or potential investment, acquisition, collaboration, public offering, merger or other similar transaction, in each case relating to
the Transferred Assets (“Authorised Third Parties”), provided that each of GSK and the Purchaser shall: 
  

	 	(A)	 procure that its Personnel and Authorised Third Parties shall be bound by confidentiality obligations at least
as strict as this Clause 22 (Confidentiality) (except, in respect of Confidential Information that is not Know-How or Intellectual Property, to the extent that a shorter confidentiality period is
customary in the industry); and 

  

	 	(B)	 each remain liable for the compliance of its Personnel or Authorised Third Parties with the obligations of
confidentiality set out in this Clause 22 (Confidentiality). 

  

	22.3	 The obligations of confidentiality set forth in Clauses 22.1 and 22.2 shall not extend to any information which
(as evidenced by competent documentation): 

  

	 	(A)	 was known or used by the Receiving Party prior to its date of disclosure to the Receiving Party;

  

	 	(B)	 either before or after the date of the disclosure to the Receiving Party, is lawfully disclosed to the
Receiving Party by sources (other than the Disclosing Party) not known by the Receiving Party to be subject to a duty of confidentiality to the Disclosing Party with respect to such Confidential Information; 

 

	 	(C)	 either before or after the date of the disclosure to the Receiving Party, becomes published or generally known
to the public (including information known to the public through the sale of products in the ordinary course of business) through no fault or omission on the part of the Receiving Party or its Affiliates; or 

 

	 	(D)	 is independently developed by or for the Receiving Party without reference to or reliance upon the Confidential
Information. 

  

	22.4	 Subject to Clause 22.3, the obligations of confidentiality set forth in Clauses 22.1 and 22.2 shall expire

  

	 	(A)	 in respect of Confidential Information that is Know-How or Intellectual
Property, when such Know-How or Intellectual Property ceases to be confidential; and 

  

	 	(B)	 in respect of other Confidential Information, [***] after the expiry or termination of this Agreement.

  

	22.5	 Clauses 22.1 and 22.2 shall not preclude the Receiving Party from disclosing Confidential Information to the
extent the Receiving Party reasonably concludes, after consultation with counsel, that the disclosure of such Confidential Information is necessary (a) to comply with Applicable Laws or any Order, including complying with the Securities Act of
1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations of the U.K. Financial Conduct Authority or other applicable securities Laws, (b) to defend or prosecute litigation or to comply with governmental
regulations, (c) in connection with the filing of 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 37 

 CONFIDENTIAL 
  

	 	
documentation in order to obtain or maintain Regulatory Approvals or (d) in connection with any filing with a Governmental Entity with respect to a Patent; provided that, unless
prohibited by Applicable Laws or any Order, the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure.

  

	22.6	 Subject to Clauses 22.3, and save to the extent necessary to comply with any continuing obligations under this
Agreement or Applicable Law, the Receiving Party shall, upon expiry or termination of this Agreement and at the other Party’s request, return or destroy all of the Disclosing Party’s Confidential Information which it has in its possession
or under its control, provided that: 

  

	 	(A)	 the Receiving Party may retain one confidential copy in the Receiving Party’s confidential files solely
for purposes of monitoring compliance with the terms of this Clause 22 (Confidentiality); and 

  

	 	(B)	 nothing in this Clause 22.6 shall require the Receiving Party or its Personnel to delete or otherwise destroy
any copies of the Disclosing Party’s Confidential Information that is stored in electronic form in back-up archives of its information technology systems that are not accessible to such Personnel in the
ordinary course of business. 

  

	22.7	 For clarity, the provisions of this Clause 22 (Confidentiality) shall not prejudice the rights or
obligations of either Party (or their respective Affiliates) under the Purchase Agreement. 

  

	23.	 FORCE MAJEURE 

 

	23.1	 If any Force Majeure Event occurs in relation to either Party which affects or may affect the performance of
any of its obligations under this Agreement, it shall notify the other Party as soon as practicable as to the nature and extent of the circumstances in question. 

 

	23.2	 The Affected Party shall not be deemed to be in breach of this Agreement, and shall not otherwise be liable to
the other Party, by reason of any delay in performance, or the nonperformance of any of its obligations under this Agreement, to the extent that the delay or nonperformance is due to any Force Majeure Event, and the time for performance of that
obligation shall be extended accordingly. 

  

	23.3	 If the performance by the Affected Party of any of its obligations under this Agreement is prevented or delayed
by a Force Majeure Event for a continuous period in excess of [***], the Parties shall enter into bona fide discussions with a view to alleviating its effects, or to agreeing upon such alternative arrangements as may be fair and reasonable in the
circumstances. 

  

	23.4	 If the Affected Party is prevented or delayed from performance of any of its obligations under this Agreement
by a Force Majeure Event for [***] or more, the other Party shall in its discretion have the right to terminate this Agreement with immediate effect by giving written notice to the Affected Party. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 38 

 CONFIDENTIAL 
  

	24.	 CAPACITY CONSTRAINTS 

 

	24.1	 If GSK or the Nominated Manufacturer is unable to Manufacture the quantities of Products forecasted or ordered
by the Purchaser due to: 

  

	 	(A)	 shortages of Materials that are used both in the Manufacture of Products and in the manufacture of products for
the GSK Group or its Third Party customers; or 

  

	 	(B)	 constraints on the capacity at: 

 

	 	(i)	 the Manufacturing Site; or 

 

	 	(ii)	 any manufacturing site operated by the GSK Group at which any Materials are manufactured,

 (the “Affected Site”), in each case including as a result of any repair or remediation
being required in respect of the Affected Site or any equipment at the Affected Site that is used in the Manufacture of Products or Materials (as applicable), then, without prejudice to Clause 23 (Force Majeure), Clauses 24.2 and 24.3 shall
apply. 
  

	24.2	 In the circumstances contemplated by Clause 24.1, GSK shall (or shall procure that its Affiliate shall)
allocate the available Materials, or available capacity at the Affected Site, between: 

  

	 	(A)	 the Products; 

  

	 	(B)	 products manufactured by the GSK Group for Commercialisation by the GSK Group that rely on the same Materials
or Affected Site; and 

  

	 	(C)	 products manufactured by the GSK Group for Commercialisation by its Third Party customers that rely on the same
Materials or Affected Site, 

 (collectively, the “Affected Products”) in a fair and reasonable manner as
if all Affected Products were to be Commercialised by and for the sole benefit of the GSK Group, taking account of all relevant factors, including the indications of each Affected Product, the risk and likely duration of any stock out of each
Affected Product, the availability in the relevant jurisdiction of alternatives to each Affected Product and whether or not each Affected Product is medically critical (the “Allocation”). 

 

	24.3	 In the circumstances contemplated by Clause 24.1: 

 

	 	(A)	 the Purchaser shall, on request, provide GSK or its Affiliate with such information as GSK or its Affiliate may
reasonably require in order to determine the Allocation in accordance with Clause 24.2; 

  

	 	(B)	 notwithstanding anything to the contrary in Clause 9 (Product Forecasts and Orders), each Firm Order
shall be deemed to be revised (as to quantities of Products and/or Delivery dates, as applicable) to the extent necessary to accord with the Allocation (and the Purchaser shall be deemed to agree with such revision); and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 39 

 CONFIDENTIAL 
  

	 	(C)	 for the purposes of Clause 10 (Delivery of Product), the due date for Delivery in respect of any Firm
Order shall reflect any revision to the such Firm Order made pursuant to this Clause 24.3. 

  

	24.4	 Following any Allocation, the Parties shall, at the Purchaser’s request,
co-operate in good faith (each acting reasonably) to devise a plan for the re-supply of Products in greater quantities than contemplated by the then-current Forecast
Schedule once the circumstances giving rise to the Allocation cease to apply (and, notwithstanding anything to the contrary in Clause 9 (Product Forecasts and Orders), future Forecast Schedules may be revised to accord with such agreed plan).

  

	25.	 AUDIT AND INSPECTION RIGHTS 

 

	25.1	 Subject to Clauses 25.2 to 25.5, the Purchaser shall have the right, not more than [***] (other than “for
cause”), to audit and inspect (i) those parts of the Manufacturing Site and related plant and machinery used for the Manufacture of Products for the Purchaser under this Agreement, (ii) GSK’s systems used for quality assurance in
respect of Third Party suppliers of Materials, and (iii) subject to any obligations of confidentiality GSK may have to a Third Party supplier of Materials, the results of any quality assurance audits conducted by GSK of any such Third Party
supplier, provided that: 

  

	 	(A)	 GSK shall, upon the Purchaser’s reasonable request, use Commercially Reasonable Efforts to obtain the
consent of any such Third Party supplier to enable the results of a relevant quality assurance audit conducted by GSK to be provided in accordance with this Clause 25.1; and 

 

	 	(B)	 GSK may redact, and shall not be required to disclose to the Purchaser, any results of any quality assurance
audit conducted by GSK of a Third Party supplier of Materials to the extent that such results do not relate to the Materials used in the Manufacture of Products. 

 

	25.2	 The Purchaser shall give GSK and/or the Nominated Manufacturer not less than [***] prior written notice of any
inspection proposed to be undertaken pursuant to Clause 25.1 and each such inspection shall occur during Working Hours at the Manufacturing Site. 

  

	25.3	 The Purchaser’s audit and inspection rights under this Clause 25 (Audit and Inspection Rights)
shall not extend to any parts of the Manufacturing Site, or any documents, records or other information, which do not relate to the Manufacture of Products for the Purchaser under this Agreement. GSK shall be entitled to redact information relating
to any other product, materials, plant, equipment or premises from any documentation made available to the Purchaser pursuant to this Clause 25 (Audit and Inspection Rights). 

 

	25.4	 Subject to Clause 25.5, the Purchaser’s audit shall be conducted by one team only and shall not last more
than [***]. 

  

	25.5	 In the Contract Year commencing on the Effective Date, the Purchaser shall: 

 

	 	(A)	 be permitted to undertake its audit pursuant to Clause 25.1 within [***] after the Effective Date; and

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 40 

 CONFIDENTIAL 
  

	 	(B)	 if Purchaser has been unable to secure the attendance of its designated Qualified Person at its scheduled audit
(having used its best efforts to do so), be entitled to have such Qualified Person undertake a separate audit during such Contract Year. 

  

	26.	 NO COMMERCIALISATION OF PRODUCT; ADDITIONAL AGREEMENTS 

 

	26.1	 The Parties acknowledge that this Agreement relates to the Manufacture and clinical supply of products and
provision of certain Development Services in respect to clinical supply and is not intended to govern the commercial Manufacture and commercial supply of any products. To the extent that any Product (or work in progress) is supplied to the Purchaser
or its Affiliates under this Agreement, neither the Purchaser nor its Affiliates shall Commercialise any such Product, or otherwise permit any such Product to be put on the market anywhere in the world. 

 

	26.2	 The Parties acknowledge that certain products and services are outside the scope of this Agreement and would be
subject to other agreements to be negotiated in good faith between the Parties, including: 

  

	 	(A)	 [***] 

  

	 	(B)	 [***] 

  

	 	(C)	 [***] 

  

	27.	 WARRANTIES 

  

	27.1	 GSK warrants that: 

  

	 	(A)	 it has full capacity and authority to enter into this Agreement and to perform its obligations under this
Agreement; 

  

	 	(B)	 it has the title and/or right to grant the Purchaser the right to use the GSK System IP in accordance with the
terms of this Agreement; 

  

	 	(C)	 the use of GSK Background IP in the performance of the Development Services does not infringe the Intellectual
Property of any Third Party; and 

  

	 	(D)	 during the Term of this Agreement, 

 

	 	(i)	 the Products will be Manufactured in accordance with cGMP and Applicable Laws and will on Delivery comply with
the Specifications; 

  

	 	(ii)	 GSK shall at all times maintain necessary licences, certifications and approvals for the Manufacturing of the
New Clinical API, New Clinical Products, and New Clinical Placebo at the Manufacturing Site; and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 41 

 CONFIDENTIAL 
  

	 	(iii)	 GSK shall maintain the Manufacturing Site and its records and personnel in accordance with cGMP.

  

	27.2	 The Purchaser warrants that: 

 

	 	(A)	 it has full capacity and authority to enter into this Agreement and to perform its obligations under this
Agreement; 

  

	 	(B)	 it has the title and/or right to grant GSK the right to use the Purchaser Intellectual Property in accordance
with the terms of this Agreement; 

  

	 	(C)	 the use by GSK or the Nominated Manufacturer of the Purchaser Intellectual Property for the purposes of this
Agreement will not infringe the Intellectual Property of any Third Party; provided that the Purchaser makes no representation regarding the Transferred IP; 

 

	 	(D)	 it holds (and will throughout the Term continue to hold) all necessary Consents to perform its obligations as
contemplated by this Agreement and: 

  

	 	(i)	 it has paid (and will throughout the Term continue to pay) all fees due in relation to such Consents;

  

	 	(ii)	 it is not (and will not during the Term be) in breach of any conditions under any such Consents where such
breach would be likely to have an adverse effect on the Purchaser’s ability to perform its obligations under this Agreement; and 

  

	 	(E)	 during the Term of this Agreement, it will perform its obligations under this Agreement in compliance with
Applicable Laws. 

  

	27.3	 Except as expressly stated in this Agreement, all warranties, representations and conditions whether express or
implied by statute, common law or otherwise (including, without limitation, any implied warranties of quality or fitness for purpose) are excluded to the extent permitted by Applicable Law. 

 

	28.	 INDEMNITIES 

  

	28.1	 Subject to Clause 29 (Liability), GSK shall indemnify the Purchaser, the Purchaser’s Affiliates and
its or their respective employees, officers and directors (each a “Purchaser Indemnitee”), and keep them indemnified, on demand, from and against any and all Losses that any of them may suffer or incur arising out of or in
connection with any Third Party Claim for any: 

  

	 	(A)	 personal injury, illness or death; or (B) damage to Third Party property, arising as a direct result of a
breach of GSK’s warranty at Clause 27.1(D). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 42 

 CONFIDENTIAL 
  

	28.2	 Subject to Clause 29 (Liability), the Purchaser shall indemnify GSK, GSK’s Affiliates and its or
their respective employees, officers and directors (each a “GSK Indemnitee”), and keep them indemnified, on demand, from and against any and all Losses that any of them may suffer or incur arising out of or in connection with any
Third Party Claim for any: 

  

	 	(A)	 personal injury, illness or death; or 

 

	 	(B)	 damage to Third Party property, 

arising from the use, storage, or Development of Products by the Purchaser, its Affiliates, agents or
sub-licensees. This indemnity shall not apply to the extent that a claim under it results from GSK’s failure to Manufacture and/or supply Products in accordance with this Agreement. 

 

	28.3	 Subject to Clause 29 (Liability), the Purchaser shall indemnify the GSK Indemnitees, and keep them
indemnified, on demand, from and against any and all Losses that any of them may suffer or incur arising out of or in connection with any Third Party Claim that any use of the Purchaser Intellectual Property infringes the Intellectual Property of a
Third Party (other than with respect to Transferred IP). 

  

	28.4	 The procedure for claiming under any indemnity under this Agreement shall be as follows: 

 

	 	(A)	 if any Person (the “Indemnified Party”) receives a claim or demand in respect of a matter
which is the subject of an indemnity in its favour under this Agreement (a “Claim”) it shall give promptly the Party obliged to indemnify it (the “Indemnifying Party”) a notice describing in reasonable detail the
facts giving rise to the claim for indemnification hereunder, (if then known) the amount or the method of computation of the amount of such claim, and a reference to the provision of this Agreement upon which such claim is based;

  

	 	(B)	 the Indemnifying Party shall have the sole and absolute right to undertake the defence, negotiation, or
settlement of any such Claim with legal counsel of its choice. The Indemnified Party shall cooperate in such defence, negotiation, or settlement and, at its expense, shall make available all records, materials and witnesses reasonably requested by
the Indemnifying Party in connection with such Claim; and  

  

	 	(C)	 if the Indemnifying Party assumes the defence of a Claim: 

 

	 	(i)	 the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses
subsequently incurred by the Indemnified Party in connection with the defence of such Claim; 

  

	 	(ii)	 the Indemnifying Party shall keep the Indemnified Party informed of, and shall from time to time consult with
the Indemnified Party regarding the status of, any Proceedings and shall provide to the Indemnified Party copies of all documents filed in, and written communications relating to, any such Proceedings, provided that the Indemnifying Party
shall not be obliged to do anything that it has been advised by external counsel would amount to a waiver of legal privilege in any information; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 43 

 CONFIDENTIAL 
  

	 	(iii)	 the Indemnifying Party shall obtain the written consent of the Indemnified Party (such consent not to be
unreasonably withheld) prior to ceasing to defend, 

  

	 	settling	 or otherwise disposing of any Claim if, as a result thereof, the Indemnified Party: 

 

	 	(a)	 would become subject to injunctive or other equitable relief; or 

 

	 	(b)	 may reasonably object to such disposition of such Claim based on a material adverse effect on the Indemnified
Party (including any anticipated adverse effect on the Indemnified Party’s goodwill or reputation); and 

  

	 	(iv)	 the Indemnifying Party shall not be liable for any Claim settled by the Indemnified Party without its consent.

  

	28.5	 For clarity, the provisions of this Clause 28 (Indemnities) shall not prejudice the rights or
obligations of either Party (or their respective Affiliates) under the Purchase Agreement, provided that no Party (together with its Affiliates) shall be entitled to recover any sum by way of damages or other compensation under this Agreement
in respect of Losses for which it has been compensated under the Purchase Agreement (and vice versa). 

  

	29.	 LIABILITY 

  

	29.1	 Notwithstanding any other provision of this Agreement, nothing in this Agreement shall exclude or limit either
Party’s liability to the extent the same may not be excluded or limited as a matter of law, including (to such extent) liability for [***]. 

  

	29.2	 Subject to Clause 29.1, neither Party shall be liable to the other under or in relation to this Agreement
(including, for the avoidance of doubt, under or in relation to any indemnity given in this Agreement), whether arising in contract, tort, negligence, breach of statutory duty or otherwise, for any: 

 

	 	(A)	 loss of profits; 

  

	 	(B)	 loss of revenue; 

  

	 	(C)	 loss of savings or anticipated savings; 

 

	 	(D)	 loss of business or business opportunities; 

 

	 	(E)	 loss of or damage to goodwill; 

 

	 	(F)	 any indirect or consequential loss or damage; or 

 

	 	(G)	 any punitive or exemplary damages, 

in each case, whether or not the possibility of such loss or damage could have been reasonably foreseen and whether or not actually
contemplated by the Parties. 
  

	29.3	 Subject to Clauses 29.1, 29.2 and 29.4, GSK’s total liability in respect of this Agreement (including, for
the avoidance of doubt, under or in relation to any indemnity given in this Agreement), whether arising in contract, tort, negligence, breach of statutory duty or otherwise, shall be limited in aggregate over the Term of this Agreement to [***] of
sales, at the Price, of Products supplied to the Purchaser under this Agreement during the Term, provided that, such limitation on GSK’s total liability shall not apply if GSK’s liability arises from [***]. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 44 

 CONFIDENTIAL 
  

	29.4	 Subject to Clause 29.1, GSK shall further not be liable for any Losses suffered or incurred by Purchaser,
Purchaser’s Affiliates or any of its or their respective employees, officers or directors, to the extent that such Losses arise from: 

  

	 	(A)	 the use by GSK and/or the Nominated Manufacturer of the Purchaser Intellectual Property for the purposes of
this Agreement (without prejudice to any liability that GSK or its Affiliate may have under the Purchase Agreement in respect of Transferred IP); 

  

	 	(B)	 the implementation of, and compliance with, Specifications and Manufacturing instructions provided by the
Purchaser to GSK (provided that GSK has complied with such Specifications and Manufacturing instructions); 

  

	 	(C)	 any failure by the Purchaser to comply with its obligations under this Agreement; 

 

	 	(D)	 any Commercialisation of the Product; 

 

	 	(E)	 any other use of the Products outside of the Territory; 

 

	 	(F)	 the late Delivery of any Products to the extent that such late Delivery was due to any failure by the Purchaser
to comply with this Agreement; or 

  

	 	(G)	 the negligence or wilful misconduct of the Purchaser or its Personnel. 

 

	30.	 TECHNOLOGY TRANSFER 

 

	30.1	 If: 

  

	 	(A)	 GSK will not be supplying Products for Commercialisation pursuant to the Commercial Manufacturing and Supply
Agreement; or 

  

	 	(B)	 Clause 30.3 applies; or 

 

	 	(C)	 Clause 31.6 applies; or 

 

	 	(D)	 Clause 36.2(ii) applies, 

GSK shall facilitate a one-time technology transfer to the Purchaser (or Purchaser’s designee)
(the “Technology Transfer”). The Parties shall use Commercially Reasonable Efforts to create a technology transfer plan relating to the Technology Transfer (the “Technology Transfer Plan”). The Technology Transfer
Plan shall relate solely to the production process employed by GSK in the Manufacture of the Products, and shall be developed based on the expected date of expiry or termination of this Agreement and the availability of GSK Personnel and resources
to support such transfer. Purchaser and GSK shall cooperate to ensure that supporting such Technology Transfer pursuant to the Technology Transfer Plan does not place 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 45 

 CONFIDENTIAL 
  

 
an undue burden on GSK personnel and other resources. GSK shall transfer (subject to the terms of the licences granted in the Purchase Agreement) applicable records, documentation, GSK Know-How and GSK Intellectual Property in accordance with the Technology Transfer Plan and the timelines, formats, and other guidelines set forth therein. Except for a Technology Transfer pursuant to Clause 30.1(C)
or 30.1(D), the Purchaser shall reimburse GSK for such Technology Transfer support services [***]. The Purchaser will reimburse GSK for such services pursuant to Clause 12 (Invoice and Payment). If there is (i) an ongoing Technology
Transfer at the time of expiration or termination of the Agreement or (ii) this Agreement is terminated by the Purchaser pursuant to Clause 31.3(A) or Clause 36.2, the Technology Transfer Plan will survive for [***] from such termination or
expiration date. For clarity, the Purchaser shall not be required to reimburse GSK for any Technology Transfer support services, or direct costs or expenses associated with such Technology Transfer, if such Technology Transfer has been initiated by
the Purchaser pursuant to Clause 30.1(C) or 30.1(D). 
  

	30.2	 A Technology Transfer may be implemented in the circumstances contemplated by Clause 30.1(A) either in
anticipation of expiry of this Agreement or in the event of termination of this Agreement. 

  

	30.3	 The Purchaser may elect to implement a Technology Transfer pursuant to Clause 30.1(B) in the event of:

  

	 	(A)	 a material or repeated failure on the part of GSK to meet, or notification by GSK that it will be unable to
meet, any Firm Order for New Clinical Product; or 

  

	 	(B)	 a material or repeated failure on the part of GSK to Manufacture New Clinical Product (or, if applicable, New
Clinical API) in accordance with cGMP or the applicable Specifications, 

 provided that (in each case) such failure: 

 

	 	(i)	 has caused (or is reasonably likely to cause) a material delay in Purchaser’s development of Clinical
Products; and 

  

	 	(ii)	 is not due to any act or omission of Purchaser. 

 

	30.4	 Following a Technology Transfer undertaken pursuant to Clause 30.1(B) or Clause 30.1(C), Purchaser shall be
relieved of its obligation under Clause 4.1 to purchase [***] of its requirements for Products from GSK. 

  

	31.	 TERM AND TERMINATION 

 

	31.1	 This Agreement shall come into force on the Effective Date and, unless terminated earlier in accordance with
the provisions of this Agreement, shall continue in force for a period [***] from the Effective Date (the “Initial Term”). The term of this Agreement may be extended (i) if any Clinical Trials are expected to extend past the
Initial Term, by the Purchaser for a period of [***] by providing written notice to GSK at least [***] prior to the expiration of the Initial Term, or (ii) by mutual agreement of the Parties (each a “Renewal Term”, and
collectively with the Initial Term, the “Term”). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 46 

 CONFIDENTIAL 
  

	31.2	 GSK shall have the right to terminate this Agreement: without prejudice to the provisions of Clause 3
(Development Services), on [***] notice in writing to the Purchaser if GSK cannot reasonably implement a required change to the Specifications or any Manufacturing process without significant interference to its other operations at the
Manufacturing Site or capital expenditure. 

  

	31.3	 Without prejudice to its other rights and remedies, either Party (the “Terminating Party”)
may, by written notice to the other Party (the “Defaulting Party”), terminate this Agreement immediately if: 

  

	 	(A)	 the Defaulting Party commits a material breach of this Agreement and, where such breach is capable of remedy,
fails to remedy the same within [***] after receipt of a written notice from the Terminating Party giving particulars of the breach and requiring it to be remedied; or 

 

	 	(B)	 an Insolvency Event or an Insolvency Proceeding occurs (save as part of a bona fide reorganisation not
involving insolvency) in respect of the Defaulting Party or its ultimate parent. 

  

	31.4	 This Agreement may be terminated at any time by the mutual written consent of the Parties.

  

	31.5	 Purchaser may terminate this Agreement at any time by giving GSK no less than [***] prior written notice.

  

	31.6	 GSK may terminate this Agreement in whole or in part at any time on giving not less than [***] written notice
to the Purchaser if the GSK Group proposes to close the Manufacturing Site; provided that upon such notice of termination, Purchaser may elect to initiate a Technology Transfer pursuant to Clause 30.1(C). 

 

	31.7	 Either Party may terminate this Agreement in respect of a Product immediately upon written notice to the other
Party if any Regulatory Authority reaches a final determination that such Product is not safe for use in humans. 

  

	31.8	 Either Party may terminate this Agreement in accordance with Clause 23.4. 

 

	31.9	 The Purchaser may terminate this Agreement in accordance with Clause 36.2. 

 

	32.	 CONSEQUENCES OF EXPIRY OR TERMINATION 

 

	32.1	 Upon expiry or termination of this Agreement for any reason, but subject to Clause 32.2: 

 

	 	(A)	 the Parties shall use reasonable efforts to wind down activities under this Agreement in a reasonable manner
and avoid incurring any additional expenditures or noncancellable obligations; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 47 

 CONFIDENTIAL 
  

	 	(B)	 unless otherwise agreed to in writing by the Parties, all stock held by GSK, the Nominated Manufacturer or the
Nominated Supplier at the date of expiry or termination shall be dealt with as soon as practicable as follows: 

  

	 	(i)	 Products which comply with the terms of this Agreement shall either be: 

 

	 	(a)	 Delivered by GSK or the Nominated Supplier to the Purchaser (and the Purchaser shall pay GSK or the Nominated
Supplier for such Products in accordance with the terms of this Agreement); or 

  

	 	(b)	 at the Purchaser’s written request and cost (in accordance with Clause 18 (Write Offs)), destroyed
by the GSK Group; 

  

	 	(ii)	 work-in-progress started by GSK
or the Nominated Manufacturer shall either be: 

  

	 	(a)	 completed by GSK or the Nominated Manufacturer and Delivered to the Purchaser (and the Purchaser shall pay GSK
or the Nominated Supplier for such Products in accordance with the terms of this Agreement); or 

  

	 	(b)	 at the Purchaser’s written request and cost (in accordance with Clause 18 (Write Offs)), destroyed
by GSK; and 

  

	 	(iii)	 after completion of any
work-in-progress pursuant to Clause 32.1(B)(ii)(a), any remaining Purchaser Materials held by GSK or the Nominated Manufacturer shall (at the Purchaser’s election)
either be: 

  

	 	(a)	 made available for the Purchaser to collect from the Manufacturing Site at its own cost; or

  

	 	(b)	 at the Purchaser’s written request and cost (in accordance with Clause 18 (Write Offs)), destroyed
by GSK; and 

  

	 	(iv)	 after completion of any
work-in-progress pursuant to Clause 32.1(B)(ii)(a), Clause 18 (Write Offs) shall apply in respect of all remaining Materials (including the inventory of safety
stock of raw materials as required pursuant to Clause 6.3) held or ordered by GSK or the Nominated Manufacturer and all such Materials shall be destroyed by GSK at the Purchaser’s cost. 

 

	 	(C)	 the terms and conditions of this Agreement shall apply to any Products completed and/or Delivered pursuant to
Clause 32.1(B); 

  

	 	(D)	 except to the extent necessary to comply with Clause 32.1(B), the licence granted by the Purchaser in respect
of Purchaser Intellectual Property and the licence granted by GSK in respect of the GSK System shall automatically terminate; and 

  

	 	(E)	 each Party shall comply with Clause 22.5, provided that neither Party shall be obliged to return or
destroy any Confidential Information required to be used in connection with the completion or Delivery of any Products pursuant to Clause 32.1(B) until such Products have been Delivered. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 48 

 CONFIDENTIAL 
  

	32.2	 If this Agreement is terminated by GSK pursuant to Clause 31.3(B) due to any Insolvency Event or an Insolvency
Proceeding occurring in relation to the Purchaser, neither GSK nor any member of the GSK Group shall be required, by virtue of Clause 32.1, to: 

  

	 	(A)	 Deliver any Product in the possession of GSK, the Nominated Manufacturer or the Nominated Supplier;

  

	 	(B)	 complete any work-in-progress
started prior to the date of such termination by GSK or the Nominated Manufacturer; or 

  

	 	(C)	 otherwise take any step that may serve to increase the amount of any debt owed by the Purchaser to GSK or any
other member of the GSK Group, 

 and Clause 18 (Write Offs) shall apply in respect of all Products, work-in-progress and Materials held or ordered by GSK, the Nominated Supplier or the Nominated Manufacturer as at the date of such termination. 

 

	32.3	 After expiry or termination of this Agreement, the Parties shall provide each other with reasonable support
with respect to any investigation carried out by a Regulatory Authority with respect to the Manufacture of any Product under this Agreement, provided that the reasonable costs of the assisting Party in providing such assistance shall be
reimbursed by the Party requesting such assistance. 

  

	32.4	 The Quality Agreement shall automatically terminate upon expiry or termination of this Agreement (save for any
provisions of such Quality Agreement that are expressly stated to survive expiry or termination of this Agreement). 

  

	33.	 SURVIVAL OF RIGHTS, DUTIES AND OBLIGATIONS 

 

	33.1	 The expiry or termination of this Agreement shall not release either Party from any liability or right of
action which at the time of expiry or termination has already accrued to such Party or which may thereafter accrue in respect of any act or omission prior to such expiry or termination. Such rights shall include recovery of any monies due under this
Agreement. 

  

	33.2	 The expiry or termination of this Agreement shall not affect the coming into force or continuation in force of
any provision hereof which is expressly or by implication intended to come into force or continue in force on or after such expiry or termination. 

  

	33.3	 Without prejudice to the generality of Clause 33.2, the provisions of the following Clauses shall survive the
expiry or termination of this Agreement: [***]. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 49 

 CONFIDENTIAL 
  

	34.	 NOTICES 

  

	34.1	 All notices and other communications provided for hereunder shall be in writing in the English language, shall
specifically refer to this Agreement, shall be addressed to the receiving Party’s address set forth below or to such other address as a Party may designate by notice hereunder: 

A notice given under or in connection with this Agreement shall be: 
  

	 	(A)	 in writing in the English language and signed by or on behalf of the Party giving the notice;

  

	 	(B)	 sent for the attention of the person and to the address given in this Clause 34 (Notices);

  

	 	(C)	 delivered by hand; 

  

	 	(D)	 delivered by commercial courier; or 

 

	 	(E)	 sent by pre-paid first-class recorded delivery post in the country in
which the recipient’s address is located (or such other next working day postal delivery service in that country). 

  

	34.2	 The addresses for service of notice are: 

 

	 	(A)	 in the case of GSK: 

  

			
	Address:	  	980 Great West Road
		  	Brentford
		  	Middlesex
		  	TW8 9GS
		  	United Kingdom
		
	[***]	  	
	
	with a copy to:
		
	Address:	  	980 Great West Road
		  	Brentford
		  	Middlesex
		  	TW8 9GS
		  	United Kingdom
		
	[***]	  	

  

	 	(B)	 in the case of the Purchaser: 

 

			
	Address:	  	Dermavant Sciences GmbH
		  	 Viaduktstrasse 8
 4051 Basel

		  	Switzerland

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 50 

 CONFIDENTIAL 
  

			
		
	[***]	  	
	
	with a copy to:
		
	Address:	  	Dermavant Sciences Inc.
		  	320 West 37th Street, 5th Floor
		  	New York, NY 10018
		
	[***]	  	

  

	34.3	 A Party may change the details recorded for it in this Clause 34 (Notices) by notice to the other Party
(in accordance with this Clause 34 (Notices)). Such change shall take effect one (1) Business Day after that notice is deemed received pursuant to Clause 34.4. 

 

	34.4	 Unless proved otherwise and subject to Clause 34.5, a notice is deemed to have been received:

  

	 	(A)	 if delivered by hand, at the time of delivery; or 

 

	 	(B)	 if delivered by commercial courier, at the time of signature of the courier’s receipt; or

  

	 	(C)	 if sent by pre-paid first class recorded delivery post or other next
working day delivery service, [***] hours from the date of posting or at the time recorded by the delivery service. 

  

	34.5	 If deemed receipt under Clause 34.4 is not within Working Hours in the place of deemed receipt, the notice will
be deemed received at the start of the next period of Working Hours in that place. 

  

	34.6	 A notice given under this Agreement is not valid if sent by e-mail or
by fax. However, this is not intended to prohibit the use of e-mail for day to day operational communications between the Parties or their Affiliates. 

 

	34.7	 This Clause 34 (Notices) does not apply to the service of documents in respect of any Proceedings.

  

	35.	 RELATIONSHIP OF THE PARTIES 

Each Party is an independent contractor and neither is the agent of the other. Save where expressly stated in this Agreement, neither Party is
authorised to incur any expenditure or cost for the other Party or any of its Affiliates without the written consent of that other Party. Nothing in this Agreement shall be deemed to create an employment, agency, joint venture or partnership
relationship between the Parties or any of their agents or employees for any purpose. 
  

	36.	 ASSIGNMENT AND NOVATION 

 

	36.1	 Subject to the remaining provisions of this Clause 36 (Assignment and Novation), neither Party may
sublicense or assign this Agreement or any of its rights or obligations under this Agreement (including the benefit of any receivable arising under this Agreement) to a Person other than an Affiliate without the prior written consent of the other
Party (acting in its sole discretion), and any such consent shall not (and shall not be deemed to) relieve the assigning Party of any of its obligations or liabilities to the other Party under or pursuant to this Agreement. Subject to the remaining
provisions of this Clause 36 (Assignment and Novation), any purported assignment without a consent shall be void. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 51 

 CONFIDENTIAL 
  

	36.2	 GSK shall be entitled at any time by notice in writing to the Purchaser: 

 

	 	(A)	 to assign the whole or any part of the benefit of, or its rights and benefits under; or 

 

	 	(B)	 to novate the whole or any part of the benefit and burden of, or its rights, benefits, obligations and burdens
under, 

 this Agreement to (i) any Affiliate (including any Nominated Manufacturer or Nominated Supplier); or
(ii) a Third Party purchaser of the Manufacturing Site, provided that in the absence of a novation, GSK shall remain liable to the Purchaser in its capacity as principal obligor. In the event that GSK assigns or novates this Agreement to
a Third Party purchaser of the Manufacturing Site, then at any time in the [***] period commencing on the date on which GSK notifies the Purchaser of such assignment or novation, Purchaser shall have the right to elect in writing to: 

 

	 	(i)	 terminate this Agreement with effect from the later of (1) the date of such election in writing and
(2) the effective date of such assignment or novation; and 

  

	 	(ii)	 provided that the Purchaser (unless otherwise agreed with GSK) also terminates any agreement with GSK
(or any of its Affiliates) in respect of the manufacture at the Manufacturing Site and supply of tapinarof products for Commercialisation with effect from the same date as this Agreement, initiate a Technology Transfer pursuant to Clause 30
(Technology Transfer), 

  

	36.3	 Following any assignment or novation pursuant to Clause 36.2, all references in this Agreement to GSK shall be
deemed, where appropriate, to include GSK’s assigns. 

  

	36.4	 The Purchaser shall, on being required to do so by GSK, execute or procure the execution of all documents which
GSK may reasonably consider necessary to effect the novation (in whole or in part) of this Agreement pursuant to Clause 36.2. 

  

	37.	 SUB-CONTRACTORS 

 

	37.1	 GSK may sub-contract the performance of any of its obligations under
this Agreement to an Affiliate (including any Affiliate appointed to act as Nominated Manufacturer or Nominated Supplier). 

  

	37.2	 For the avoidance of doubt, if GSK appoints a sub-contractor to perform
its obligations in accordance with this Clause 37 (Sub-Contractors), GSK shall remain liable to the Purchaser for the performance of all its obligations and for any act or omission under this Agreement
of such sub-contractor in the performance of such obligations. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 52 

 CONFIDENTIAL 
  

	38.	 ENTIRE AGREEMENT 

This Agreement, including the Schedules, and the Purchase Agreement represent the entire agreement and understanding between the Parties and
supersedes all prior agreements between the Parties with respect to its subject matter and constitutes a complete and exclusive statement of the terms of the agreement between the Parties with respect to its subject matter. This Agreement may not be
amended or modified except by a written agreement duly executed by each of the Parties hereto pursuant to Clause 40. 
  

	39.	 SEVERABILITY 

If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this
Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. 

 

	40.	 VARIATION, WAIVER AND AMENDMENT 

 

	40.1	 A variation of or amendment to this Agreement shall be in writing and signed by or on behalf of each Party.

  

	40.2	 Any waiver of any right in connection with this Agreement: 

 

	 	(A)	 is only effective if it is in writing, refers expressly to this Clause 40 (Variation, Waiver and
Amendment) and is signed by the waiving Party; and 

  

	 	(B)	 applies only in the circumstances for which it is given and shall not prevent the Party who has given the
waiver from subsequently relying on the provision it has waived. 

  

	40.3	 No failure to exercise or delay in exercising any right or remedy provided under or in connection with this
Agreement or by any Applicable Law constitutes a waiver of such right or remedy or shall prevent any future exercise in whole or in part thereof. The waiver of a right to require compliance with any provision of this Agreement in any instance shall
not operate as a waiver of any further exercise or enforcement of that right and the waiver of any breach shall not operate as a waiver of any subsequent breach. 

 

	40.4	 No single or partial exercise of any right or remedy under this Agreement shall preclude or restrict the
further exercise of any such right or remedy. 

  

	40.5	 Unless specifically provided otherwise, rights arising under this Agreement are cumulative and do not exclude
rights provided by any Applicable Law. 

  

	41.	 COUNTERPARTS 

This Agreement and any amendment hereto may be executed in any number of counterparts, each of which when executed and delivered shall be
deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument. The exchange of copies of this Agreement or amendments thereto and of executed signature pages by facsimile transmission or by
email transmission in portable document format (PDF), or similar format, shall constitute effective execution and delivery of such instrument(s) as to the Parties and may be used in lieu of the original Agreement or amendment for all purposes.
Signatures of the Parties transmitted by facsimile or by email in portable document format (PDF), or similar format, shall be deemed to be their original signatures for all purposes. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 53 

 CONFIDENTIAL 
  

	42.	 NO SET OFF 

Unless and to the extent expressly stated otherwise in this Agreement, neither Party shall be entitled to set off against any sum owed by that
Party or its Affiliates any sum owed by the other Party or its Affiliates. 
  

	43.	 LANGUAGE 

  

	43.1	 Any notice given under or in connection with this Agreement shall be in English. Any document provided in
connection with this Agreement shall be provided in English or provided with a certified English translation. If there is any inconsistency between the English version of this Agreement and any version in any other language, the English version
prevails. 

  

	43.2	 If Applicable Law requires this Agreement to be executed in a language other than English, or if Applicable Law
requires a Party to submit to any Governmental Entity a translation of this Agreement into a language other than English: 

  

	 	(A)	 the Purchaser shall procure, at its own cost and expense, a translation of this Agreement; and

  

	 	(B)	 GSK shall, at its own cost and expense, in good faith and acting reasonably, review and endeavour to agree the
accuracy of that translation. 

  

	43.3	 If the Parties are unable to agree the accuracy of a translation prepared pursuant to Clause 43.2, that dispute
shall be resolved by an Independent Expert and the decision of the Independent Expert shall be final and binding on the Parties. The Independent Expert’s fees shall be borne by the Party against whom the Independent Expert’s decision is
given. 

  

	43.4	 The Parties shall not execute a translation of this Agreement or (as the case may be) submit a translation of
this Agreement to any Governmental Entity until such translation has been agreed by the Parties (or the matter has been determined by the Independent Expert). 

 

	43.5	 Notwithstanding any requirement under Applicable Law for this Agreement to executed in a language other than
English, the Parties shall in any event execute one or more counterparts of this Agreement in the English language and: 

  

	 	(A)	 any copy of this Agreement that is executed in a translation that has been agreed between the Parties (or
determined by the Independent Expert) shall be deemed to be an additional counterpart of this Agreement for the purposes of Clause 41 (Counterparts); and 

 

	 	(B)	 as between the Parties, in the event of any conflict or inconsistency between the English language version of
this Agreement and any translation of this Agreement, the provisions of the English language version shall prevail. 

  

	44.	 NO COMPENSATION 

Without prejudice to any remedies for breach or Clause 32 (Consequences of Expiry or Termination), no compensation, whether for loss of
profit or otherwise, shall be payable to either Party by virtue of the expiry or termination of this Agreement. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 54 

 CONFIDENTIAL 
  

	45.	 DISPUTE RESOLUTION 

 

	45.1	 The provisions of this Clause 45 (Dispute Resolution) shall not apply in relation to any dispute arising
under any of Clauses 11.8, 15.3, 20.5 and 43.3. Each such dispute shall be determined by an Independent Expert in accordance with the provisions of the applicable Clause. 

 

	45.2	 Subject to Clause 45.1, each Party shall use its reasonable endeavours to resolve any dispute or difference
arising out of or in connection with this Agreement (a “Dispute”) by prompt discussion in good faith at a managerial level appropriate to the Dispute in question. This discussion shall be a
pre-condition to the commencement of legal Proceedings before any court. This procedure shall be invoked by either Party giving notice to the other setting out the issues in the Dispute and referring to this
Clause 45 (Dispute Resolution) and, unless the Parties agree otherwise, shall be treated as having been exhausted if the Dispute has not been resolved within [***] after the giving of the notice. 

 

	45.3	 Subject to Clause 45.4, nothing in Clause 45.2 precludes any Party from commencing or continuing Proceedings in
any court at any time: 

  

	 	(A)	 for an interim order to restrain any other Party from doing any act or compelling any other Party to do any
act; or 

  

	 	(B)	 for a judgment for a liquidated sum to which there is no arguable defence; or 

 

	 	(C)	 the purpose of which is to prevent a claim from becoming time-barred due to the expiry of any statutory or
contractual limitation period. 

  

	45.4	 Clause 45.3 shall not permit any Party to continue any court Proceedings without compliance with Clause 45.2:

  

	 	(A)	 if the Proceedings were commenced in reliance upon Clause 45.3(A), once the court has ordered, or the Parties
have agreed in writing, that the defendant should have permission to defend; or 

  

	 	(B)	 if the Proceedings were commenced in reliance upon Clause 45.3(C), once the Proceedings have been issued and
served, and the defendant has acknowledged service. 

  

	46.	 GOVERNING LAW AND JURISDICTION 

 

	46.1	 This Agreement and its negotiation, execution, performance or
non-performance, interpretation, termination, construction and all claims or causes of action (whether in contract, in tort, at law, or otherwise) that may be based upon, arise out of, or relate to this
Agreement or the transactions contemplated hereby (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in connection with this Agreement or as an inducement to enter this Agreement),
shall be exclusively governed by, and construed in accordance with, the laws of the State of Delaware regardless of laws that might otherwise govern under any applicable conflict of laws principles. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 55 

 CONFIDENTIAL 
  

	46.2	 Each Party hereby irrevocably submits to the exclusive jurisdiction of the Delaware courts in relation to all
matters, whether contractual or non-contractual, arising out of or in connection with this Agreement or its negotiation, existence, validity or enforceability. Any Proceeding concerning such matters shall be
brought only in the Delaware courts. Each Party hereby waives (and agrees not to raise) any objection, on the ground of forum non conveniens or on any other ground, to the taking of Proceedings in the Delaware courts. 

 

	46.3	 Each Party undertakes not to contest the enforcement against it of any judgment of the Delaware courts in
Proceedings on the ground that those courts did not have jurisdiction over it. 

 [The signatures follow on the next
page.] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 56 

 CONFIDENTIAL 
  

 IN WITNESS of which each Party has caused this Clinical Manufacturing and Supply Agreement in respect
of Tapinarof and Clinical Placebo to be duly executed by its duly authorised representative in a manner binding upon it on the day and year first before written. 

[The Schedules follow the signatures.] 
  

							
		 	)	  		  	
	Signed by /s/ E. Rindel
                                         
           	 	)	  		  	
	for and on behalf of	 	)	  		  	
	[***]	 		  	 Elizabeth Rinder
	  	
		 	)	  		  	                        
				
		 	)	  		  	
	Signed by Sascha
Bucher                                        
        	 	)	  		  	
	[***]	 		  	 /s/ Sascha Bucher
	  	
		 	)	  		  	

  

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED. 
 57 

 CONFIDENTIAL 
  

 SCHEDULE 1 

PRODUCTS AND PRICES 
 PART A: THE
PRODUCTS 
 [***] 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 PART B: PRICES 

Existing Clinical API, Existing Clinical Products and Existing Clinical Placebo: 

[***] 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 [***] 
 New
Clinical Products and New Clinical Placebo: 
 The Price for New Clinical Products and New Clinical Placebo Manufactured under this Agreement shall be
determined as follows: 
  

	 	(A)	 [***] 

  

	 	(B)	 [***] 

[***] 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 [***] 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 New Clinical API: 

The Price for New Clinical API Manufactured under this Agreement shall be determined as follows: 

 

	 	(A)	 [***] 

  

	 	(B)	 [***] 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 SCHEDULE 2 

SCOPE OF WORK FOR DEVELOPMENT SERVICES 

Each Scope of Work describes the activities and deliverables contemplated by the Parties for the applicable Development Services, together with the non-binding timeline for the performance or delivery of those Development Services. 
  

	1.	 General assumptions 

In addition to any specific assumptions set forth in a Scope of Work for the applicable Services, the following assumptions apply generally to all Development
Services undertaken pursuant to or in connection with such Scope of Work: 
  

	1.1	 Where applicable, GSK or its Affiliate will perform the Development Services set forth in a Scope of Work in
accordance with, and subject to, the GSK Group’s policies and standard operating procedures and Applicable Law. 

  

	1.2	 The Price payable by the Purchaser under a Scope of Work includes [***]. Unless otherwise provided in a Scope
of Work, Development Services shall be charged at the defined FTE Rate set forth in Schedule 4 (Fees) together with all of GSK’s direct costs and expenses for such Development Services and, if applicable, a management fee. Any
Manufacturing required to support Development Services under a Scope of Work will be charged at an agreed per batch cost as set forth in the applicable Scope of Work. 

 

	1.3	 Following the performance of the Development Services by GSK, GSK or its Affiliates shall invoice the Purchaser
in accordance with Clause 12 (Invoice and Payment) and notify the Purchaser in writing of the completion of the relevant Development Service. The Purchaser must notify GSK of its approval of such Development Service and any related
deliverables in writing within [***] of receipt of the notification of completion of such Development Service. GSK shall not be obliged to proceed with any activities for subsequent Development Services (if any) prior to receiving in writing the
Purchaser’s approval and acceptance of each preceding Development Service and related deliverables (if any), unless otherwise agreed between the Parties. 

 

	1.4	 In the event that any dispute or difference arises out of or in connection with the performance of a
Development Service under a Scope of Work and the Purchaser does not give its acceptance in respect of a Development Service and any related deliverables in accordance with paragraph 1.3 above (a “Service Dispute”), each Party shall
use its reasonable endeavours to resolve any such Service Dispute by prompt discussion in good faith at a managerial level appropriate to the Service Dispute in question. This procedure shall be invoked by either Party giving notice to the other
setting out the issues in the Service Dispute and referring to this paragraph and, unless the Parties agree otherwise, shall be treated as having been exhausted if the Service Dispute has not been resolved within [***] after the giving of the
notice. If the Service Dispute is treated as having been exhausted, GSK may terminate the relevant Scope of Work with immediate effect. 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

	1.5	 Neither GSK nor any of its Affiliates shall support any development work or undertake any capital expenditure
in respect of the performance of the Development Services or the Manufacture of the Products under this Agreement. If any capital expenditure is identified during the Term as being required in respect of the Development Services or the Products, the
Parties shall discuss and agree in writing what is required and the expenditure shall be borne by the Purchaser. In the event that the Purchaser fails to pay any sum in respect of capital expenditure for which it is to bear the cost pursuant to this
paragraph 1.5, neither GSK nor its Affiliates shall bear any liability under this Agreement for any breach of its terms resulting from any failure to undertake, or delay in undertaking, such capital expenditure or any consequential failure to
Manufacture (or delay in Manufacturing) the Products pursuant to this Agreement. 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 Form of Scope of Work - Development Services 

The Purchaser’s request is for GSK to (i) [•] and (ii) [•]. 

The estimated Price (in aggregate) for GSK to complete the performance of these Development Services is [•]. 

In order to progress with [•], the following activities are to be performed by the Parties: 

Service 1: TBD 
  

			
	 Target Start
  

Target Completion
  

Assumptions

		
	Activities	  	 Goal:
  

GSK responsibilities:
  

Purchaser responsibilities:
  

•

		
	Deliverables	  	•
		
	Estimated Price	  	•

 Service 2: TBD 
  

			
	 Target Start
  

Target Completion
  

Assumptions

		
	Activities	  	 Goal:
  

GSK responsibilities:
  

Purchaser responsibilities:
  

•

		
	Deliverables	  	•
		
	Estimated Price	  	•

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 SCHEDULE 3 

TOLL MANUFACTURE PROVISIONS 
  

	1.	 SUPPLEMENTARY PROVISIONS IN RELATION TO TOLL MANUFACTURE OF NEW CLINICAL PRODUCTS 

Save to the extent expressly amended or disapplied by virtue of this Schedule 3 (Toll Manufacture Provisions), all other terms and
conditions of this Agreement apply. In this Schedule 3 (Toll Manufacture Provisions), unless otherwise specified, any reference to a paragraph is to a paragraph of this Schedule 3 (Toll Manufacture Provisions). 

 

	2.	 USE OF TOLL MATERIALS 

 

	2.1	 Title to the Toll Materials, that part of any
work-in-progress containing the Toll Materials (“WIP”) and that part of New Clinical Products containing the Toll Materials shall at all times remain
with and vest in the Purchaser. GSK or the Nominated Supplier shall use such Toll Materials, WIP and New Clinical Products solely for the purposes of this Agreement. 

 

	2.2	 The risk in (but not title to) the Toll Materials shall pass to GSK on Delivery to GSK (or the Nominated
Supplier) (or shall remain with GSK in respect of Toll Materials that the Parties agree shall be left in GSK’s possession in consignment). 

  

	2.3	 The Toll Materials, WIP and New Clinical Products shall at all times be stored separately from (but may be
stored in the same warehouse or other facility as) other goods and merchandise in the possession of GSK or the Nominated Supplier and the containers holding the Toll Materials, WIP and New Clinical Products shall be clearly marked in such a way as
to identify that they are owned by the Purchaser or for use only for the Purchaser. 

  

	3.	 LOSS AND RECONCILIATION OF TOLL MATERIALS 

 

	3.1	 The Parties agree that the Expected Loss in respect of each New Clinical Product shall be [***]. The Expected
Losses identify in percentage terms the proportion of each Toll Material reasonably expected to be lost in the Manufacture of the relevant New Clinical Product(s), including in the event of a batch rejection. The Expected Losses take into account
GSK’s and the Nominated Supplier’s requirements to retain samples of the Toll Materials and/or New Clinical Products in accordance with Applicable Law. The Expected Losses shall be applicable throughout the Term unless otherwise mutually
agreed by the Parties. 

  

	3.2	 GSK shall report quarterly to the Purchaser and/or its Affiliate on the usage of each Toll Material it
achieves, in order for the Parties to calculate the actual usage achieved by GSK and the Nominated Supplier, and for this purpose shall provide to the Purchaser by the end of the month following each Calendar Quarter Day and the date of termination
or expiry of this Agreement a reconciliation report (in respect of the previous Calendar Quarter or period and Reporting Year to date) in such format as the Parties may agree showing: 

 

	 	(A)	 the opening quantities of each Toll Material held by GSK or the Nominated Supplier at the start of the Calendar
Quarter; 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

	 	(B)	 the receipts of each Toll Material from the Purchaser (or its Affiliate) during that Calendar Quarter;

  

	 	(C)	 the actual usage of each Toll Material during that Calendar Quarter and during that Reporting Year through the
end of such Calendar Quarter in the Manufacture of New Clinical Products and the quantities of New Clinical Products Manufactured; and 

  

	 	(D)	 the stock of each Toll Material and related WIP and New Clinical Products containing the same, held by GSK or
the Nominated Supplier remaining unprocessed or not yet Delivered to the Purchaser or its Affiliate at the end of such Calendar Quarter; 

provided that the first such report in respect of each New Clinical Product shall relate to the period commencing on the Effective Date
and ending on the first Calendar Quarter Day falling at least one (1) month after the Effective Date. 
  

	3.3	 On the last Business Day of the month following the end of each Reporting Year during the Term (including
following the final Reporting Year of the Term), the Parties shall calculate the Reconciliation Value for the Reporting Year just ended as follows: 

[***] 
  

	3.4	 If the Reconciliation Value is positive, GSK shall reimburse the Purchaser (or its Affiliate) for such
Reconciliation Value. 

  

	3.5	 If the Reconciliation Value is negative, such Reconciliation Value shall be carried forward to the next
Reporting Year and used in calculating the subsequent Reconciliation Value in accordance with the formula set forth at paragraph 3.3. 

  

	3.6	 For the purposes of the calculation in paragraph 3.3, the loss of any of the Toll Materials that are Defective
(other than as a result of any negligent act or omission of GSK or its Affiliates following Delivery of such Toll Materials) or written off pursuant to Clause 18 (Write Off Costs) and paragraph 5 (Supplementary Write Off Provisions)
shall be disregarded. 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

	3.7	 The provisions of Clause 11.8 shall apply mutatis mutandis in the event of any dispute in respect of the
calculation of any Reconciliation Value under this paragraph 3 (Loss and Reconciliation of Toll Materials). 

  

	4.	 REQUIREMENTS FOR TOLL MATERIALS 

 

	4.1	 On the [***] of each calendar month (or on such other Business Day during each month as may be agreed), GSK
shall notify the Purchaser of its requirements for Toll Materials based on the Forecast Schedule and the applicable Lead Time for the relevant New Clinical Product. 

 

	4.2	 GSK shall be released of its obligations to supply the relevant New Clinical Product to the Purchaser to the
extent that the quantity of Toll Materials in its possession is not sufficient to Manufacture such New Clinical Product (other than as a result of GSK’s failure to comply with its obligations in respect of any agreed Manufacture of New Clinical
API or due to a Defect in Purchased Clinical API or Maintained Excess Clinical API). 

  

	5.	 SUPPLEMENTARY WRITE OFF PROVISIONS 

For the avoidance of doubt, in determining any sum to be reimbursed by the Purchaser (or its Affiliate) to the GSK Group pursuant to Clause 18 (Write Off
Costs), the cost to the GSK Group of any Toll Materials required to be written off shall be [***]. 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 CONFIDENTIAL 
  

 SCHEDULE 4 

FEES 
 [***] 

  
 Schedule 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]